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Brain metastases (BM) are the most common intracranial malignant neoplasm in adults 
and occur in up to 25% to 35% of metastasized cancer patients and in 9% of all patients 
diagnosed with cancer.[1,2] BM originate from lung cancer (± 60%), breast cancer (± 
10%), colorectal cancer (± 10%), melanoma (± 5%), renal cell cancer (± 5%), or other 
primary tumors (± 10%), and often determine the quality of life and prognosis of cancer 
patients. Life expectancy is usually expressed in weeks to months, with only a small 
minority of patients (1-5%) surviving several years.[3] Therefore, the vast majority of 
patients is treated with palliative intent, with the aim of maintenance of quality of life 
and neurologic function and avoidance of neurologic death by intracranial cancer pro-
gression.  
 
 
Figure 1. Brain metastasis illustrated on T1-weighted magnetic resonance imaging of the brain (marked with 
red arrows) before (A) and after surgical resection (B).  
TREATMENT OPTIONS 
Therapeutic options for patients with BM include surgery, radiation therapy, systemic 
therapy (or combinations of these), and best supportive care. Surgical resection is per-
formed for accessible, generally single lesions but is reserved for patients with larger 
BM with significant mass effect or patients for whom histological confirmation of the 
intracranial tumor is needed (Figure 1).[4] For the vast majority of patients with multiple 
lesions or active extracranial disease, however, radiation therapy is the preferred 
treatment choice.  
A 
B 
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Traditionally, whole brain radiation therapy (WBRT) has been the cornerstone of treat-
ment for (multiple) BM. Typically, a homogenous radiation dose is delivered in 5-10 
fractions to the entire brain, including the BM.[5] Prognosis after WBRT remains poor, 
with a median survival of approximately 2-6 months. The most important prognostic 
factors are the patient’s performance status, the presence or absence of extracranial 
tumor activity, and age. Although WBRT is still being used frequently in clinical practice, 
its exact palliative value compared to best supportive care is still a matter of debate.[6] 
WBRT causes several side effects, such as temporary hair loss, fatigue, and neurocogni-
tive damage.[7] Therefore, in patients having a poor prognosis with estimated survival 
measured in weeks, withholding WBRT seems to be appropriate.[6,8] 
STEREOTACTIC RADIOSURGERY 
In the past few decades, an alternative focal radiation treatment has become available 
for patients with a limited number of BM: stereotactic radiosurgery (SRS). The technol-
ogy and principle of SRS was developed by the Swedish neurosurgeon Lars Leksell in 
1949. SRS differs from WBRT in that only the BM volume is treated and the uninvolved 
brain tissue is spared to as much as possible (Figure 2). The delivered radiation dose to 
the BM with SRS is biologically much larger than WBRT, resulting in a higher tumor con-
trol probability. Being a minimally or non-invasive treatment modality, the morbidity 
and mortality of general anesthesia and surgical resection is avoided.[9-11] SRS is deliv-
ered at an outpatient clinic with avoidance of the hospitalization needed with surgery. 
Tumor cells are destroyed by the usage of multiple photon beams generally in 1 up to 3 
fractions. Side effects such as neurocognitive damage and hair loss of WBRT is mostly 
avoided because of the local nature of SRS.[12] With a single SRS dose of ≥ 18 Gy, re-
ported 1 year local control rates vary from 73% up to 98%, dependent on size and pri-
mary tumor type of the BM. In general, for small BM, SRS can be regarded as equally 
effective as resection, but surgical resection can be more appropriate for larger metas-
tases (> 8-10 cm3). The disadvantage of SRS is the relatively high cumulative risk of de-
velopment or outgrowth of new BM during follow-up in the non-irradiated parts of the 
brain. However, salvage therapy in the form of repeat-SRS, WBRT, or even surgery can 
be applied in selected patients.[13] The efficacy of SRS alone or given in combination 
with WBRT for patients with BM has been investigated in several studies.[10,13-15] 
These studies showed comparable median overall survival rates in patients with 1-4 
brain metastases treated with SRS alone vs SRS plus WBRT, suggesting that WBRT could 
be omitted in the initial management of brain metastases. Patients who received WBRT 
in addition to SRS or surgery experienced poorer neurocognitive function, more fatigue, 
more hair loss, and in general a decreased quality of life compared to SRS or resection 
only.[10,11] 
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Another disadvantage of SRS is the risk of causing a complication called radiation necro-
sis (RN). RN is focal structural damage of the nearby brain tissue that may cause perma-
nent neurologic symptoms. Patients suffering from RN can become dependent on med-
ication (corticosteroids) or even require surgical treatment to relieve the neurologic 
symptoms. The risk of RN is dependent on the volume of surrounding healthy brain 
tissue being exposed to high doses. For single-fraction SRS, the volume of healthy brain 
tissue receiving 12 Gy (V12Gy) is considered the most significant prognostic factor for RN. 
If the V12Gy is kept below ca. 10 cm3, the risk of RN has been described as less than 10%. 
The risk of surpassing this threshold mainly occurs when irradiating larger (> 2 cm in 
diameter) BM with SRS, which increases the risk of RN.[16-18] 
 
  
Figure 2. Color-wash representation of a typical dose distribution for WBRT (left) and SRS (right).   
 
The technology to deliver SRS has developed rapidly over the past few decades (Figure 
3). At present, even multiple BM can be treated with a single-fraction within minutes 
with advanced and patient friendly techniques. The patient is positioned in a custom-
made mask, which renders the use of invasive frames obsolete. Modern onboard tech-
nologies, such as cone-beam CT or orthogonal imaging, allow for accurate positioning of 
the patients with sub-millimeter precision. With modern dedicated LINACs, SRS can be 
delivered with comparable plan quality as other radiation therapy devices, such as the 
Gamma Knife (GK). LINAC-based SRS offers comparable plan conformity and dose gradi-
ents as GK.[19,20] SRS (either LINAC based or with GK) is currently the standard treat-
ment according to Dutch guidelines for patients with a maximum of 3 BM.[21] 
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Figure 3. Frameless mask for convenient patient positioning. (Image courtesy of Varian Medical Systems, Palo 
Alto, CA, USA). 
PATIENT SELECTION FOR SRS 
Being both efficient and patient friendly, SRS alone has become an attractive treatment 
option for patients with BM. It remains important to identify patients whose expected 
survival justifies application of SRS, and several prognostic classification systems that 
have been developed can be used to estimate life expectancy. However, the currently 
available prognostic classification systems suffer from several limitations, as the patient 
cohorts on which these classifiers have been trained and validated were mainly treated 
with other modalities than SRS alone, such as WBRT. Moreover, the predicted treat-
ment outcome probability is presented for groups of patients with poor, intermediate, 
or favorable prognoses, instead of for individual patients. Outside of trial settings, the 
proportion of patients in the intermediate prognostic group dominates the proportion 
of patients in both the favorable and poor prognostic classes. In the current era in 
which systemic agents also may control BM, potentially relevant tumor characteristics 
have not been incorporated into prognostic classification systems.[22,23] Considering 
the limitations of currently available prognostic classification systems, there is an urgent 
need to develop individualized prediction tools per treatment modality and per out-
come parameter, incorporating all relevant prognostic factors. These individualized 
prediction tools may help both physicians and (ultimately) patients choose the optimal 
treatment strategy for each patient with BM. Assessing the value of current clinical 
outcome prediction tools, specifically for patients treated with SRS alone, followed by 
the generation of an individualized outcome prediction tool is the subject of the first 
part of this thesis.  
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EFFECTIVENESS OF SRS AS A SINGLE MODALITY TREATMENT IN 
PATIENTS WITH MULTIPLE BM 
Technical advances that have been accomplished in the past few decades with LINAC-
based SRS have paved the way to treat patients with more than 3 BM. According to 
current Dutch guidelines, WBRT is the standard of care in patients with more than 3 
BM. There is a tendency of better survival after WBRT in patients with a favorable prog-
nostic profile by early sterilization of microscopic disease, but as mentioned before, 
some side effects of WBRT can be avoided with SRS.[9,15] Therefore the effectiveness 
and safety of SRS alone compared to standard-of-care WBRT needs to be determined in 
randomized studies in patients with more than 3 BM before this treatment can be ap-
plied in general clinical practice. The second goal in this thesis was the description of 
the background of the need for a prospective studies in patients with more than 3 BM 
and the actual initiation of a phase III randomized trial to determine which treatment 
provides the best quality of life in patients with 4 to 10 BM. 
Improving SRS outcome for large BM 
Another challenge in current daily clinical practice with SRS for BM is its application in 
large BM. The majority of institutes in the Netherlands use a risk-adaptive approach, in 
which BM with a small volume (< 10 cm3) are treated with high doses (a single fraction 
of 21 or 24 Gy), and BM with a larger volume are treated with lower prescribed doses (a 
single fraction of 15 or 18 Gy). In this way, high local control rates at 1 year (ca. 85%) 
and low risk of RN (< 10%) can be achieved for small BM, whereas for larger BM, a very 
high risk of RN is avoided at the cost of a lower tumor control probability (ca. 
40%).[24,25] To safely increase the probability of local control while maintaining a low 
risk of RN in patients with larger BM undergoing SRS, there is a clear need to optimize 
the risk-adaptive approach for single-fraction SRS.   
Hence, the third goal of this thesis was to perform a modelling study to test an individu-
alized dose prescription strategy to safely improve the tumor control probability with 
SRS for larger BM. 
HYPOTHESES OF THIS THESIS 
(1) Individualized prognostic models predict survival and the occurrence of distant 
brain recurrences after SRS alone for BM more accurately than currently availa-
ble prognostic models 
(2) A multicenter randomized phase III trial can be initiated to investigate whether 
SRS alone provides a better quality of life than WBRT in patients with 4 to 10 BM  
Chapter 1 
14 
(3) The 1-year tumor control probability of SRS for large BM can be improved by iso-
toxic dose prescription in a modelling study 
OUTLINE OF THIS THESIS 
In Figure 4 the outline of this thesis is presented. 
 
 
Figure 4 Outline of this thesis 
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The first 5 chapters address the first hypothesis of this thesis. In chapter 2, the value 
and limitations of several currently available prognostic models are discussed with re-
spect to survival prediction. In chapters 3 to 6, newly developed prediction models are 
described for different clinical endpoints after SRS alone for BM: survival, local control, 
and distant brain recurrences. In chapters 7 to 9 the second hypothesis was tested. In 
these chapters, the value of SRS, WBRT, resection, or a combination is provided for 
patients with BM and a study protocol is described of a randomized trial. The third hy-
pothesis is discussed in chapters 10 and 11. Chapter 10 reviews the currently available 
clinical evidence of isotoxic dose prescription (IDP) for radiotherapy and especially its 
value with SRS. Chapter 11 is a modelling study and describes the application of IDP for 
SRS in large BM. 
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Chapter 2 
The clinical utility of prognostic scoring 
systems in patients with brain metastases 
treated with radiosurgery 
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ABSTRACT 
Purpose The RTOG recursive partitioning analysis (RPA) classification is the gold stand-
ard for assessing the prognosis of patients with brain metastases (BM). Newer prognos-
tic scoring systems for BM patients have been proposed, but their superiority over RPA 
needs to be established for patients treated with radiosurgery. 
Methods 380 patients with 1–3 BM were treated at the VUmc with radiosurgery (RS) 
from 2002 to 2011. Using baseline characteristics, patient scores were calculated for 
RPA, the Rotterdam-system, the score index for radiosurgery (SIR), the basic score for 
BM (BSBM), the graded prognostic assessment (GPA), the diagnosis-specific GPA, the 
Rades score, and the Golden grading system (GGS) for comparison with survival time 
and survival classification (≤3 months or ≥12 months). 
Results Median survival after RS was 7.7 months, with 3-month and 1-year overall sur-
vival (OS) of 76% and 39%, respectively. Multivariate analysis confirmed the prognostic 
value of performance status, age, absence of extracranial metastases, primary tumor 
site, gender, and steroid response for OS. The percentage of patients included within 
the intermediate prognostic classes ranged from 48% to 77%, and was 64% for the RPA. 
All scoring systems highly correlated with OS (p < 0.001). The specificity for predicting 
early death ranged from 85% to 98% (RPA 88%), with the unfavorable classes of Rades, 
GGS, BSBM and SIR performing best. The sensitivity for predicting long-term survival 
ranged from 10% to 69% (RPA 29%), and was highest for the favorable classes of Rades 
and GGS. 
Conclusions All prognostic scoring systems correlated very well with OS. All scores 
shared the limitation of unbalanced proportions of patients within the prognostic clas-
ses. As the clinical superiority of more recently developed prognostic scoring systems 
was only modest in predicting early death and long term survival, the well-known and 
easy to use RPA system currently remains the standard. 
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INTRODUCTION 
Stereotactic radiosurgery (RS) is an established treatment modality for patients with a 
limited number of brain metastases (BM) from solid tumors [1]. In patients treated with 
RS with or without upfront whole brain radiotherapy (WBRT) [2], median survival dura-
tion ranges from 6 to 12 months [3] and [4]. The increasing availability of RS facilities 
and the introduction of frameless RS techniques has considerably lowered the threshold 
for the application of RS in terms of patient condition, tumor status and number of BMs. 
Although modern frameless RS is generally considered to be a well tolerated patient-
friendly technique, it remains a time-consuming and relatively costly treatment modali-
ty for palliation, underscoring the need for appropriate patient selection. 
Many prognostic factors for the survival of patients with BM have been identified in the 
medical literature including performance status, presence or absence of extracranial 
metastases, primary tumor control, and age. In order to facilitate the use of these prog-
nostic factors in clinical practice, Gaspar et al. published the recursive partitioning anal-
ysis (RPA) prognostic classification system, which was derived from patient groups 
treated with WBRT in several RTOG studies [5]. The RPA classification which is still the 
most commonly used prognostic classification system was subsequently validated for 
patients treated with RS [6] and [7] and surgery [8]. However, the unbalanced distribu-
tion of patients within the three RPA classes with the majority of patients included in 
the intermediate group remains the major limitation of this classification system [9]. 
In an attempt to improve the clinical utility of prognostic classification systems, several 
alternatives to the RPA have been published; i.e. the Rotterdam score [10], the scoring 
index for radiosurgery (SIR) [11], the basic score for BM (BSBM) [12], the graded prog-
nostic assessment (GPA) [13], disease-specific GPA (DS-GPA) [14], Rades score [15], and 
the Golden grading system (GGS) [16]. All classification systems share two common 
factors performance status and absence or presence of extracranial metastases, but 
differ by the addition of other prognostic factors such as age, primary tumor control, 
site of primary tumor, volume and number of BM, time interval between the diagnosis 
of the primary tumor and BM, and clinical response to steroid treatment (Table 1). The 
different classification systems also vary with respect to the patient population that 
these were derived from; the SIR, BSBM, and GGS were developed in RS patients, the 
RPA was based on WBRT patients, whereas the Rotterdam, Rades, GPA, and DS-GPA 
were derived from patient populations treated with WBRT, surgery, RS or a combination 
of treatment modalities. 
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Table 1 Baseline characteristics included in various prognostic scoring systems for patients with brain metas-
tases. Legend: Recursive partitioning analysis (RPA), Rotterdam score (Rotterdam), the scoring index for 
radiosurgery (SIR), basic score for brain metastases (BSBM), graded prognostic assessment (GPA), disease-
specific GPA (DS-GPA), Rades score, and Golden grading system (GGS) 
 
It remains unclear whether newer proposed classification systems perform better than 
the current standard of RPA in BM patients treated with RS. An optimal prognostic clas-
sification system with a high clinical utility should not only be correlated with overall 
survival, but should also be able to identify patients who are likely to have short survival 
(e.g. ≤3 months) despite adequate treatment or alternatively identify patients who are 
likely to have long-term (e.g. ≥12 months) survival. In addition, these should result in a 
balanced distribution of patients in clinical practice and be as simple as possible for use 
in clinical practice. Such an optimal classification system would allow for a better selec-
tion of patients suitable and less suitable for RS. In a cohort of RS patients, we studied 
the clinical utility of the eight reported prognostic classification systems for BM by as-
sessing the aforementioned characteristics for clinical utility. 
MATERIALS AND METHODS 
The VUmc institutional database contains baseline characteristics, treatment details and 
follow-up data of newly diagnosed BM patients treated with Linac-based RS. At our 
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center, patients with 1–3 BM diagnosed on high resolution contrast-enhanced MRI 
scans are eligible for RS as a single modality. RS has been delivered using 5 dynamic 
conformal arcs on a Novalis (2002–2008) or Novalis TX (2008 onwards) linear accelera-
tor. Patient fixation was performed using the relocatable Gill–Thomas–Cosman frame, 
and as of 2008 using the BrainLAB’s frameless mask system [BrainLAB, Feldkirchen, 
Germany]. RS was prescribed using a ‘risk-adapted’ fractionation, with lesions ≤7.5 cm3 
receiving 21 Gy prescribed at the encompassing 80% isodose line. The RS target vol-
umes consisted of the gross target volume contoured on the planning MRI with a 1 mm 
margin to correct for potential setup-inaccuracies. For lesions measuring 7.5–25 cm3 or 
BM that were adjacent to the brainstem, the prescription dose was lowered to 18 Gy at 
the 80% isodose. For the largest lesions with volumes exceeding 25 cm3, a single frac-
tion of 15 Gy or 3 fractions of 8 Gy, both prescribed at the 80% isodose was used. 
Between December 2002 and July 2011, a total of 380 patients with 536 newly diag-
nosed BM were treated with Linac-based RS. The most relevant baseline characteristics 
are summarized in Table 2. Briefly, the median age of the patient group was 61 years, 
with the majority of patients (58%) having primary lung cancer. Sixty-four percent of 
patients underwent RS for a single BM, 30% for two lesions and only 6% of patients 
underwent RS for 3 lesions. Follow-up consisted of 3-monthly clinic visits with contrast-
enhanced MRI during the first year, followed by 6-monthly MRI scans during the second 
year, and yearly thereafter. Survival was calculated from the date of RS. The median 
follow-up duration calculated using the reverse Kaplan–Meier method was 32 months. 
 
Table 2 Baseline characteristics of study population (n=380) 
Number of patients N = 380 (Dec ’02-July ’11) 
Gender 
Female 202 (53%) 
Male 178 (47%) 
WHO performance score 
0–1 310 (82%) 
2–4 70 (18%) 
Median age (range) 61 years (16–89 years) 
Primary tumor site 
Lung cancer 220 (58%) 
Breast cancer 40 (11%) 
Colorectal cancer 30 (8%) 
Renal cell cancer 27 (7%) 
Melanoma 24 (6%) 
Other 34 (9%) 
Unknown primary 5 (1%) 
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Number of patients N = 380 (Dec ’02-July ’11) 
Primary tumor active 
No 204 (54%) 
Yes 176 (46%) 
Extracranial metastases 
No 204 (54%) 
Yes 176 (46%) 
Median interval primary tumor - BM (range) 1 month (range 0–28 months) 
Response to steroid treatment 
Good/no steroids needed 254 (67%) 
Moderate/little response 93 (24%) 
Unknown 33 (9%) 
Number BM 
1 245 (64%) 
2 114 (30%) 
3 21 (6%) 
Median volume largest BM (range) 5.7 cc (range 0.1–44.7 cm3) 
Median total volume treated BM (range) 6.2 cc (range 0.1–44.7 cm3) 
Median size largest BM diameter 24 mm (range 3–50 mm) 
RS dose largest BM 
21 Gy 176 (46%) 
18 Gy 136 (36%) 
15 Gy 25 (7%) 
8 Gy (3X) 43 (11%) 
 
Univariable Log-rank test and multivariable Cox regression analysis was used to deter-
mine risk factors for death for the baseline clinical variables. From the collected base-
line characteristics, individual scores for all prognostic classification systems were calcu-
lated, i.e. the RPA, Rotterdam score, SIR, BSBM, GPA, DS-GPA, Rades score, and GGS. 
The distribution of patients within the separate prognostic classes was evaluated, and 
the prognostic value for the different classification systems for survival was determined 
using Kaplan–Meier analysis. The ability of the different prognostic classification sys-
tems to identify patients at high risk of early death following RS was evaluated by de-
termining the sensitivity and specificity of the most unfavorable subclasses for predict-
ing death within 3 months. Conversely, for assessing the ability to identify patients with 
long-term survival (≥12 months), the sensitivity and specificity of the most favorable 
classes for predicting 12-month survival were calculated. The 3- and 12 month cut-off 
values for these analyses have been arbitrarily selected, as more validated definitions of 
good- and poor prognosis patient outcomes are currently lacking. 
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RESULTS 
The distribution of patients within the various prognostic classification systems is shown 
in Fig. 1. The group size within the intermediate RPA class was 64%. All other prognostic 
classification systems showed similar proportions of patients within the intermediate 
group(s), ranging from 48% to 77%. By definition, the four-tiered BSBM, GPA, and DS-
GPA have two intermediate groups. The proportion of patients in the most favorable 
class ranged from only 5% (GPA) to 49% (Rades), while the proportion of patients in the 
most unfavorable class ranged from 3% (Rades) to 19% (GPA). 
 
 
Figure 1 Distribution of patients in eight prognostic scoring systems 
 
The median overall survival (OS) was 7.7 months, with OS rates of 76%, 57% and 39% at 
3-, 6- and 12 months, respectively. Univariable analysis for baseline characteristics 
showed several factors to be correlated with better OS. In multivariable analysis, better 
performance status (p = 0.014), younger age (p = 0.008), primary breast (p = 0.003) and 
renal cell cancer (p < 0.001), female sex (p = 0.042), absence of extracranial metastases 
(p < 0.001) and a good response to steroid treatment (p = 0.040) or no clinical need for 
steroid treatment (p = 0.033) were correlated with significantly better OS. All eight 
investigated prognostic scoring systems were highly correlated with OS (p < 0.001) in 
univariable analysis, because of the high overlap between classification systems, these 
were not included in the multivariable analysis assessing individual factors. 
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A total of 91 patients (24%) of the entire population died within 3 months. The median 
survival in the most unfavorable groups of the different classification systems ranged 
from 2.6 to 5.0 months. The percentage of patients included in the most unfavorable 
prognostic groups dying within 3 months (i.e. positive predictive value) following RS 
varied between 37% (DS-GPA) and 58% (Rades). The sensitivity and specificity of the 
unfavorable groups for predicting early death ranged from 8% (Rades) to 38% (RPA) and 
85% (GPA) to 98% (Rades), respectively (Table 3). 
A total of 135 (39%) patients of the entire population had a survival exceeding 12 
months. The median survival in the most favorable groups ranged from 13.4 to 24.3 
months in the eight prognostic scoring systems. The percentage of patients included in 
the most favorable prognostic groups, actually surviving more than 12 months (positive 
predictive value) following RS varied between 49% (Rades) and 74% (GPA). The sensitivi-
ty and specificity of the favorable groups for predicting long-term survival ranged from 
10% (GPA) to 69% (Rades) and 62% (Rades) to 98% (GPA) (Table 3). 
DISCUSSION 
To our knowledge, this is the first study to systematically evaluate the predictive value 
of all currently known prognostic classification systems for BM in a homogeneous co-
hort of RS patients. In these patients treated with RS as a single modality the prognostic 
value of the well-known factors performance status, presence or absence of extracrani-
al metastases and age were confirmed. In addition, primary tumor site, sex, and re-
sponse to treatment with steroids were independent prognostic factors for survival. The 
multitude of independent prognostic factors [17] underscores the need for a relatively 
simple prognostic scoring system to aid clinicians in decision making. The RPA, originally 
described in 1997 by Gaspar et al., remains the most commonly used scoring system; 
however, it has been criticized because of the large proportion of patients included in 
the intermediate groups, limiting its use in clinical practice. In recent years several al-
ternative scoring systems have been described, but it remains unclear whether these 
perform actually better than the RPA [9]. Similar to what has been previously reported, 
almost two thirds of our patients in this RS cohort were classified in the intermediate 
RPA class II. However, all other classification systems also suffered from the limitation of 
an unbalanced proportion of patients within prognostic classes (Fig. 2). 
All scoring systems were highly predictive for survival, and the survival data are in good 
agreement with previously reported series. In clinical practice it may be useful to identi-
fy patients who are likely to have short survival as this could avert overtreatment with 
unjustified patient burden and health economic costs. The patient numbers in the unfa-
vorable groups were relatively small for all scoring systems with a median OS ranging 
Chapter 2 
28 
from 2.6 to 5.0 months. As patients in very poor condition or with fast progressive ex-
tracranial disease are not considered candidates for RS at our center, the unfavorable 
study patients constitute a sub-selection which may explain the relatively low sensitivity 
for predicting early death in the unfavorable groups. However, it may be even more 
important not to exclude patients from RS as a result of an incorrect prediction of early 
death. In regard of the latter, a high specificity (i.e. a low false positive rate) of the unfa-
vorable classes in predicting early death may be considered the most valuable outcome 
measure. This specificity for predicting early death was high for all scoring systems, 
ranging from 85% to 98%, which is comparable the specificity rates reported previously 
by Nieder et al. [18]. 
 
 
Figure 2 Overall survival for eight prognostic scoring systems 
 
Similarly, it is important to identify patients who are likely to have long-term survival 
and may therefore be potential candidates for more aggressive intracranial- and extra-
cranial treatment. Patients in the most favorable classes of the tested scoring systems 
had a 12-month survival rate between 49% and 74%. However, as a result of the varying 
proportions of patients included in these most favorite classes, the sensitivity for pre-
dicting 1 year survival ranged significantly from 10% to 69%, in comparison to 29% for 
the RPA system. 
It remains difficult to draw firm conclusions as to which classification system performs 
overall best based on the available data and analysis. All systems shared the limitation 
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of an unbalanced proportion of patients within prognostic classes and all were highly 
correlated with overall survival. As was found in a recent review, the Rades, and GGS 
scores generally correlated best with the most relevant clinical endpoints of early death 
and long term survival, but the benefits of these scoring systems were modest [19]. In 
the absence of information that clearly demonstrates superiority, it seems preferable to 
retain the most widely used and relatively simple RPA classification system. Yamamoto’s 
suggestion to further subdivide the intermediate RPA class II based on performance 
score, primary tumor control, extracranial metastases and number of BM [20] adds to 
the complexity of the RPA system. The application of this modified RPA resulted in a 
balanced distribution of RS patients within the five subgroups, and the survival curves of 
these subgroups were significantly separated (Supplementary Table online available). 
However, just as was the case for the newer four-tiered prognostic scoring systems 
such as the BSBM, GPA, DS-GPA, and GGS, this does not improve the identification of 
poor- respectively long prognosis patients. 
The limitations of this retrospective study include the relatively low number of patients 
in comparison with the original reports of other various classification systems [5], [10], 
[13], [14] and [15], which most often included more than 1000 patients. Secondly, the 
pre-selection of patients suitable for RS explains the relatively small proportion of pa-
tients in the poor prognosis classes, and the results of our study cannot be extrapolated 
to all BM patients. 
 
Supplementary table Modified RPA classification according to Yamamoto et al.(20) Legend: N=number of 
patients; OS=median overall survival 
RPA group N   (% of all 380 pts) OS (months) Death ≤ 3 months Survival ≥12 months 
I (favorable) 66 (17%) 15.0 12% 60% 
IIa 50 (13%) 10.2 10% 41% 
IIb 102 (27%) 8.1 14% 42% 
IIc 92 (24%) 5.7 34% 29% 
III (unfavorable) 70 (18%) 3.2 47% 20% 
 
In conclusion, all eight prognostic scoring systems correlated very well with OS but 
shared the limitation of an unbalanced proportion of patients within prognostic classes. 
As the clinical superiority of more recently developed prognostic scoring systems was 
modest, the well-known and easy to use RPA system currently remains the standard for 
patients with BM treated with RS. 
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ABSTRACT 
Purpose. The objective of this investigation was to identify independent pretreatment 
factors that predict for control of local brain metastases (BM) in a large single-
institution series of patients receiving stereotactic radiosurgery (SRS). Recursive parti-
tioning analysis was used to potentially identify a class of patients with durable lesion 
control characteristics. 
Methods. A retrospective SRS database containing baseline characteristics, treatment 
details, and follow-up data of newly diagnosed patients with 1–3 BM (on magnetic res-
onance imaging) treated with linear accelerator-based SRS was created. Three study 
endpoints were used: time to progression (primary endpoint, individual lesion progres-
sion; n 536), time to first progression (secondary endpoint, first lesion progression on 
an individual patient basis; n  380), and overall survival (secondary endpoint; n 380). 
Recursive partitioning analysis (RPA) was performed to identify predictors of time to 
progression. Results. Multivariable analysis demonstrated that lesion aspect/ phenotype 
and radiotherapy schedule were independent factors associated with both progression 
outcomes. Presence of tumor necrosis was found to be associated with a significant 
hazard of progression (hazard ratio 3), whereas use of the most intense radiotherapy 
fractionation schedule (21 Gy in one fraction) was associated with significant reductions 
in progression (hazard ratio 0.3). RPA using SRS dose and lesion aspect/phenotype was 
created and described three distinct prognostic groups. 
Conclusions. RPA of a large retrospective database of patients receiving SRS confirmed 
previous observations regarding the importance of SRS dose and lesion aspect/ pheno-
type in lesion control and overall survival. The SRS lesion analysis may help to stratify 
future clinical trials and better define patient care options and prognosis.  
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IMPLICATIONS FOR PRACTICE 
The importance of this work is primarily in the confirmation of previously reported as-
sociations between lesion dose and MRI phenotype with local lesion control after stere-
otactic radiosurgery. This manuscript extends these associations into a clinical useful 
risk stratification system to relate how lesion dose and MRI phenotype can relate to 
lesion control and overall survival. This new risk stratification system may assist in clini-
cal care and clinical trial design by better defining expected treatment outcomes after 
stereotactic radiosurgery.  
INTRODUCTION 
The diagnosis of brain metastases (BM) is frequently related to the natural history of 
the spread of many primary tumors, including those arising in the lung, breast, colorec-
tal, renal, and skin (i.e., melanoma) [1]. Development of metastatic disease in the brain 
can lead to clinically significant reductions in health-related quality of life, neurologi-
cal/neurocognitive compromise, and life expectancy [2]. Treatment selection is highly 
dependent on pretreatment clinical factors, prognosis (as estimated by various pub-
lished risk stratification prognostic indices), and patient treatment preferences [3, 4].  
A published randomized controlled trial (RCT) comparing whole brain radiotherapy 
(WBRT) plus stereotactic radiotherapy (SRS) boost versus WBRT alone supported the 
use of the SRS technique in oligometastatic (1–3 brain metastases ≤3.0 cm) patients [5]. 
This clinical trial demonstrated clinically important improvements in lesion control, 
performance status, and survival (in the solitary metastasis subgroup). Subsequent 
published RCTs have addressed the issue of whether or not the WBRT component is 
advisable for the initial treatment of de novo brain metastases [6–9]. In general, inclu-
sion of WBRT has been shown to improve regional intracranial control but at the ex-
pense of additional neurocognitive effects.  
Durable lesion control, ideally lasting during the expected patient lifespan, is an im-
portant goal of high-quality SRS to prevent symptomatic recurrence that would man-
date consideration of one or more salvage procedures including WBRT, neurosurgical 
resection, and various forms of drug therapy [10]. Various investigations have been 
published on the topic of predictive factors associated with lesion control in the context 
of SRS treatment [11–18]. Factors that have been shown in at least one publication to 
be a significant predictor of lesion control include lesion dose, lesion radiological char-
acteristics (i.e., lesion aspect), lesion target volume, patient performance status, pres-
ence of extracranial disease, cancer histology, and inclusion of WBRT.  
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The objective of this investigation is to identify independent pretreatment factors that 
predict for lesion control in the context of a large single-institution series of SRS for 
brain metastases. Recursive partitioning analysis was used to potentially identify a class 
of patients with durable lesion control characteristics. Our findings are discussed in the 
context of previously published investigations.  
METHODS 
The SRS database contains baseline characteristics, treatment details, and follow-up 
data of patients who were newly diagnosed with BM and treated with linear accelerator 
(LINAC)-based SRS. Patients with 1–3 newly diagnosed BM (including those near the 
brainstem and posterior fossa) that were confirmed on high-resolution contrast-
enhanced magnetic resonance imaging (MRI) were eligible for single-modality SRS. 
Patients with recurrent disease after previous radiotherapy were not included in this 
series.  
SRS was delivered using five dynamic conformal arcs either on a Novalis linear accelera-
tor (2002–2008) or a Novalis TX linear accelerator (2008 onwards; BrainLAB, Feldkir-
chen, Germany). Patient fixation was performed using the relocatable Gill-Thomas-
Cosman frame (2002–2008) or with BrainLAB's frameless mask system (2008 onwards; 
BrainLAB, Feldkirchen, Germany).  
The SRS target volumes consisted of the outer contrast-enhancing border of the lesions 
contoured on the planning MRI with a 1-mm margin to correct for residual setup error. 
All lesion target volumes were prescribed to the 80% isodose line. SRS was generally 
prescribed using a prospectively defined risk-adapted fractionation scheme, with the 
smallest lesions (≤7.5 cm3) receiving 21 Gy, lesions measuring 7.5–25 cm3 or those BM 
adjacent to the brainstem receiving 18 Gy, and the largest lesions (>25 cm3) receiving 
either a single fraction of 15 Gy or 24 Gy in three fractions of 8 Gy. The prescription 
dose was always determined after contouring the target volume in the planning system. 
Because brain metastases are often spherical, the 21-Gy cutoff value generally corre-
sponds to lesions with a maximum diameter of approximately 2.5 cm; the 18-Gy cutoff 
value corresponds to lesions of approximately 3.6 cm.  
The recommended follow-up for patients receiving SRS consisted of clinic visits includ-
ing neurological examination with contrast-enhanced MRI every 3 months during the 
first 2 years, followed by clinic visits and MRI scans every 6 months thereafter. The me-
dian follow-up duration of the database calculated using the reverse Kaplan-Meier 
method was 32 months [19].  
Lesional aspect was classified based on the pattern of contrast enhancement on gado-
linium-enhanced T1 sequences of the MRI, as was previously described by Goodman et 
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al. [18]. Lesions were classified as follows: (a) lesions with homogeneous (i.e., uniform) 
contrast enhancement; (b) lesions with heterogeneous contrast enhancement, if there 
were areas of nonhomogeneous contrast enhancement; (c) thin-walled cystic lesions 
(either simple cystic or multicystic); and (d) lesions with a necrotic center. Radiological 
evidence of lesional progressive disease was defined according to the criteria described 
by Shiau et al. [17] and specifically was defined as “at least 25% increase in the product 
of three perpendicular diameters (craniocaudal, anterior-posterior, and mediolateral)”. 
Date of death and intracranial and extracranial disease status at time of death was also 
captured in the retrospective database.  
Endpoints  
Three separate endpoints were used in conjunction with this predictive analysis. Time 
to progression (n = 536 lesions) was the primary endpoint, defined as time from initia-
tion of stereotactic radiosurgery to development of progressive disease on a per-lesion 
level. Each lesion was evaluated according to the previously described follow-up guide-
lines to determine whether or not radiological and/or clinical evidence of progressive 
disease was indeed present (yes/no) as well as the date of evaluation.  
Time to first progression (n = 380 patients) was one of the secondary endpoints. This 
endpoint was derived from the time-to-progression endpoint at a per-patient level. 
Patients were first evaluated as having either progressive intracranial disease at any 
lesion/site (yes/no), then further evaluated to determine in which lesion(s) progression 
first occurred. If two or three lesions showed progression at same time, the largest 
lesion was used in the final analysis [20]. This analysis was performed to further assess 
the stability of findings from the primary analysis of time to progression (per lesion) in 
terms of possible nonindependence issues resulting from the inclusion of more than 
one lesion per patient.  
Survival (n=380 patients) was used as the other secondary endpoint. Survival was de-
fined as time from initiation of stereotactic radiosurgery to date of last follow-up and/or 
death, whichever came first. This endpoint was reported for descriptive purposes only 
and was not used for any predictive modeling.  
Statistical Methodology  
Univariable Cox regressions were constructed for time to progression (model 1) and 
time to first progression (model 2) to identify significant predictors of progressive dis-
ease; they were performed at the lesion level (n = 536) and patient level (n = 380), re-
spectively. Multivariable Cox regression analyses were performed, incorporating all 
factors found to be somewhat significant from univariable Cox regression (i.e., p < .30), 
followed by automated backward elimination technique to sequentially remove factors 
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until all remaining covariates had p values less than .15. Adjustment for clustering was 
performed for univariable and multivariable analyses related to time to progression due 
to the fact that each patient contributed different numbers of lesions to the analysis.  
Recursive partitioning analysis (RPA) was performed at the lesion level (n = 536), incor-
porating significant predictors identified from multivariable Cox regression (model 1 
factors: lesion radiological phenotype [aspect] and radiation dose) [21]. The SRS lesion 
RPA was performed in two ways: (a) primarily as a time-to-event outcome (taking into 
account time to progressive disease) and (b) modeling progressive disease as a binary 
outcome (yes/no) to assess the robustness of the SRS lesion RPA model created. Kaplan-
Meier estimates of time to progression (n = 536) and time to first progression (n = 380) 
were performed. Kaplan-Meier estimates stratified by baseline characteristics and pro-
posed SRS lesion RPA stratifications were also calculated (for all three endpoints includ-
ing overall survival) and different classes were compared using log-rank test statistic. 
Statistical analysis was performed using SAS (version 9.2; SAS Institute, Cary, NC) and 
the open-source R software platform (www.r-project.org).  
RESULTS 
Between December 2002 and July 2011, a total of 380 patients with 536 newly diag-
nosed BM were treated with LINAC-based SRS as a single modality. Patient, tumor, and 
treatment-related descriptive statistics organized per patient (n = 380) and per lesion (n 
= 536) are summarized in Table 1. A variety of dose fractionation schedules were used 
for the 536 lesions treated: 21 Gy in one fraction (292 lesions, 54.5%), 18 Gy in one 
fraction (170 lesions, 31.7%), 24 Gy in three fractions (47 lesions, 8.8%), and 15 Gy in 
one fraction (27 lesions, 5.0%). Progressive disease was identified in 71 of 536 lesions 
(13%) in 65 of 380 patients (17%). Fifty-five patients (15%) were alive at last follow-up.  
 
Table 1 Baseline characteristics of patients and lesions   
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Results from the univariable Cox regression analysis for both the lesional (time to pro-
gression) and patient (time to first progression) analyses are depicted in Table 2. Results 
of multivariable Cox regression analysis for both time to progression and time to first 
progression are summarized in supplemental online Tables 1 and 2, respectively. Both 
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models demonstrate that lesion aspect/phenotype and radiotherapy schedule are inde-
pendent factors associated with both progression outcomes. Presence of tumor necro-
sis was found to be associated with a significant hazard of progression (hazard ratio >3), 
whereas use of the most intense radiotherapy fractionation schedule (21 Gy in one 
fraction) was associated with significant reductions in progression (hazard ratio <0.3).  
 
Table 2 Univariable Cox regression models examining relationship between individual predictors of time to 
progression (n=536) and time to first progression (n=380) 
 
 
Kaplan-Meier curves for all eligible patients and subdivided into relevant groups for 
both progression outcomes are summarized in supplemental online Fig. 1. As depicted 
in Fig. 1, SRS lesion RPA time-to-event and binary analyses partitioned the patient popu-
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lation into four possible groupings based on radiotherapy schedule (21 Gy in one frac-
tion vs. the other less intense regimens) and lesion aspect/phenotype (different combi-
nations observed; however, the 21 Gy/1 fraction arm was split identically between 
homogeneous/heterogeneous vs. cystic/necrotic). Kaplan-Meier curves for each of the 
SRS lesion RPA groups were created for both progression outcomes using both RPA 
approaches (time to event and binary; Fig. 2).  
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Inspection of these Kaplan-Meier depictions demonstrated that three distinct groups of 
patients were present: a good prognosis group (group 1), intermediate groups consist-
ing of the two middle SRS lesion RPA groups (groups 2 and 3), and a poor prognosis 
group (group 4). Individual Kaplan-Meier progression curves for each aspect/phenotype 
combination with the 21 Gy/1 fraction schedule versus other fractionation schedules 
are shown in supplemental online Fig. 2. Supplemental online Fig. 3 summarizes the 
Kaplan-Meier overall survival curves for all patients and curves divided by lesion/aspect 
and highest radiation biological equivalent dose fractionation. Kaplan-Meier overall 
survival estimates were affected by the SRS lesion RPA group, with a statistically signifi-
cant log-rank test (p = .05) in terms of overall survival.  
 
 
Figure 2 Time to progression (n = 536) and time to first progression (n = 380) Kaplan-Meier curves for derived 
recursive partitioning classes. Legend: RPA, recursive partitioning analysis; SRS, stereotactic radiosurgery. 
Legend: RPA, recursive partitioning analysis; SRS, stereotactic radiosurgery 
DISCUSSION 
This study summarized the progression and survival outcomes of a large SRS database, 
with a particular focus on the determination of factors that predict for brain metastasis 
local lesion control. Lesion aspect/phenotype and radiation dose schedule were both 
found to be critical independent factors both in the prediction of time to lesion progres-
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sion and also time to first lesion progression at the patient level. The presence of extra-
cranial disease was found to have a borderline significant effect on radiological confir-
mation of lesional progression. This may be due to a confounding effect in which pa-
tients with extracranial disease may suffer from extracranial progression and death 
prior to intracranial lesion progression. Regine et al. previously observed this relation-
ship in a cohort of 36 patients in which presence of extracranial disease reduced the 
rate of observed symptomatic brain recurrence by more than half [13]. Tumor histology 
was not found to inform the SRS lesion RPA despite statistical significance on univaria-
ble analysis. It is hypothesized that, in the context of SRS dosing, histology may not be 
important given the ablative doses being used and/or that the prognostic impact of 
histology may be exerted indirectly through lesion phenotype (i.e., necrotic lesions) 
having inferior local control.  
An RPA approach was used to further investigate the relationship between lesion as-
pect/phenotype and RT schedule with progression outcomes. This analysis demonstrat-
ed that three distinct groups exist that predict for time to progression, time to first 
progression, and overall survival. Specifically, this SRS lesion RPA has identified a high-
risk subgroup of patients that potentially do not fully benefit from SRS therapy. This 
high-risk patient population may have been alternatively treated with whole brain radi-
otherapy alone, with the potential advantages of treatment simplicity and lower cost 
and/or resource expenditure (dependent on practice setting). However, it is important 
to note that identifying this high-risk patient population may lead to future treatment 
innovation research. The therapeutic ratio could be improved by optimization of dose 
escalation, dose targeting, treatment delivery, and novel drug therapy.  
The three SRS lesion groups are summarized as follows:  
1. Low progression risk: Homogeneous or heterogeneous lesion treated with 21 Gy in 
one fraction 
2. Intermediate progression risk: Any cystic lesion treated between 15–21 Gy in one or 
24 Gy in three fractions or necrotic lesions treated with 21 Gy in 1 fraction or homo-
geneous lesions treated with 15–18 Gy in one fraction or 24 Gy in three fractions  
3. High progression risk: Heterogeneous or necrotic lesions treated with 15–18 Gy in 
one fraction or 24 Gy in three fractions 
Shiau et al. previously reported the interaction of radiotherapy schedule and lesion 
aspect on lesion control [17]. In this retrospective series of 119 patients with 219 le-
sions treated with SRS from 1991–1994, patients were treated with a median SRS dose 
of 18.5 Gy (range: 10–22 Gy) with a median lesion size of 1.3 cc (range: 0.02–30.9 cc). 
Multivariable Cox proportional hazards analysis demonstrated that SRS dose ≥18 Gy, 
lesion aspect/phenotype, and interval between diagnosis and SRS therapy were inde-
pendent predictors of freedom from progression. The authors suggest that SRS dose 
could be a surrogate for lesion dose; however, tumor volume was not found to be inde-
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pendently significant on multivariable analysis. Our analysis further demonstrated a 
correlation between SRS dose and lesion size and identified SRS dose as the independ-
ent predictor of progression over lesion size.  
Other investigators have studied the interaction of SRS dose, lesion size, and various 
patient outcomes [11, 12, 14]. Breneman et al. published a predictive analysis of 84 
patients and 145 lesions, which observed that patients receiving SRS dose ≥18 Gy 
and/or melanoma histology had improved local control. Similarily, Schomas et al. [14] 
observed that dose prescription, minimum tumor dose, histology, and tumor volume 
were predictive of local control on univariable analysis. Minimum tumor dose was the 
only factor predictive of local control on multivariable analysis (p = .03).  
Molenaar et al. also observed that SRS dose, planning target volume, and patient per-
formance status were predictive of time to local failure [12]. Shetata et al. suggested 
that the use of whole-brain radiation therapy in conjunction with SRS improved lesion 
control [15]; however, this claim has not been reported elsewhere in literature. A sys-
tematic review formally exploring the relationship between dose and local control was 
conducted by Wiggenraad et al. [16]. This review assessed 11 papers and demonstrated 
that 6-month local control was greater than 80% irrespective of SRS dose fractionation 
schedule. One-year local control rates with single-dose SRS treatment were observed to 
be more variable and depended on dose: >80% for ≥ 21 Gy), >60% for ≥18 Gy), and 
<50% for <15 Gy.  
The major limitation of this work is that the database is derived from a retrospective 
analysis of patients who received SRS. Mitigating the issue of the retrospective nature 
of the database was the prospective approach regarding patient selection, treatment 
simulation/delivery, dose-fractionation selection, and follow-up procedures relating to 
this patient population. Future work in this area will include validation of our findings in 
other existing SRS databases. Additionally, modeling of regional (out-of-field) failure risk 
may provide insight into patients better served with the integration of whole-brain 
radiation therapy in conjunction with SRS therapy.  
CONCLUSIONS 
A recursive partitioning analysis of a large retrospective SRS database has confirmed 
previous observations regarding the importance of SRS dose and lesion as-
pect/phenotype in lesion control. The SRS lesion RPA describes three distinct prognostic 
groups of patients in terms of time to lesion progression. Use of the SRS lesion RPA 
groups also predicted for overall survival using an actuarial log-rank test analysis. The 
SRS lesion RPA analysis may help to stratify future SRS clinical trials and better define 
patient care options and prognosis in conjunction with SRS therapy.   
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ABSTRACT 
Purpose This investigation defined patient populations at high-, intermediate-, and low-
risk of regional failure (RF) after stereotactic radiosurgery (SRS) lesion treatment using 
clinical nomograms and recursive partitioning analysis (RPA). 
Methods and materials We created a retrospective database compiling 361 oligometa-
static brain metastases patients treated with single-modality Linac-based SRS. Logistic 
analysis was performed to identify factors to be included in a RPA to predict for cumula-
tive RF at 1-year. A 1-year cumulative RF clinical nomogram was constructed and vali-
dated (c-index statistic). 
Results Age, number of brain metastases, World Health Organization (WHO) perfor-
mance status (PS), and maximum gross tumor volume (GTV) size were found to be sta-
tistically significant predictors of the primary outcome. RPA classifications were defined 
as follows: low-risk (<25% 1-year RF): solitary lesion AND age >55Y; intermediate-risk 
(25–40% 1-year RF): age 65 years AND solitary lesion OR WHOP1 AND 2–3 lesions; and 
high-risk (>40% 1-year RF): WHO PS = 0 AND 2–3 lesions. These classifications were 
highly statistically significant (p < 0.01) for RF. A clinical nomogram (containing patient 
age, lesion number, largest GTV volume, and WHO PS) for the prediction of 1-year cu-
mulative RF was created (c-index 0.69). 
Conclusion A risk-adapted treatment approach can be applied for BM radiosurgery ei-
ther using RPA categories and/or nomogram-based risk estimates. 
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INTRODUCTION 
In patients with a limited number (1–3) of small (≤4.0 cm) brain metastases (oligometa-
static brain disease), the use of SRS with WBRT versus WBRT alone has been shown to 
be associated with improvements in various clinical outcomes including: lesion control, 
performance status, and survival (for the solitary brain metastasis sub-population) [1]. 
Clinical information on the comparison of SRS lesional treatment without WBRT sug-
gests equivalent survival outcome with a potential improved survival for subpopulations 
of patients with superior prognostic factors (younger age, good performance status, 
lack of extracranial progressive disease, and fewer brain metastases) [2] and [3]. 
Other clinical investigations have studied whether or not the addition of upfront WBRT 
to SRS treatment is warranted to improve the therapeutic ratio of SRS therapy [4], [5], 
[6], [7], [8], [9], [10], [11], [12] and [13]. These investigations do demonstrate a reduc-
tion in intracranial local and regional failure but have failed to convincingly show a sur-
vival benefit associated with the use of WBRT in this setting [14]. Furthermore, the 
negative neurocognitive impacts associated with the utilization of WBRT have led to a 
controversy regarding the optimal management of this patient population [15] and [16]. 
A significant gap in the medical literature exists with regard to models for regional fail-
ure risk prediction. Such models would support physician and patient decision-making 
regarding the potential utility of the WBRT component of SRS treatment of oligometa-
static brain disease. Therefore, the purpose of this investigation is to report a clinical 
nomogram risk calculator and a recursive partitioning analysis (RPA) based risk stratifi-
cation system for the prediction of 1-year regional brain failure post-SRS treatment 
without WBRT. 
METHODS AND MATERIALS 
SRS database 
The SRS database contains baseline characteristics, treatment details, and clinical out-
come follow-up (death, intracranial local and regional failure) data of newly diagnosed 
BM patients from solid tumors treated with Linac-based SRS for up to three brain me-
tastases without whole brain radiotherapy, which have been previously published after 
local Institutional Review Board approval [17], [18] and [19]. The median actuarial fol-
low-up duration of the database calculated using the reverse Kaplan–Meier method was 
32 months [20]. 
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Endpoints 
Four separate endpoints (one primary and three secondary) were utilized in conjunction 
with this predictive analysis. The primary endpoint for this analysis was cumulative re-
gional failure (RF) at 1-year (binary variable, n = 361 patients), This was was defined as 
the presence of at least one regional failure occurring outside of the 95% PTV isodose 
line of the treated lesions and occurring within one year of initiation of stereotactic 
radiosurgery. The 1-year time-point was selected prior to any statistical analysis in order 
to balance a clinically relevant cut-point (that may compel a clinician to either in-
clude/exclude WBRT) with having enough events for appropriately powered statistical 
modeling. All patients in this investigation had baseline MRI and CT imaging reviewed by 
study investigators in order to ensure the absence of any untreated le-
sions/abnormalities at the time of stereotactic treatment planning. Secondary end-
points included overall survival, time to regional failure, and cumulative regional failure. 
Statistical methodology 
Univariable logistic and Cox regressions were constructed to identify significant predic-
tors of 1-year RF and time to 1-year RF, respectively. Predictors assessed in this investi-
gation included: age, gender, primary tumor site, primary tumor activity (con-
trolled/resected vs. other), histology, systemic metastases status, World Health Organi-
zation performance status, treatment year, gross tumor volumes (GTV, maximum, min-
imum, and total), use of systemic therapy, and SRS RT schedule. Multivariable logistic 
and Cox regression analyses were performed, incorporating all factors found to be sig-
nificant from univariable logistic and Cox regressions respectively (i.e. p < 0.05). Nomo-
grams based on statistically significant factors identified from multivariable logistic 
modeling of 1-year regional failure probability were constructed. 
To internally validate the nomogram, 10-fold cross-validation techniques were used as 
described by Iasonos et al. [21]. The nomogram was also validated in terms of calibra-
tion, the extent to which the observed 1-year RF was over- or under-estimated by the 
nomogram. Receiver operator curves (ROC) and bias corrected concordance indices (c-
index) were calculated for the multivariable logistic model, nomogram, and constituent 
variables. 
Recursive partitioning analysis (RPA) was performed, incorporating significant predictors 
identified from univariable logistic regression (age, number of brain metastases, WHO 
PS, and maximum GTVsize), modeling RF at 1-year as a dichotomous outcome. Kaplan–
Meier estimates were generated for both RF and OS endpoints, utilizing the log-rank 
test to explore differences in outcome between the different risk classifications. The 
RPA generated in this analysis was compared to a pre-existing system described by 
Rades et al. [22] for the prediction of total intracranial failure to gauge the potential 
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improvement in classification. Comparison of the RPA to the Rades system was accom-
plished by calculation of operating characteristics for 1-year regional failure, area under 
the receiver operator curve, log-rank testing of Kaplan–Meier curves for regional failure, 
as well as the calculation of the Net Reclassification Improvement parameter [23]. 
All general statistical analyses were performed using SAS 9.2 Software (SAS institute, 
Cary, NC) and the R language environment for statistical computing (open source, 
www.r-project.org), using two-sided statistical testing at the 0.05 significance level. 
Recursive partitioning analysis, nomogram and bias-corrected concordance indices (c-
index) obtained using R. 
RESULTS 
Between December 2002 and July 2011, a total of 361 patients with 508 newly diag-
nosed BM were treated with linac-based SRS as a single modality. Patient, tumor, and 
treatment-related descriptive statistics are summarized in Table 1. Dose fractionation 
schedules were as follows: 21 Gy/1 fraction (171/361 – 47.4%), 18 Gy/1 fraction 
(129/361 – 35.7%), 24 Gy/3 fractions (39/361 – 10.8%), and 15 Gy/1 fraction (22/361 – 
6.1%). RF was identified in 115/361patients (31.9%), 90/361 patients (24.9%) within 1-
year of follow-up, and 54/361 (15.0%) within 6-months of follow-up. Fifty-five (15%) 
patients were alive at the last follow-up. 
 
Table 1 Baseline characteristics of all patients (n=361) stratified by 1 year regional failure status (yes/no) 
Characteristic All patients 
(n = 361) 
1-YEAR Regional Failure p-Value 
Yes (n = 90) No (n = 271) 
Age – mean ± SD, median, (min, max) 61.28 ± 11.66 
61.33 
(16.47, 89.10) 
58.70 ± 10.56 
59.34 
(28.87, 86.03) 
62.14 ± 11.90 
62.25 
(16.47, 89.10) 
0.015 
≤55 113 (31.3) 38 (42.2) 75 (27.7)  
>55 to ≤65 112 (31.0) 25 (27.8) 87 (32.1)  
>65 to ≤75 92 (25.5) 22 (24.4) 70 (25.8)  
>75 44 (12.2) 5 (5.6) 39 (14.4)  
Male – n (%) 168 (46.5) 38 (42.2) 130 (48.0) 0.344 
Primary tumor – n (%) 
Lung 206 (57.1) 48 (53.3) 158 (58.3) 0.553 
Breast 38 (10.5) 11 (12.2) 27 (10.0)  
Renal/adrenal? 27 (7.5) 10 (11.1) 17 (6.3)  
Colon 29 (8.0) 7 (7.8) 22 (8.1)  
Melanoma 23 (6.4) 7 (7.8) 16 (5.9)  
Other 38 (10.5) 7 (7.8) 31 (11.4)  
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Characteristic All patients 
(n = 361) 
1-YEAR Regional Failure p-Value 
Yes (n = 90) No (n = 271) 
Histology – n (%) 
Adenocarcinoma (non-lung) 163 (45.2) 48 (53.3) 115 (42.4) 0.170 
NSCLC 118 (32.7) 21 (23.3) 97 (35.8)  
Melanoma 23 (6.4) 7 (7.8) 16 (5.9)  
Squamous (non-lung) 21 (5.8) 4 (4.4) 17 (6.3)  
Renal/adrenal 12 (3.3) 5 (5.6) 7 (2.6)  
Other 24 (6.7) 5 (5.6) 19 (7.0)  
Number of brain metastases – n (%) 
1 232 (64.3) 44 (48.9) 188 (69.4) < 0.001 
2 or 3 129 (35.7) 46 (51.1) 83 (30.6)  
Active primary tumor – n (%) 168 (46.5) 39 (43.3) 129 (47.6) 0.482 
Systemic metastases – n (%) 170 (47.1) 40 (44.4) 130 (48.0) 0.562 
Location – n (%) 
Supra (tentorial?) 269 (74.5) 65 (72.2) 204 (75.3) 0.297 
Infra 55 (15.2) 12 (13.3) 43 (15.9)  
Both 37 (10.3) 13 (14.4) 24 (8.9)  
WHO performance status – n (%) 
0 78 (21.6) 30 (33.3) 48 (17.7) 0.003 
1 215 (59.6) 51 (56.7) 164 (60.5)  
2 57 (15.8) 9 (10.0) 48 (17.7)  
3 11 (3.1) -- 11 (4.1)  
Treatment year – n (%) 
2002–2004 69 (19.1) 23 (25.6) 46 (17.0) 0.130 
2005–2007 121 (33.5) 32 (35.6) 89 (32.8)  
2008–2009 102 (28.3) 18 (20.0) 84 (31.0)  
2010–2011 69 (19.1) 17 (18.9) 52 (19.2)  
GTV (Max) – mean ± SD, median, (min, max) 7.64 ± 7.30 
5.60 
(0.10, 44.70) 
6.14 ± 4.89 
4.80 
(0.10, 21.10) 
8.14 ± 7.90 
6.10 
(0.10, 44.70) 
0.005 
≤2.50 91 (25.4) 23 (25.6) 68 (25.4)  
>2.50 and ≤5.60 90 (25.1) 27 (30.0) 63 (23.5)  
>5.60 and ≤10.80 90 (25.1) 25 (27.8) 65 (24.3)  
>10.80 87 (24.3) 15 (16.7) 72 (26.9)  
Systemic treatment – n (%) 
None 55 (15.2) 9 (10.0) 46 (17.0) 0.279 
Palliative 164 (45.4) 43 (47.8) 121 (44.7)  
Radical 142 (39.3) 38 (42.2) 104 (38.4)  
RT Schedule – n (%) 
15 Gy in 1 fraction 22 (6.1) 6 (6.7) 16 (5.9) 0.509 
18 Gy in 1 fraction 129 (35.7) 32 (35.6) 97 (35.8)  
21 Gy in 1 fraction 171 (47.4) 46 (51.1) 125 (46.1)  
24 Gy in 3 fractions 39 (10.8) 6 (6.7) 33 (12.2)  
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Characteristic All patients 
(n = 361) 
1-YEAR Regional Failure p-Value 
Yes (n = 90) No (n = 271) 
RF RPA – n (%) 
1 68 (18.8) 9 (10.0) 59 (21.8) 0.039 
2 231 (64.0) 62 (68.9) 169 (62.4)  
3 62 (17.2) 19 (21.1) 43 (15.9)  
 
Results from the univariable logistic and Cox regression analyses for RF at 1-year are 
depicted in Table 2. Significant predictors of 1-year RF from univariable logistic regres-
sion were: age (p = 0.016), number of brain metastases (p < 0.001), WHO performance 
status (p = 0.002) and GTV size (p = 0.026). Significant predictors of time to 1-year RF 
from univariable Cox regression only included number of brain metastases (p < 0.001). 
Similar results to the univariable logistic regression were obtained from descriptive 
statistical analysis with age (p = 0.015), number of brain metastases (chi square p < 
0.001), WHO performance status (chi square p = 0.003) and maximum GTV size (chi 
square p = 0.005) remaining significantly associated with 1-year RF (aspect lesion mor-
phology, chi square p = 0.046; and Radiation Therapy Oncology Group Recursive Parti-
tioning Analysis Group, chi square p = 0.039: Table 1). 
 
Results of multivariable logistic and Cox regression analyses incorporating significant 
predictors from univariable analysis are also summarized in Table 2. Significant predic-
tors of 1-year RF from multivariable logistic regression included: number of brain me-
tastases (p = 0.001), WHO performance status (p = 0.017) and GTV size (p = 0.045). 
However, age (p = 0.101) was found to be only of borderline significance. In the context 
of 1-year RF, number of brain metastases was found to also be a significant predictor of 
time to RF (p < 0.001) on multivariable analysis, however age (p = 0.460), GTV size (p = 
0.194) and WHO performance status (p = 0.456) were not predictive of time to RF. 
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A clinical nomogram for the prediction of 1-year regional failure probability was created 
using the primary multivariable logistic regression predictive factors of age, lesion num-
ber, maximum GTV size, and WHO performance status (Fig. 1, see also online supple-
mental materials for a nomogram calculator). The calculated concordance index for this 
nomogram is 0.694, which is superior to the indices of the constituent variables as-
sessed individually (age = 0.596, lesion number = 0.604, GTV size = 0.551, and WHO 
performance status = 0.610, Supplemental Fig. e1). The calibration plot confirmed a 
high correlation between observed and predicted probability (r2 = 0.9647, Supple-
mental Fig. e2). These findings confirm that the four-variable nomogram provides im-
proved predictive ability over any individual variable in isolation. 
 
 
Figure 1 Clinical nomogram for the prediction of 1-year regional failure probability 
 
As depicted in Fig. 2, the RPA analysis for the dichotomous endpoint, 1-year RF, parti-
tioned the patient population into 3 risk strata defined as follows: low-risk (i.e. <25% 1-
year RF): age > 55Y AND solitary lesion; intermediate-risk (between 25% and 40% 1-year 
RF): age ≤ 55Y AND solitary lesion OR WHO ≥1 AND 2–3 lesions; high-risk (i.e. >40% 1-
year RF): WHO = 0 AND 2–3 lesions. The maximum GTV was selected instead of cumula-
tive GTV size for RPA analysis for two reasons: (1) it had favorable statistical properties 
including superior statistical significance upon univariable logistic regression (p = 0.045 
vs. p = 0.074) and lack of redundancy with the number of brain metastases being al-
ready incorporated in the RPA model. 
Comparison of the RPA vs. Rades classification demonstrated superior operating charac-
teristics for the prediction of regional failure at 1-year in favor of the RPA including 
accuracy (75% vs. 66%), positive predictive value (53% vs. 26%), negative predictive 
value (77% vs. 75%) and well as likelihood ratio positive (3.41 vs. 1.04). Area under the 
receiver operator curve for the RPA and Rades classifications were 0.66 and 0.50, re-
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spectively. Net reclassification improvement was in favor of the RPA system (NRI = 
0.30). The Kaplan–Meier curve assessing regional failure at 1-year per Rades group is 
depicted in Supplemental Fig. e3. There was no statistical difference between the low 
and intermediate Rades system groups in terms of regional failure at 1-year (log rank p 
= 0.139) whereas a statistical difference between RPA groups was found (Fig. 3, log rank 
p < 0.001). 
Hazard/odds ratios related to both primary and secondary endpoints comparing inter-
mediate- and high-risk patients against the reference standard low-risk category 
demonstrated stepwise increases in risk for 1-year regional failure and time to 1-year 
regional failure (Supplemental Table e1). Both intermediate- (HR 0.80) and high-risk (HR 
0.77) patients had reduced risk of death compared to the low-risk cohort that was not 
found to reach statistically significant levels (Supplemental Table e1). 
Kaplan–Meier curves for all eligible patients using the proposed RF risk stratification 
system were generated for both time to 1-year RF and OS, as summarized in Fig. 3 and 
Supplementary Fig. e4, respectively. As depicted in these figures, the classification sys-
tem demonstrated sufficient divergence in terms of 1-year RF (log-rank p < 0.001). For 
1-year RF (Fig. 3), each of the risk classifications followed a similar profile during the first 
phase of follow-up (0–3 months due to lack of early post-treatment imaging, see SRS 
database methods), after which stage there was substantial divergence in respective 
risk of RF with 22/164 (13.4%) patients at low-risk, 51/165 (30.9%) patients at interme-
diate-risk, and 17/32 (53.1%) patients at high-risk developing RF within 1-year of initia-
tion of treatment. For OS (Supplemental Fig. e4), there appeared to be a noticeable 
decline in survival among low-risk patients (median survival: 6.67 months) compared to 
intermediate- (9.73 months) and high-risk (8.09 months) patients. This effect was ap-
parent during the entire first two years of follow-up (as shown in Supplemental Fig. e4). 
Actuarial estimates (abstracted from the Kaplan–Meier Curves) for time to regional 
failure and overall survival at 3, 6, 9, and 12 months are summarized in Supplemental 
Table e2. 
DISCUSSION 
Assessment and prediction of clinical outcome after radiotherapy for brain metastases 
are areas of active research in the medical literature [24], [25] and [26]. Four factors 
were found to predict for the presence or absence of regional failure within a year of 
SRS therapy as a single modality; which included patient age, maximum gross tumor 
volume, WHO PS, and the number of brain metastases. Only number of brain metasta-
ses was found to predict for the timing of such a failure within the 1-year time frame 
post-SRS. The clinical nomogram that was created in this investigation incorporates 
each of the four factors as listed previously to calculate a 1-year RF risk probability (Fig. 
A Clinical Nomogram and Recursive Partitioning Analysis to Determine the Risk 
55 
1). Interestingly, smaller GTV size confers a higher RF risk in the multivariable model and 
its associated clinical nomogram. It is hypothesized that patients with one or more 
smaller lesions are likely to have better local control of disease that may provide an 
increased risk of RF to manifest itself. Alternatively, one or more small lesions may pre-
dict for subclinical microscopic disease not detected by baseline MRI imaging; whereas 
patients with larger lesions without additional lesions (detected by baseline MRI) may 
be at lower RF risk due to the true absence of such disease. The lack of impact of extra-
cranial metastases and primary tumor status on 1-year RF suggests that the impact of 
reseeding of the brain from extracranial sites may not be a predominant issue in RF risk. 
A RPA for the risk stratification of 1-year RF was created using the four statistically sig-
nificant multivariable factors as initial input. The RPA had superior operating character-
istic, Kaplan–Meier, and Net Reclassification Improvement properties when compared 
to the Rades system predicting for total intracranial control. This finding is not surprising 
as the RPA was specifically designed to predict for regional failure; whereas, the Rades 
classification was designed to assess total intracranial failure (both lesional and region-
al). Nothwithstanding this issue, this comparison does illustrate the utility of the RPA 
over another pre-existing classification system. 
Interestingly, although the RPA was designed to assess the 1-year timepoint, close in-
spection of the Kaplan–Meier curves in Fig. 3 demonstrate that this RPA system does 
start to discriminate patients into separate risk groups as early as two-month post-SRS. 
Ultimately, a RPA using three factors (age with 55-year cutoff, number of metastases 
with 1 vs. 2/3 metastases cutoff, and WHO PS 0 vs. ≥1, Fig. 2) was created to define 
three distinct risk groupings as follows: 
-  Low-risk (<25% 1-year RF): {Age > 55Y AND solitary lesion} 
-  Intermediate-risk (25–40% 1-year RF): {Age ≤ 55Y AND solitary lesion} OR {WHO ≥ 1 
AND 2–3 lesions} 
-  High-risk (>40% 1-year RF): {WHO = 0 AND 2–3 lesions} 
A risk-stratification RPA approach may be less versatile than a clinical nomogram given 
the lack of a precise estimate of RF risk at 1-year; however, the definition of specific 
groups (with defined outcomes) based on clinically available information at the time of 
patient evaluation for SRS can still be highly attractive to clinicians and for the stratifica-
tion of clinical trials. Clinical management and outcome prediction using risk stratifica-
tion systems are common in the medical literature and in clinical practice with examples 
in brain metastases, prostate cancer, among other cancers. Alternatively, this clinical 
nomogram can provide an estimate of RF at 1-year that can specifically advise physi-
cians and patients on the advisability of integrating upfront WBRT as part of SRS thera-
py. Whereas the RPA risk-stratification system “locks” clinicians to a priori defined 1-
year RF cutoffs of 25% and 40%, clinical nomograms can provide continuous risk esti-
mates for individualized risk assessment and decision-making by clinicians and patients. 
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Specifically, the number of patients needed to observe (NNO, for patients treated with 
SRS without WBRT) to detect one RF at 1-year can be calculated by taking the inverse of 
the clinical nomogram risk estimate. For example, if the clinical nomogram predicts a 
risk of 20% vs. 50% risk of RF at 1-year, the NNO would be calculated at 5 patients and 2 
patients, respectively. This information can be communicated to patients in order to 
make individualized decisions regarding the advisability of WBRT given the known re-
duction of RF risk (estimated to be as high as a 65% relative risk reduction) associated 
with the integration of WBRT with SRS therapy [10] and [14]. 
 
 
Figure 2 Recursive partitioning analysis grouping into three risk categories for the prediction of 1-year regional 
failure risk 
The limitation of this work is that it is based on retrospective single institutional data 
and validation of its findings in an external dataset will need to be performed. Histology 
was not found to be statistically associated with regional risk in this analysis. Further 
analysis of the relationship between specific subtypes of cancer (HER-subtypes of breast 
cancer, adenocarcinoma of lung) as well as other factors described in the literature (e.g. 
extracranial control in NSCLC) to regional failure risk may further shed light on this is-
sue. Other limitations include the lack of robust neurocognitive outcome data and 
WBRT/SRS data in the database to extend our analyses. Future research should contin-
ue to define the indications for the integration of WBRT with SRS therapy in order to 
balance the positive neurocognitive effects of regional control with the negative neu-
rocognitive effects inherent with regional treatment of the cranium. Other modeling 
strategies, such as artificial neural networks, may provide additional insight in optimiz-
ing treatment decision-making for this challenging patient population. Further investiga-
tion to define a very early failure endpoint in terms of timing and extent of relapse 
would be of interest. 
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Figure 3 Kaplan-Meier curve for 1-year regional failure by RPA-risk group 
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Chapter 5 
Patterns of distant brain recurrences after 
radiosurgery alone for newly diagnosed brain 
metastases: Implications for salvage therapy 
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ABSTRACT 
Introduction Single modality radiosurgery (RS) is an established treatment option for 
patients with brain metastases (BM) with the aim of achieving optimal local control 
while avoiding toxicity from whole brain radiotherapy (WBRT). Published studies gener-
ally lack detailed data on distant brain recurrence (DBR) rates and characteristics. This 
study describes the patterns of DBR and consequences for salvage treatment in a group 
of patients treated with RS alone for 1–3 BM. 
Materials and methods Between 2002 and 2012, 443 patients were treated with RS 
alone in doses ranging 15–24 Gy in 1–3 fractions. Patient selection for RS was per-
formed using triple dose gadolinium-enhanced MRI scans, obtained with slice distance 
of 2 mm (until 2008), 1.5 mm (2008–2012), and of 1 mm (from 2012). During follow-up, 
a DBR was observed in 147 patients, but in 20 of these patients (14%) these “new le-
sions” could retrospectively be seen on the planning MRI scan. These missed metasta-
ses had a median size of 2 mm, and in order to study real DBR patterns, these patients 
were excluded from analysis. 
Results Actuarial DBR rates at 6, 12 and 24 months in the remaining 423 patients were 
21%, 41% and 54%, respectively, with a median time to DBR of 5.6 months. In 42% of 
DBR, a single new lesion was seen, in 70% there were ≤3 new lesions. Median diameter 
of the DBR was 6 mm; 97% of lesions were ≤30 mm. Salvage therapy was delivered in 
82% of DBR patients, consisting of WBRT (46%), repeated RS (27%), or systemic treat-
ment (9%). A RPA classification system (DBR-RPA), based on WHO performance status 
and interval between initial RS and diagnosis of DBR, was developed to estimate life 
expectancy after the development of DBR, which can be used to guide salvage therapy. 
Conclusions In this study of patients treated with RS alone, only 25% of treated patients 
needed salvage treatment for DBR, and ultimately only 18% of all patients underwent 
WBRT at any time during follow-up. A three-monthly MRI follow-up scheme identifies 
DBR at an early stage with respect to size and number of lesions, and most patients 
were asymptomatic at radiological diagnosis. 
  
Patterns of distant brain recurrences after radiosurgery alone 
63 
INTRODUCTION 
Radiosurgery (RS) is an established treatment modality for patients with a limited num-
ber of brain metastases (BM) in a good physical condition [1]. After single modality RS 
for oligometastatic BM, there is a substantial risk of developing distant brain recurrenc-
es (DBRs) of 52% up to 76%, which can cause neurologic morbidity or mortality [2] and 
[3]. High resolution imaging is useful to detect DBR at an early stage [4]. The incidence 
of DBR can be reduced by combining RS and whole brain radiotherapy (WBRT), but the 
randomized EORTC 22952–26001 study has confirmed previous reports showing that 
the addition of WBRT does not prolong overall survival in patients with up to 3 BM 
treated with RS or surgery [3] and [5]. Characteristics on DBR and salvage treatments 
have not been reported in detail. 
The frequency of follow-up after RS for BM remains a matter of debate. The ASTRO 
guidelines for follow-up of these patients after RS do not specify the frequency and 
imaging protocol [6]. Within the EORTC 22952–26001 study, patients were imaged at 
every three month follow-up with MRI. At our center, MRI scans are similarly performed 
at 3 monthly intervals during the first 2 years, and every half year thereafter, as long as 
this is indicated by the clinical condition with consequences for salvage therapy. 
This study was performed to assess the characteristics of DBR with respect to number, 
size and timing after RS alone, detected with such systematic follow-up, and to describe 
the frequency of salvage options used in a clinical setting. 
MATERIALS AND METHODS 
Radiosurgery 
In our institutional database, baseline characteristics, treatment details and follow-up 
data of newly diagnosed BM patients treated with Linac-based RS have been collected 
retrospectively [1]. According to our protocol, patients with 1–3 BM are eligible for RS 
as a single modality. Patient selection for RS alone was performed using triple dose 
gadolinium-enhanced MRI scans (1.5–2 Tesla), prior to 2008 obtained with 2 mm slice 
distance, from 2008 to 2011 with 1.5 mm slice distance, and from early 2012 with 1 mm 
slice distance. RS has been delivered using 5 dynamic conformal arcs on a Novalis 
(2002–2008) or Novalis TX (2008 onwards) linear accelerator (BrainLAB AG, Feldkirchen, 
Germany). Patient fixation was performed using the relocatable Gill–Thomas–Cosman 
frame (2002–2008), and as of 2008 using the BrainLAB’s frameless mask system (Brain-
LAB, Feldkirchen, Germany). The RS target volumes consisted of the gross target volume 
contoured on the planning MRI with a 1 mm margin to correct for potential setup-
inaccuracies. RS was prescribed using a ‘risk-adapted’ fractionation, with lesions ≤7.5 
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cm3 receiving 21 Gy prescribed at the encompassing 80% isodose line. For lesions 
measuring 7.5–25 cm3 or BM that were adjacent to the brainstem, the prescription 
dose was 18 Gy at the 80% isodose. For the largest lesions with volumes exceeding 25 
cm3, a single fraction of 15 Gy or 3 fractions of 8 Gy, both prescribed at the 80% isodos-
es were used. Follow-up included clinical visits and MRI scans at three-monthly intervals 
during the first two years of follow-up, and every half year thereafter as long as clinically 
indicated. Additional imaging was performed as indicated by neurological symptoms. 
Follow up MRIs were co-registered with pretreatment planning MRIs to assess whether 
early DBRs had already been visible prior to RS in retrospect. The maximal diameter of 
the largest DBR at first diagnosis was determined on T1 gadolinium-enhanced axial MRI 
slices. The medical chart of the patient was consulted to determine if a patient was 
symptomatic or asymptomatic at the time of diagnosis of DBR. Moreover, considera-
tions regarding the application and outcome of salvage treatments were noted. 
Statistics 
Survival was calculated from the date of RS, survival after DBR was calculated from the 
date of the MRI on which the DBR was diagnosed. Follow-up was calculated with the 
reverse Kaplan–Meier method [7]. Univariable Log-rank test and multivariable Cox re-
gression analysis were used to determine risk factors for death after the diagnosis of 
DBR. Based on 2 significant risk factors for survival after DBR, a recursive partitioning 
analysis was done to divide the population into three groups: favorable, intermediate, 
and poor survival. All statistical analyses were performed using SPSS (version 19.0, IBM), 
using two-sided statistical testing at the 5% significance level. 
RESULTS 
Between 2002 and 2012, a total of 443 patients with 595 newly diagnosed BM were 
treated with RS as a single modality. A total of 147 patients with DBR were identified. 
However, in 20 patients these “DBR” could be seen in retrospect on the stereotactic plan-
ning MRI scan. These missed metastases had a median size of 2 mm, and in order to study 
real DBR patterns, these patients were excluded from analysis. The remaining 423 pa-
tients had a median age of 62 years (range 16 up to 89 years) with the majority of patients 
(59%) having primary lung cancer. In total 271 (64%) of patients underwent RS for a single 
BM, 132 (31%) for two lesions and only 20 (5%) underwent RS for 3 lesions [1]. 
In the 423 analyzed patients, the median overall survival (OS) was 7.9 months, with OS 
rates of 58% and 15% at 6 and 24 months, respectively. The median follow-up duration 
was 29.7 months. A DBR was diagnosed in 127 (30%) of 423 treated patients. The medi-
an time from RS to development of DBR was 5.6 months (range 1.5–57.3 months), with 
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actuarial DBR free survival rates of 79% and 46% at 6 and 24 months, respectively (Fig. 
1). In a previous publication of this cohort of patients, a clinical nomogram was de-
scribed for the prediction of 
 
 
Figure 1 Kaplan–Meyer analysis for risk of DBR after RS for BM (N = 423). Legend: DBR = distant brain recur-
rence, RS = radiosurgery, BM = brain metastases. 
 
At the time of DBR, the majority of patients (70%) had 1–3 new BM, with 42% present-
ing with only a single lesion (Fig. 2A). The median size of the largest new BM was 6 mm, 
with 77% of the patients having a new BM ≤1 cm, 92% ≤2 cm, and 97% ≤3 cm (Fig. 2B). 
Most DBRs were asymptomatic (65%) at the time of diagnosis; in 10% no record on the 
clinical status at the time of DBR could be found. 
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Figure 2 Number (A) of new BM and diameter (B) of the largest BM (N = 127) at diagnosis of DBR. Legend: BM 
= brain metastases, DBR = distant brain recurrence. 
 
The median OS after diagnosis of a DBR was 6.1 months with OS rates of 25% and 7% at 
12 and 24 months, respectively. In both univariate and multivariate analyses, the four 
characteristics that were predictive for survival at the time of diagnosis of DBR were 
WHO performance status, early occurrence of DBR (e.g. within 6 months after RS), di-
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ameter of the largest new brain metastasis, and the presence of extracranial metastases 
(Table 1). 
Based on the above results, a recursive partitioning analysis (DBR-RPA) was developed 
for the prediction of OS after diagnosis of a DBR (Fig. 3). Patients with WHO perfor-
mance status ≥2 were found to have the poorest prognosis with an OS of 3.4 months, 
i.e. DBR-RPA class III. At the next level, patients with WHO performance score 0–1 were 
divided with respect to the interval between the initial RS and the diagnosis of DBR. The 
most favorable subgroup (DBR-RPA class I) was patients with a long interval (i.e. ≥6 
months) who had a median OS of 10.3 months. The intermediate DBR-RPA class II group 
with short interval between RS and DBR had a median OS of 5.4 months. The OS of the 
derived DBR-RPA groups was significantly different; (p < 0.001; Fig. 4). There appeared 
to be a balanced distribution of the DBR population over the prognostic groups, with 45 
(35%) patients in DBR-RPA class I, 40 (32%) patients in DBR-RPA class II, and 42 (33%) in 
DBR-RPA class III. 
Salvage therapy was eventually delivered in 104 patients (82% of DBR patients; 25% of 
all RS patients), consisting of salvage WBRT in 58 patients (46% of DBR patients; 14% of 
all patients), repeat RS in 34 patients (27% of DBR patients; 8% of all patients) or sys-
temic treatment in 12 patients (9% of DBR patients; 3% of all patients). Salvage therapy 
for DBR was more frequently delivered to symptomatic patients (89%) than for asymp-
tomatic patients (75%). Salvage treatment was delivered in 60% (25/42) of DBR-RPA 
class III patients, in 87% (35/40) of RPA class II patients, and in 98% (44/45) of DBR-RPA 
class I patients. For all 127 patients with a DBR, the median OS after repeat-RS was 9.9 
months, after WBRT salvage 6.2 months, and without salvage treatment 3.5 months. 
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Table 1 Prognostic factors for survival after diagnosis of DBR (N=127). Legend: DBR=distant brain recurrence, 
OS=overall survival, NS=non-significant, RS=radiosurgery 
Characteristics of DBR Number of patients Median OS  
(in months) 
p-Value multivariate 
analysis 
Hazard 
ratio 
Number of DBR    NS 
1–2 69 (54%)    
3 or more 58 (46%)    
Diameter of the largest DBR    NS 
<6 mm 57 (45%)    
≥6 mm 70 (55%)    
Time from RS to DBR   <0.001 2.4 
<6 months 65 (51%) 4.0   
≥6 months 62 (49%) 9.5   
Asymptomatic DBR 82 (65%) 8.9 <0.001 1.9 
Symptomatic DBR 32 (25%) 4.9   
Unknown symptomatology 13 (10%) 3.0   
DBR only 107 (84%)   NS 
DBR and local recurrence 20 (16%)    
Age    NS 
<65 years 88 (69%)    
≥65 years 39 (31%)    
Gender    NS 
Male 54 (43%)    
Female 73 (58%)    
WHO performance status at the 
diagnosis DBR 
  0.032 1.7 
0–1 85 (67%) 8.9   
2–4 42 (33%) 3.4   
Primary tumor    NS 
Lung 70 (55%)    
Breast 18 (14%)    
Renal 14 (11%)    
Melanoma 9 (7%)    
Colon 8 (6%)    
Other primary tumors 8 (6%)    
Extracranial metastases   <0.001 2.5 
Yes 78 (61%) 5.8   
No 49 (39%) 9.9   
Primary tumor active    NS 
Yes 71 (56%)    
No 56 (44%)    
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Figure 3 Prognostic classification for survival after diagnosis of DBR (DBR-RPA). Legend: DBR = distant brain 
recurrence, RS = radiosurgery, BM = brain metastases, WHO = World Health Organization performance status, 
RPA = recursive partitioning analysis. 
DISCUSSION 
As a result of several randomized studies, RS alone is the preferred treatment in pa-
tients with a limited number of BM in good performance status. Additional WBRT and 
its associated toxicity can be avoided without compromising survival [3], [9], [10], [11] 
and [12]. RS alone provides high rates of local control with low toxicity, is a non-invasive 
outpatient treatment, however carries a substantial risk of the development of DBR. 
One of the first, although obvious, observations is the importance of high-resolution 
imaging for the selection of RS alone patients, which has been highlighted in the litera-
ture [4]. In 5% of our patients (14% of patients initially diagnosed with DBR), ‘new le-
sions’ were in retrospect already discernable on the planning MRI with a median size of 
2 mm. This incidence of missed BM has decreased dramatically at our center in recent 
years with growing awareness and the introduction of thin-slice high resolution pre-RS 
imaging from 7% (16/230 patients) prior to 2009 to 2% (4/213 patients) after 2009. 
Risk factors for the occurrence of DBR after RS as a single modality for BM have previ-
ously been reported for this patient series and a clinical nomogram has been published 
recently for assessing the risk of DBR from baseline factors, including the number of 
brain metastases, WHO performance status, and the volume of the largest treated BM 
[8]. The actuarial incidence of DBR in this study of 21% and 54% at 6 and 24 months, 
respectively, correlates well with that observed in the RS alone arm of the EORTC 
22952–26001 trial [3]. This incidence has to be viewed with caution as in both studies 
only small proportions (5% and 9% for this study and the EORTC study, respectively) 
underwent RS for three BM. In the JROSG 99-1 study reported by Aoyama et al. [2], a 
higher cumulative incidence of 76% of DBR at 12 months was reported, however, in this 
study only 49% of patients received RS for a single lesion and up to 4 BM were consid-
ered eligible. 
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Routine follow-up after RS alone for BM at our center consists of 3 monthly clinic visits 
combined with MRI for the first 2 years after RS, and every half year thereafter. The 
most recent ASTRO guidelines also recommend regular follow-up after RS procedures, 
but the frequency and imaging protocol were not specifically addressed [6]. In view of 
the median time to the development of DBR of 5.6 months, a three-monthly follow-up 
scheme seems to be a reasonable approach. Not only does such an approach capture 
DBRs at an asymptomatic stage in 65% of patients, but also with a size ≤3 cm in 97% of 
patients, allowing for repeat-RS when indicated by the number of DBR. The observation 
that OS after RS alone is similar to that of RS combined with WBRT, despite a significant 
higher risk of intracranial relapses, has been attributed to effective salvage therapy for 
DBR. Several salvage treatment options are available for DBR such as repeat-RS, WBRT, 
or systemic therapy. The median survival of 6.1 months (and even longer than 1 year for 
selected patients with repeat-RS) underscores the importance of standardized follow-
up allowing for the detection of DBR at an early stage. 
Just as in the primary setting of RS [1] and [13], WHO performance status appeared to 
be the most important prognostic factor for OS at the time of diagnosis of a DBR. Pa-
tients with poor performance status had a median OS of only 3.4 months, despite 60% 
(25/42) of patients receiving some form of salvage therapy. The second most important 
prognostic factor for OS after DBR was the interval between RS and DBR with a longer 
interval being indicative for longer survival. Based on these two prognostic factors a 
prognostic classification system (Fig. 3) was derived with median OS of 3.4, 5.4, and 
10.3 months for DBR-RPA class III, II, and I, respectively (Fig. 4). As there was a balanced 
distribution of patients over the prognostic groups, this prognostic classification system 
could be useful in clinical practice. Though, the unbalanced number of patients having 
received salvage treatment within the described DBR-RPA classes indicates that perfor-
mance status and interval between RS and DBR already were important factors for clini-
cal decision making at our department. This may have biased the results of the DBR-RPA 
classification and this underscores the need for validation of the DBR-RPA in larger 
groups of patients. 
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Figure 4 Kaplan–Meyer analysis for survival after DBR for DBR-RPA class I, II, and III patients. 
Legend: DBR = distant brain recurrence, RPA = recursive partitioning analysis. DBR-RPA class I favorable prog-
nosis with a median OS of 10.3 months, DBR-RPA class II intermediate prognosis with a median OS of 5.4 
months, DBR-RPA class III unfavorable prognosis with a median OS of 3.4 months. 
 
Whether salvage treatment should be given at the time of a radiological but asympto-
matic presentation of DBR remains unestablished [14]. Although survival after salvage 
was better for asymptomatic patients, this comparison is biased because these lesions 
were generally smaller and an absence of extracranial tumor progression may also have 
influenced the decision to deliver treatment at the asymptomatic stage. 
In this study of patients treated with RS alone, only 25% of treated patients needed 
salvage treatment for DBR, and ultimately only 18% of all patients underwent WBRT at 
any time during follow-up. A three-monthly MRI follow-up scheme identifies DBR at an 
early stage with respect to size and number of lesions, and most patients are asympto-
matic at radiological diagnosis. 
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ABSTRACT 
Introduction: Commonly used clinical models for survival prediction after stereotactic 
radiosurgery (SRS) for brain metastases (BMs) are limited by the lack of individual risk 
scores and disproportionate prognostic groups. In this study, two nomograms were 
developed to overcome these limitations. 
Methods: 495 patients with BMs of NSCLC treated with SRS for a limited number of BMs 
in four Dutch radiation oncology centers were identified and divided in a training cohort 
(n = 214, patients treated in one hospital) and an external validation cohort n = 281, 
patients treated in three other hospitals). Using the training cohort, nomograms were 
developed for prediction of early death (<3 months) and long-term survival (>12 
months) with prognostic factors for survival. Accuracy of prediction was defined as the 
area under the curve (AUC) by receiver operating characteristics analysis for prediction 
of early death and long term survival. The accuracy of the nomograms was also tested 
in the external validation cohort. 
Results: Prognostic factors for survival were: WHO performance status, presence of 
extracranial metastases, age, GTV largest BM, and gender. Number of brain metastases 
and primary tumor control were not prognostic factors for survival. In the external vali-
dation cohort, the nomogram predicted early death statistically significantly better (p < 
0.05) than the unfavorable groups of the RPA, DS-GPA, GGS, SIR, and Rades 2015 (AUC = 
0.70 versus range AUCs = 0.51–0.60 respectively). With an AUC of 0.67, the other nom-
ogram predicted 1 year survival statistically significantly better (p < 0.05) than the fa-
vorable groups of four models (range AUCs = 0.57–0.61), except for the SIR (AUC = 0.64, 
p = 0.34). The models are available on www.predictcancer.org. 
Conclusion: The nomograms predicted early death and long-term survival more accu-
rately than commonly used prognostic scores after SRS for a limited number of BMs of 
NSCLC. Moreover these nomograms enable individualized probability assessment and 
are easy into use in routine clinical practice. 
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INTRODUCTION 
Stereotactic Radiosurgery (SRS) is an established treatment for a limited number of 
brain metastases (BMs) with a maximum diameter up to 4 cm [1]. To predict survival in 
BM patients, several prognostic models have been published in the past decades [2–4]. 
The most commonly used is the Recursive Partitioning Analysis (RPA), which is a rela-
tively simple scoring system, initially developed in patients who were treated with 
whole brain radiotherapy (WBRT), and subsequently validated for other treatment mo-
dalities [5]. RPA classification takes into account age, presence of extracranial metasta-
ses, primary tumor control, and performance status. The RPA divides the patient cohort 
into three prognostic categories; however, a major disadvantage of the RPA is that ap-
proximately two-third of patients suitable for SRS will fall in the intermediate prognostic 
class, and probabilities for both short and long-term survival are group-based and not 
individualized [2]. Lack of individualized survival probability and disproportional size of 
prognostic groups were also observed in other more recently published prognostic 
models for survival, such as the Golden Grading System (GGS), Disease-Specific Graded 
Prognostic Assessment (DS-GPA), Score Index for Radiosurgery in brain metastases 
(SIR), and Rades 2015 [2,6–12]. With nomograms, however, it is possible to assess indi-
vidualized probabilities for endpoints, and relevant prognostic factors can be evaluated. 
In this study, two validated nomograms were developed for the prediction of early 
death (<3 months) and long-term (>1 year) survival of patients treated with SRS for a 
maximum of four BMs of NSCLC. The rationales for these endpoints were that (1) accu-
rate prediction of early death can be relevant for SRS patient selection, and (2) accurate 
prediction of long-term survival can be particularly useful for the choice of either radical 
or palliative treatment of extracranial disease [13,14]. 
MATERIALS AND METHODS 
Data 
This multicenter cohort study was approved by the local institutional review board of 
MAASTRO clinic and registered at ClinicalTrials.gov (NCT02265549). Clinical data were 
collected from all patients with newly diagnosed BMs treated with linear accelerator-
based SRS between December 2002 and March 2015 in four participating Dutch Radia-
tion Oncology centers: MAASTRO clinic in Maastricht (MC), VU University medical cen-
ter (VUmc) in Amsterdam, Verbeeten Institute in Tilburg (VT), and Catharina Hospital in 
Eindhoven (CZE). Patients were generally eligible for SRS if they had a maximum of 
three BMs, with a maximum diameter of 4 cm, on diagnostic magnetic resonance imag-
ing (MRI) performed by the referring hospital. Prior to treatment, a contrast enhanced 
high-resolution MRI serving radiation planning purposes was performed with three-
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dimensional distortion correction. If a fourth BM was identified on this planning-MRI, 
three of the four participating centers also treated these patients with SRS as the single 
treatment modality. The gross tumor volume (GTV) was defined as the contrast en-
hancement on the planning-MRI. An isotropic margin of 1–3 mm was used to generate 
the planning target volume (PTV) [15]. SRS dose was prescribed at the PTV in the range 
of 15–24 Gy in one to three fractions. Treatment planning in VUmc and CZE have been 
described previously [2,15]. MC used iPlan (Brainlab AG, Feldkirchen, Germany) and 
Eclipse (Varian, Palo Alto) software, and treatment planning was performed with non-
coplanar dynamic conformal arcs or coplanar volumetric modulated arc therapy 
(VMAT). At VT, the XiO software (Elekta, Stockholm, Sweden) was used for treatment 
planning, which was accomplished with a non-coplanar static arcs technique or VMAT. 
During follow-up, MRI scans were acquired every three months; an outpatient visit was 
planned if both the physical and mental conditions of the patient allowed it. 
Variable selection 
A database was available of all patients treated with SRS for newly diagnosed brain 
metastases of several primary tumors (n = 929) in four Dutch hospitals. For this study, 
patients with BM of NSCLC from whom the date of death was known, or patients with 
BM of NSCLC who had a follow-up of at least of 1 year were selected (n = 495). In the 
training cohort (n = 214) Kaplan–Meier analysis including multivariate Cox regression 
analysis was performed on the baseline characteristics to identify significant prognostic 
factors for survival. Dependent prognostic factors were excluded from the multivariate 
analysis: PTV largest BM is dependent on GTV largest BM; cumulative GTV is dependent 
on GTV largest metastasis; and dose is dependent on GTV largest BM. In the training 
cohort, the following baseline characteristics were statistically significant prognostic 
factors for survival in multivariate cox regression analysis: WHO performance status (p < 
0.01, beta regression coefficient (b) = 0.41, odds ratio (OR) = 1.50, 95% confidence 
interval (95% CI) = 1.20–1.88), presence of extracranial metastases (p < 0.01, b = 0.73, 
OR = 2.08, 95% CI = 1.44–3.00), age (p < 0.01, b = 0.03, OR = 1.03, 95% CI = 1.02–1.05), 
GTV largest BM (p = 0.01, b = 0.03, OR = 1.03, 95% CI = 1.01–1.06), and gender (p = 
0.04, b = -0.35, OR = 0.70, 95% CI 0.51–0.98); Other baseline characteristics were not 
prognostic for survival: primary tumor control (p = 0.98), and number of treated BM (p 
= 0.18). 
Nomograms 
The patient cohort treated in the VUmc (n = 214) was used as the training cohort for 
development of the two nomograms. The other patient cohort (n = 281, patients treat-
ed in MC, VT, and CZE) was used as an external validation cohort in which the two de-
veloped nomograms were tested independently from the training cohort. Prognostic 
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factors for survival identified with Cox multivariate analysis in the training cohort of 
patients (n = 214) were used to develop the nomograms for the prediction of early 
death (<3 months) and long-term survival (>1 year), respectively. Nomograms were 
made based on logistic regression analysis and learned on the VUmc cohort. The prima-
ry endpoint of this study was the area under the curve (AUC) obtained using receiver 
operating characteristics (ROC) analysis for early death and long-term survival predic-
tion. In the training and validation cohorts, the AUCs of the developed nomogram mod-
els were compared with the AUCs of the RPA, DS-GPA, GGS, SIR, and Rades 2015 prog-
nostic models. Comparison of ROC curves was done using DeLong’s test for correlated 
ROC curves. Statistical analyses were performed using SPSS (version 23, IBM, New York), 
using R (version 3.1.3, R Foundation for Statistical Computing, Vienna, Austria) using the 
rms, PredictABEL, and pROC packages. Validation was performed according to estab-
lished methods [16]. Calculating AUC confidence intervals and calibration R2 values 
(predicted versus observed risk) was done according previously described methods 
[17,18]. 
RESULTS 
Median survival of the total cohort of patients (n = 495) was 6.8 months. Baseline char-
acteristics of the training (n = 214) and validation (n = 281) cohorts are shown in Table 
1. The first developed nomogram specific for the prediction of early death is shown in 
Fig. 1 containing the previously identified prognostic factors for survival. With an AUC of 
0.77, the nomogram predicted early death statistically significantly better than the 
unfavorable groups of the RPA, DS-GPA, GGS, SIR, and Rades 2015 (range AUC = 0.52–
0.59). Similar results were observed in the external validation cohort with an AUC = 0.70 
of the nomogram versus range AUCs = 0.51–0.60 with the other prognostic models, 
Table 2). For the ROC curves of the nomogram, see Supplementary materials 1. Calibra-
tion curves (predicted versus observed probability) of the nomogram are shown in Sup-
plementary materials 2 with R2 values of 0.98 and 0.82 in respectively the training and 
validation cohort. The independently developed second nomogram is specific for the 
prediction of long-term survival and shown in Fig. 2 containing the same prognostic 
factors for survival, but otherwise ranked in the nomogram. With an AUC = 0.77, this 
nomogram predicted 1 year survival statistically significantly better than the favorable 
groups of the RPA, DS-GPA, GGS, SIR, and Rades 2015 in the training cohort (range AUCs 
= 0.55–0.68, Table 2). In the external validation cohort comparable results were ob-
served with AUC = 0.67 of the nomogram versus range AUCs = 0.57–0.61, p < 0.05 of 
four of the five other prognostic models (Table 2). Although the AUC of the nomogram 
was higher than that of the favorable prognostic group of the SIR (0.67 versus 0.64, p = 
0.34), this difference was not statistically significant. ROC curves of the nomogram are 
provided in Supplementary materials 3. Calibration curves (predicted versus observed 
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probability) of the nomogram are shown in Supplementary materials 4 with R2 values of 
0.97 and 0.76 in respectively the training and validation cohort. The training cohort was 
divided in three equal sized groups based on the probability of 1 year survival as deter-
mined by the nomogram. The probability on 1 year survival per patient ranged in the 
first, second, and third group respectively from <24%, 24–47%, and >47%. There was a 
statistically significant difference in survival between the three risk groups in both the 
training as the validation cohort with Kaplan–Meyer analysis and log-rank test (p < 
0.001, Supplementary materials 5). Long term survival over several years was mainly 
seen in the favorable (>47% one year survival probability) groups of both the training as 
the validation cohort. Regression coefficients and other characteristics of both the 
nomogram for early death prediction as the nomogram for long term survival prediction 
are provided in Supplementary materials 6. 
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Table 1 Baseline characteristics of training and validation cohort of 495 patients treated with SRS for BM of 
NSCLC 
   Training cohort  n= 214 
External validation cohort 
n= 281 
Radiation Oncology center VUmc 100% 0% 
 MC     0% 55% 
 VT 0% 25% 
 CE 0% 20% 
 
Gender Female 47% 46% 
 Male  53% 54% 
Mean age ± SD (years)  63 +/- 10 63 +/- 11 
WHO performance score 0 or 1 83% 83% 
 2 13% 16% 
 3 4% 1% 
Number of BM lesions 1 66% 64% 
 2 30% 24% 
 3 4% 11% 
 4 0% 1% 
Extracranial metastases Yes 38% 26% 
 No 62% 74% 
Primary tumor control Yes 41% 55% 
 No 59% 45% 
Mean GTV of largest BM (cm3) ± SD  6.8 +/- 6.6 7.3 +/- 7.9 
RPA Favorable 30% 33% 
 Intermediate 54% 60% 
 Unfavorable 16% 17% 
DS-GPA  Favorable 7% 11% 
 Intermediate 87% 82% 
 Unfavorable 6% 7% 
GGS  Favorable 29% 33% 
 Intermediate 67% 63% 
 Unfavorable 4% 4% 
SIR  Favorable 29% 33% 
 Intermediate 69% 65% 
 Unfavorable 2% 2% 
Rades 2015 Unfavorable 24% 25% 
 Favorable 76% 75% 
Median survival (95% CI)  6.3 (5.0-7.6) 7.0 (6.0-8.1) 
Death at 3 months  33% 24% 
Alive at 1 year  36% 30% 
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Figure 1 Nomogram for prediction of early death based on 214 patients treated with SRS for BM of NSCLC. 
Legend: SRS=stereotactic radiosurgery, BM=brain metastasis, NSCLC=non-small cell lung cancer, WHO=World 
Health Organization performance status, GTV=gross tumor volume, extramets=extracranial metastases   
 
 
Figure 2. Nomogram for prediction of long-term survival based on outcome of 214 patients treated with SRS 
alone for BM of NSCLC. Legend: SRS=stereotactic radiosurgery, BM=brain metastasis, NSCLC=non-small cell 
lung cancer, WHO=World Health Organization performance status, GTV=gross tumor volume, ex-
tramets=extracranial metastases   
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DISCUSSION 
Current published models for the prediction of survival of BM patients treated with SRS 
have several limitations for clinical applicability, and are mainly limited by the lack of 
individualized probability assessment. Most published models were developed in or 
included patients who were treated with other modalities such as WBRT, surgery, or a 
combination of SRS and WBRT. These models have an unbalanced patient distribution in 
common, with only a small proportion of patients in the favorable- and unfavorable 
prognostic category, which are the most relevant for clinical decision making. However, 
the major limitation is that none of the prognostic models have an individualized prob-
ability assessment of survival; rather, they distribute patients only according to a prog-
nostic groups, which is undesirable in the current era of personalized medicine [2]. In 
this study, nomograms were developed for the prediction of early death (<3 months) 
and long-term survival (>1 year), respectively, in patients treated with SRS for BM of 
NSCLC. The models were based on and validated in a homogeneous cohort of patients, 
with a maximum of four BM lesions each, who were treated with SRS alone in four 
Dutch radiation oncology centers. The nomogram allows for an upfront calculation of 
the probability of early death and long-term survival on an individual patient basis. Pre-
diction of early death is of relevance for patient selection for SRS to avoid overtreat-
ment of patients. Prediction of long-term survival is of particular relevance when de-
termining extracranial treatment strategies. In patients with a relatively high chance of 
surviving more than one year, more aggressive therapy for extracranial disease sites 
may be beneficial to maintain long-term quality of life and disease control [19,20].  
Our first nomogram predicts early death more accurately than the unfavorable groups 
of the RPA, GGS, DS-GPA, SIR, and Rades 2015 in both the training as the validation 
cohorts. Our second nomogram predicted long term survival more accurately than the 
favorable groups of the RPA, DS-GPA, GGS, SIR, and Rades 2015 in the training cohort. It 
has to be noted that in the validation cohort the nomogram predicted long term surviv-
al better than the other prognostic models except the SIR. However, the nomogram has 
still the advantage over the SIR that there is an individualized probability assessment 
instead of a group based probability assessment. Moreover, the nomogram is easier in 
use than the SIR in routine clinical practice. It is important to further validate these 
nomograms in other BM populations treated with SRS, within and outside the Nether-
lands. Moreover, it is of interest to assess the applicability of these nomogram models 
for patients with more than four BM lesions, especially as the number of lesions was 
found not to be an important prognostic factor in patients treated with SRS alone in this 
study [21].  
The choice to only include NSCLC patients in this model was based on the fact that the 
proportion of other primary tumors was relatively small in our database of in total 929 
patients treated with SRS for BM in four Dutch hospitals. Therefore, we questioned the 
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applicability of our nomograms for other primary tumors than NSCLC. Combining da-
tasets of patients treated with SRS for BM of other primary tumors than NSCLC may 
allow the development of predictive models per tumor type. The data to develop mod-
els for these outcomes is readily available from centers worldwide. Unfortunately, shar-
ing these data is hampered by political, legal, ethical and administrative boundaries. In 
order to circumvent these boundaries, a distributed learning approach can be employed 
[22]. In the distributed learning approach, a model application is sent to each hospital. 
There, the model learns from the data and is sent back to the modeler. Each locally 
learned model is combined into a global model that integrates the knowledge of all 
locally learned models. Using this approach, privacy sensitive patient data never leaves 
the center. In the future, we intend to use a distributed learning strategy to develop 
more nomogram models for BM patients. 
Despite the use of multiple relevant prognostic factors there is still opportunity for 
improvement for the accuracy of the nomograms. Further research should focus on 
improving the accuracy of survival prediction by incorporating additional factors, e.g., 
using radiographic analysis of the primary tumor or BM (Radiomics), and assessing the 
value of biomarkers [23–27]. These tools may contribute to more accurate survival 
prediction, although clinical applicability may be complex and challenging. Therefore, 
risk assessment based on clinical factors alone remains valuable and relevant for many 
hospitals that do not have the capacity to perform radiomics and/or biomarker analysis. 
Accurate prediction of survival, local control, distant brain recurrence, and toxicity is 
important for patients and clinicians regarding the choice for treatment options; this is 
also known as shared decision [28–33]. Shared decision will be possible if the patient is 
informed by individualized probabilities for clear endpoints, such as early death within 3 
months and long term survival over 1 year. With these probabilities available and guid-
ance of the physician for interpretation, the patient together with his family may be 
able to choose between treatment options. The limitations of our study are the retro-
spective design and the risk of selection bias, although the developed nomograms are 
based on outcome data in routine clinical practice. These nomograms cannot be used 
for patients with very large BM of more than 4 cm in diameter, patients with more than 
3 brain metastases, or patients treated with other modalities than SRS alone for newly 
diagnosed BM of NSCLC. The strength of our study is the external validation of both 
nomograms. 
In conclusion, two novel clinical nomogram models were developed and validated for 
the prediction of respectively early death (<3 months) and long-term (>1 year) survival 
after SRS for patients with a maximum of four BMs of NSCLC. These nomogram models 
can be used for individual probability assessments, and to avoid the limitations of previ-
ously published prognostic classification systems. The nomograms can be found at 
www.predictcancer.org. Supplementary data associated with this article can be found, 
in the online version, at http://dx.doi.org/10.1016/j.radonc.2017.02.006. 
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Chapter 7 
Postoperative management after resection of 
a single brain metastasis: 
whole brain radiotherapy, local radiotherapy, 
or ‘wait and scan’?  
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ABSTRACT 
The optimal policy following total resection of a single brain metastasis remains a mat-
ter of debate. Randomized studies, such as the recently published EORTC study 22952-
26001, have confirmed the lack of a survival benefit of postoperative whole brain radio-
therapy (WBRT) in comparison to observation; nor did WBRT improve the survival with 
functional independency. The benefit of WBRT appeared to be a decrease in neurologi-
cal death, as a result of a diminished risk of local relapses at the site of the resection 
and a decreased incidence of new metastases elsewhere in the brain. This advantage of 
WBRT has to be weighed against early and late potential side effects of this approach. 
The above results have led a growing number of Dutch centers to adapt their policy 
towards either ‘wait and scan’ or local radiotherapy to the resection cavity. This paper 
discusses the results of the EORTC study in more detail, as well as possible further ran-
domized studies including local radiotherapy in this setting, which have already been 
initiated in the United States. 
SAMENVATTING 
Het postoperatieve beleid na een totale resectie van een hersenmetastase staat ter 
discussie. Gerandomiseerde studies, waaronder de recentelijk gepubliceerde EORTC 
22952-26001-studie, hebben bevestigd dat de tot voorheen standaard uitgevoerde 
totale schedelbestraling geen overlevingswinst oplevert ten opzichte van observatie 
gevolgd door behandeling van een eventueel recidief, noch een winst in de duur dat 
patiënt in een goede conditie verkeert. Het voordeel van totale schedelbestraling be-
staat uit een verlaging van de kans op overlijden door een neurologische oorzaak als 
gevolg van een vermindering van het risico op een lokaal recidief in de resectieholte en 
een kleinere kans op het ontwikkelen van nieuwe metastasen elders in de hersenen. Dit 
voordeel dient te worden afgewogen tegen de mogelijke vroege en late bijwerkingen 
van totale schedelbestraling. De bovengenoemde resultaten hebben geleid tot een 
verandering van het postoperatieve beleid in vele Nederlandse centra, waarbij in toe-
nemende mate ofwel een ‘wait and scan’-beleid ofwel lokale bestraling op de resectie-
holte wordt toegepast. In dit artikel worden de resultaten van de gepubliceerde EORTC-
studie in meer detail besproken. Ook worden mogelijke gerandomiseerde vervolgstu-
dies met onder andere lokale bestraling van de resectieholte besproken, zoals de stu-
dies die in de Verenigde Staten inmiddels zijn opgestart. 
  
Postoperative management after resection of a single brain metastasis 
89 
INLEIDING 
Hersenmetastasen zijn een belangrijke oorzaak voor morbiditeit en mortaliteit bij patiën-
ten met kanker. De onderliggende primaire tumor bij hersenmetastasen is meestal long-
carcinoom of mammacarcinoom, maar kan ook niercelcarcinoom, melanoom of een 
andere maligniteit zijn.[1] De indicatie voor de verschillende behandelingsmogelijkheden 
wordt beschreven in de recentelijk geactualiseerde Nederlandse richtlijn over de di-
agnostiek en behandeling van hersenmetastasen.[2]Bij patiënten in een goede conditie 
met beperkte of behandelbare extracraniële ziekte is totale schedelbestraling (‘whole 
brain radiotherapy’; WBRT) of stereotactische radiochirurgie (SRS) de behandeling van 
keuze met als doel om progressie van neurologische symptomen of overlijden ten gevol-
ge van neurologische uitval te voorkomen. De Nederlandse richtlijn beschrijft een gese-
lecteerde groep patiënten waarbij resectie van hersenmetastasen de voorkeur heeft. 
Meestal gaat het om een enkelvoudige hersenmetastase, waarbij een histologische dia-
gnose dient te worden verkregen die een significant massa-effect vertoont of te groot is 
om voor SRS in aanmerking te komen. Sinds eind jaren 90 van de vorige eeuw bestaat 
een controverse of een totale resectie van een enkelvoudige hersenmetastase routine-
matig moet worden gevolgd door adjuvante WBRT om microscopisch achtergebleven 
ziekte in de resectieholte en elders in de hersenen te behandelen.[3-7] De verkregen 
winst in intracraniële controle moet worden afgezet tegen de potentiële bijwerkingen 
van WBRT op korte en lange termijn, naast de beschikbaarheid van verschillende salva-
getherapieën voor recidiefmetastasen in de hersenen. Op basis van de eerste gerando-
miseerde studie tussen chirurgie met of zonder postoperatieve WBRT, gerapporteerd 
door Patchell et al. in 1998, is adjuvante WBRT op basis van een significant betere lokale 
controle lange tijd de standaardbehandeling geweest in de meeste Nederlandse cen-
tra.[8] In deze studie werd geen winst in overleving gevonden tussen beide groepen. 
Deze studie was echter ook niet gepowered om een overlevingsvoordeel aan te tonen. 
De publicatie van de recente EORTC-studie 22952-26001 heeft de discussie over het nut 
van adjuvante WBRT opnieuw doen oplaaien.[9,10] Op basis van de resultaten van deze 
gerandomiseerde studie, die hierna zullen worden beschreven, is een toenemend aantal 
centra inmiddels overgegaan op een ‘wait and scan’-beleid of uitsluitend lokale adjuvan-
te radiotherapie op de resectieholte. In dit artikel wordt dieper ingegaan op de verschil-
lende adjuvante beleidsmogelijkheden na resectie van een enkele hersenmetastase.  
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Tabel 1 Gerandomiseerde fase III studies met betrekking tot postoperatieve WBRT 
 
 
 
Figuur 1 Pre- en post-operatieve MRI na subtotale resectie van een hersenmetastase.  
Pre-operatieve (1A) en post-operatieve MRI cerebrum (1B) met en zonder gadoliniumcontrast van een gere-
serceerde enkele hersenmetastase van een niet-kleincellig longcarcinoom bij een 39 jarige man. Ventraal in 
de resectieholte aankleurend gebied verdacht voor resttumor (1B). 
‘WAIT AND SCAN’ VERSUS WBRT NA TOTALE RESECTIE VAN EEN ENKELE 
HERSENMETASTASE 
Bij een ‘wait and scan’-beleid wordt afgezien van een adjuvante behandeling na een 
macroscopisch totale resectie van een enkelvoudige hersenmetastase en wordt vol-
staan met routinematige MRI-follow-up (vaak driemaandelijks) om een eventueel reci-
dief in het operatiegebied of elders in de hersenen vroegtijdig op het spoor te komen. 
Van belang voor de keuze van dit beleid is het bevestigen van de volledigheid van de 
resectie op basis van het operatieverslag en een vroeg (binnen 72 uur) postoperatief 
vervaardigde MRI-scan met contrast; in de meeste centra behorend bij het standaard-
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beleid. Aanwijzingen voor resttumor in de operatieholte zal vrijwel altijd een indicatie 
voor aanvullende behandeling zijn, meestal radiotherapie of re-resectie. Overigens 
werd in de recente EORTC-studie postoperatieve beeldvorming bij slechts 74% van de 
patiënten verricht. In de overige gevallen werd afgegaan op de inschatting van de radi-
caliteit door de neurochirurg.9 Het ‘wait and scan’-beleid na een radiologisch bevestig-
de totale resectie wordt ondersteund door de bevindingen van de 2 gerandomiseerde 
studies naar het effect van adjuvante bestraling, waarbij in geen van beide studies een 
overlevingsvoordeel of verbetering van functioneel onafhankelijke overleving werd 
waargenomen.[8,9] De kans op een lokaal recidief in of nabij de resectieholte na een 
‘wait and scan’-beleid is echter aanzienlijk en werd gezien bij respectievelijk 46% en 
59% van de patiënten in de Patchell- en EORTC-studie. De winst van postoperatieve 
WBRT werd vooral gezien in de secundaire eindpunten van de gerandomiseerde stu-
dies. Er was sprake van een vermindering van de kans op overlijden als gevolg van neu-
rologische progressie; in de Patchell-studie van 44% na ‘wait and scan’ naar 14% met 
WBRT en in de EORTC-studie van 44% naar 28% met WBRT. Daarnaast was er een signi-
ficante vermindering van het recidiefpercentage na WBRT. De lokale controle verbeter-
de van 54% naar 90% en van 41% naar 73% met WBRT bij respectievelijk de Patchell- en 
de EORTC-studie, terwijl de kans op het ontwikkelen van metastasen elders in de herse-
nen afnam van 37% naar 14% in de Patchell-studie en van 42% naar 23% in de EORTC-
studie (zie Tabel 1). Een belangrijke afweging voor het interpreteren van bovenstaande 
bevindingen wordt gevormd door de mogelijke toxiciteit van WBRT op korte en lange 
termijn. Vroege bijwerkingen van WBRT zijn haaruitval, vermoeidheid en lusteloosheid, 
terwijl op de lange termijn vooral het risico op neurocognitieve achteruitgang van be-
lang is.[11,12] De met chirurgie behandelde groep patiënten vormt over het algemeen 
juist een gunstig geselecteerde groep patiënten met een mediane overleving van rond 1 
jaar en daarom zijn met name langetermijneffecten van belang. [8,9] Begin 2013 zijn de 
resultaten van een subanalyse van de EORTC-studie naar de kwaliteit-van-
levengegevens gepubliceerd.10 Patiënten die adjuvante WBRT kregen na een resectie 
van hersenmetastasen hadden op meerdere tijdstippen, maar met name in de eerste 
maanden na resectie, een slechtere kwaliteit van leven dan patiënten die geen adjuvan-
te WBRT kregen. De belangrijkste uitkomsten waren dat de WBRT-groep 8 weken na de 
behandeling vermoeider was en fysiek slechter functioneerde en 9 maanden na de 
behandeling een slechtere algehele gezondheid had. Na 12 maanden had de WBRT-
groep een significant slechtere cognitie op basis van geheugenproblemen (gemiddelde 
EORTC QLQ-C30-cognitiescore van 80,4 in de observatiegroep versus 69,7 in de WBRT-
groep). 
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Figuur 2 Voorbeelden van bestralingsplannen van lokale radiotherapie na subtotale resectie van een hersen-
metastase. Drie voorbeelden van een mogelijk bestralingsplan van lokale radiotherapie op de resectieholte 
geprojecteerd op een post-operatieve CT van de patiënt uit Figuur 1. Bij Figuur 2A wordt de dosisverdeling 
getoond van 5 fracties van 5 Gy tot een totaaldosis van 25 Gy gedoseerd op de rand van het doelgebied (rode 
lijn). Het plan heeft een relatief homogene dosisverdeling. Bij figuur 2B wordt een geïntegreerde boost gege-
ven op de resttumor ventraal in de resectieholte (5 fracties van 6 Gy tot een totaaldosis van 30 Gy) en het 
overige doelgebied krijgt 5 fracties van 5 Gy tot een totaaldosis van 25 Gy (100% voorgeschreven dosis is 25 
Gy). Bij figuur 2C wordt een eenmalige fractie van 21 Gy op alleen de resttumor gegeven. 
LOKALE RADIOTHERAPIE ALS ALTERNATIEF 
Een toenemend aantal recente publicaties beschrijft het toepassen van postoperatieve 
lokale radiotherapie op de resectieholte, met als doel enerzijds om de lokale controle te 
optimaliseren en anderzijds om de potentiële bijwerkingen van WBRT te voorkomen. 
Op incidenteel toegepaste technieken, zoals neoadjuvante radiochirurgie of intra-
operatieve brachytherapie, wordt in dit artikel niet ingegaan.[13,14] Een recent over-
zichtsartikel van Roberge et al. beschrijft de preliminaire resultaten van voornamelijk 
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retrospectieve studies naar de waarde van radiochirurgie of gefractioneerde stereotac-
tische radiotherapie op de resectieholte.[15] Hoewel er een variatie bestaat in de ver-
schillende publicaties in de definitie van het doelgebied (vrijwel altijd de resectierand 
met een marge van enkele millimeters; zie Figuur 1 en 2) en de gebruikte dosis, lijkt de 
lokale controle na postoperatieve lokale radiotherapie, zoals ook verwacht, minstens 
even goed als beschreven in de chirurgie plus WBRT-groep van de eerdere studies. Het 
gewogen gemiddelde van de beschreven studies voor lokale controle bedraagt onge-
veer 85% na 1 jaar. Het risico op symptomatische radionecrose wordt geschat op 0-6%, 
afhankelijk van de gebruikte bestralingsdosis. In vervolg op de recentelijk afgesloten 
EORTC-studie wordt op dit moment een aantal prospectief gerandomiseerde studies 
met lokale radiotherapie in een van de onderzoeksgroepen verricht. Met name de lo-
pende N107C-studie, waarbij wordt gerandomiseerd tussen postoperatieve WBRT en 
radiochirurgie op de resectieholte bij patiënten met 1-4 hersenmetastasen, verdient 
hier vermelding.[16] Deze studie beoogt een totaal van 192 patiënten te includeren en 
heeft als hoofdeindpunten neurocognitief functioneren en overleving. Het zal echter 
nog enige jaren duren voordat de resultaten van deze studie bekend zullen zijn. 
BELEID NA INCOMPLETE RESECTIE VAN EEN ENKELE HERSENMETASTASE 
Het beleid na een incomplete resectie van een hersenmetastase is niet goed beschre-
ven in de literatuur, maar in het algemeen zal hierbij vrijwel altijd tot aanvullende be-
handeling (re-resectie, adjuvante radiotherapie) worden besloten. In het geval van ad-
juvante radiotherapie zijn er meerdere mogelijkheden; WBRT (met of zonder een ‘sur-
dosage’ op de resectieholte) of uitsluitend lokale bestraling. De meest eenvoudige ma-
nier is om adjuvante lokale radiotherapie te geven op de gehele resectieholte inclusief 
de tumorrest, zoals beschreven na een complete resectie. Daarnaast is het mogelijk om 
uitsluitend de resttumor (stereotactisch) te bestralen (zie Figuur 1 en 2), ofwel de gehe-
le resectieholte met een geïntegreerde ‘surdosage’ op de resttumor. Welke van deze 
lokale bestralingstechnieken de voorkeur verdient is onduidelijk en zal per patiënt en 
per instituut verschillen; verreweg de meeste Nederlandse radiotherapie instituten 
kunnen tegenwoordig dit soort precisiebestralingen uitvoeren. 
CONCLUSIE 
Sinds de publicatie van de recente EORTC-studie staat het beleid na een (bevestigde) 
complete resectie van een enkele hersenmetastase opnieuw ter discussie. De overle-
ving na ‘wait and scan’ of totale schedelbestraling was in beide groepen gelijk. Het risico 
op een recidief in de hersenen was echter significant kleiner na schedelbestraling. Op 
basis van deze resultaten zijn beide strategieën postoperatief verdedigbaar. De waarde 
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van lokale radiotherapie op de resectieholte is vooralsnog onbekend, maar gepubli-
ceerde resultaten van retrospectieve studies laten een lokale controle op de resectie-
holte zien die minstens even goed is als beschreven na totale schedelbestraling. Het valt 
te verwachten dat met lokale bestraling de kans op langetermijneffecten, die bij totale 
schedelbestraling wel worden gezien, kunnen worden vermeden. Lopende gerandomi-
seerde studies zullen hierover in de toekomst uitsluitsel geven. 
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ABSTRACT 
Background Maintenance of quality of life is the primary goal during treatment of brain 
metastases (BM). This is a protocol of an ongoing phase III randomized multicenter 
study. This study aims to determine the exact additional palliative value of stereotactic 
radiosurgery (SRS) over whole brain radiotherapy (WBRT) in patients with 4–10 BM.  
Methods The study will include patients with 4–10 BM from solid primary tumors diag-
nosed on a high-resolution contrast-enhanced MRI scan with a maximum lesional diam-
eter of 2.5 cm in any direction and a maximum cumulative lesional volume of 30 cm3. 
Patients will be randomized between WBRT in five fractions of 4 Gy to a total dose of 20 
Gy (standard arm) and single dose SRS to the BMs (study arm) in the range of 15–24 Gy. 
The largest BM or a localization in the brainstem will determine the prescribed SRS 
dose. The primary endpoint is difference in quality of life (EQ5D EUROQOL score) at 3 
months after radiotherapy with regard to baseline. Secondary endpoints are difference 
in quality of life (EQ5D EUROQOL questionnaire) at 6, 9 and 12 months after radiother-
apy with regard to baseline. Other secondary endpoints are at 3, 6, 9 and 12 months 
after radiotherapy survival, Karnofsky≥70, WHO performance status, steroid use (mg), 
toxicity according to CTCAE V4.0 including hair loss, fatigue, brain salvage during follow-
up, type of salvage, time to salvage after randomization and Barthel index. Facultative 
secondary endpoints are neurocognitive function assessed with the Hopkins verbal 
learning test revised, quality of life EORTC QLQ-C30, quality of life EORTC BN20 brain 
module and fatigue scale EORTC QLQ-FA13. 
Discussion Worldwide, most patients with more than 4 BM will be treated with WBRT. 
Considering the potential advantages of SRS over WBRT, i.e. limiting radiation doses to 
uninvolved brain and a high rate of local tumor control by just a single treatment with 
fewer side effects, such as hair loss and fatigue, compared to WBRT, SRS might be a 
suitable alternative for patients with 4–10 BM.  
Trial registration www.clinicaltrials.gov: NCT02353000, trial registration date 15th Janu-
ary 2015, open for accrual 1st July 2016, nine patients were enrolled in this trial on 14th 
April 2017. 
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BACKGROUND 
In this randomized study, in patients with 4–10 brain metastases (BM), the standard 
treatment of whole brain radiotherapy (WBRT) is compared to stereotactic radiosurgery 
(SRS) for all lesions with the primary endpoint of quality of life (QOL) at 3 months after 
radiotherapy. We hypothesize that SRS provides better QOL than WBRT because of 
better local tumor control and avoidance of potential side effects of WBRT. Brain me-
tastases are an important cause of morbidity and mortality in patients with metasta-
sized cancer, and therefore, optimal tumor control is essential. Dutch guideline recom-
mends SRS for patients with 1–3 BM and WBRT for patients with 4 or more BM. WBRT 
has side effects such as hair loss, fatigue and cognitive dysfunction, which may result in 
decreased QOL that is undesirable in a palliative setting.[1] There are important ad-
vantages of SRS over WBRT, i.e., limiting radiation doses to the uninvolved brain and a 
high rate of local tumor control by just a single treatment compared to WBRT, in which 
a relatively low palliative radiation dose is delivered to both the brain and the BM (Fig-
ure 1). SRS is widely available in most Dutch radiotherapy centers. Because of recent 
technical advances, SRS can be delivered in relatively short treatment time in 10–45 min 
in patients with multiple BM. With SRS, there is a relatively low risk (5%) of sympto-
matic radionecrosis: damage of the surrounding brain tissue, which may occur several 
months after treatment. Radionecrosis may cause neurologic symptoms, often tempo-
rary, which are treated with dexamethasone. Moreover, the clinical value of WBRT over 
the best supportive care is controversial. A recent interim analysis of the QUARTZ study 
showed equal QOL and survival for patients treated with WBRT versus treatment with 
steroids alone. [2] A recent (non-randomized) study in a large cohort of patients with 
BM showed that after SRS, survival of patients with 5–10 BM was comparable to that of 
patients treated with 2–4 BM.[3] Thus far, WBRT has never been compared directly 
with SRS in patients with 4–10 BM, and therefore a randomized trial is needed. In the 
United States, the NAGKC 12-01 (NCT01731704) was initiated in patients with 5 or more 
brain metastases in which SRS was directly compared with WBRT. However, this study 
was closed prior to enrolment of patients because of insufficient staff. Many systemic 
therapies do not have satisfactory tumor control of BM because of poor passage of the 
blood brain barrier. In the future, SRS may be the optimal treatment choice to control 
BM and in patients with multiple brain metastases to maintain long-term QOL, whereas 
new innovative systemic therapies may control extracranial disease.  
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Figure 1 Dose distribution difference between WBRT (left) and SRS (right). Legend: figure 1 A typical dose 
distribution on a planning-CT of WBRT on the left side and of SRS on the right side. With WBRT, the healthy 
brain tissue receives the same low palliative radiation dose (non-ablative). With SRS, only the metastatic 
tissue receives a high ablative dose. 
METHODS/DESIGN 
Design 
The study is a randomized phase III study with two study arms. The standard arm is 
WBRT and the experimental arm is SRS. We hypothesize that SRS provides better QOL 
than WBRT because of better local tumor control and avoidance of potential side ef-
fects of WBRT. 
Objectives and endpoints 
The primary objective is to determine whether QOL is better preserved after SRS than 
after WBRT in patients with 4–10 BM. The primary endpoint is difference in QOL (EQ5D 
EUROQOL score) at 3 months after radiotherapy with regard to baseline. The secondary 
objective is to determine whether SRS provides better survival and less toxicity than 
WBRT.[1,2] Secondary endpoints are difference in QOL (EQ5D EUROQOL questionnaire) 
at 6, 9 and 12 months after radiotherapy with regard to baseline. Survival at 3, 6, 9 and 
12 months after radiotherapy, Karnofsky≥70, WHO performance status, steroid use 
(mg), toxicity according CTCAE V4.0 including hair loss, fatigue, neurocognitive function 
and brain salvage during follow-up, type of salvage, time to salvage after randomization 
and Barthel index. Facultative secondary endpoints are neurocognitive function with 
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the Hopkins verbal learning test, quality of life EORTC QLQ-C30, quality of life EORTC 
BN20 brain module and fatigue scale EORTC QLQ-FA13. 
Study population 
The study will include patients with 4–10 BM from solid tumors diagnosed on a high 
resolution contrast-enhanced MRI scan referred for radiotherapy, with a maximum 
lesional diameter of 2.5 cm. Before randomization, a new neuronavigation MRI (T1 
gadolinium) is made for the definitive evaluation of the inclusion and exclusion criteria. 
The inclusion criteria are age≥18; minimum of 4 BM up to a maximum of 10 BM on 
diagnostic MRI scan; maximum diameter of single gross tumor volume (GTV) 2.5 cm; 
maximum cumulative GTV of 30 cm3; Karnofsky performance status ≥ 70; any solid 
primary tumor, small cell lung carcinoma, germinoma and lymphoma are excluded; and 
patients’ ability to provide written informed consent. The exclusion criteria are a contra-
indication for MRI, prior treatment for BM (i.e. surgery, SRS or WBRT), concurrent use 
of systemic therapy (systemic therapies should be stopped at least 1 week prior until 1 
week after the radiotherapy), maximum cumulative GTV of more than 30 cm3 on plan-
ning-MRI, more than 10 BM on planning-MRI, leptomeningeal disease and brainstem 
metastasis with a PTV of more than 20 cm3. If a patient is not eligible based on the in-
clusion or exclusion criteria of this study based on the planning-MRI results prior to 
randomization (e.g. >10 BM, GTV diameter>2.5 cm, cumulative GTV>30 cm3), these 
non-eligible patients will be replaced by a new patient. These patients are not included 
in the statistical analysis of the trial.  
Study procedures WBRT  
On a gadolinium contrast-enhanced (single – triple dose Gd is allowed) MRI (1.0T-3T) 
with a maximal slice thickness of 1.5 mm, the definitive number of BM and the defini-
tive maximum lesion diameter in any direction of the largest BM are determined. Pa-
tients randomized for WBRT will be treated with five fractions of 4 Gy up to a total dose 
of 20 Gy delivered in five consecutive working days. Dose prescription is according to 
ICRU 50 criteria.[4] The brain is contoured as a clinical target volume (CTV) until the 
foramen magnum. The CTV is equal to the PTV. To determine the size of the GTVs of the 
metastases, all BMs and lenses are contoured. Patients are positioned with a mask. The 
use of a planning CT is mandatory with slice thickness of ≤3 mm. The use of a contrast 
medium is not obliged. The planning-MRI is co-registered for contouring of the BM. The 
daily prescription dose will be 4 Gy prescribed at the ICRU reference point, and the 95% 
isodose must encompass 99% of the planning target volume (PTV); the maximum dose 
to the PTV should not exceed 107% of the prescribed dose. Generally, two opposed 
lateral fields are used with shielding of lenses and the pharyngeal space. All techniques 
that result in the dose requirements being met are allowed. 
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Study procedures of SRS  
Only single fraction treatments are allowed within this protocol. For any given patient, 
all brain metastases will be treated with the same dose, which will be determined by 
the PTV of the largest BM or brainstem location in the range of 15–24 Gy.(Table 1) The 
dose gradient outside the PTV will be as steep as possible to spare healthy brain tissue. 
Within the PTV, there will be considerable dose inhomogeneity, with a maximum al-
lowed dose within the PTV of 140% of the prescribed dose. The GTV is defined by con-
touring the outer contrast-enhancing border of the BM on T1 gadolinium-weighted MRI 
images. BM are named GTVp1, GTVp2, GTVp3, from the cranial to the caudal side. Or-
gans at risk (brainstem, optic nerves, chiasma, pituary gland, cochleae, and lenses) are 
contoured according to Scoccianti et al. [5]. The PTV is defined by a 0–2 mm isotropic 
expansion of the GTV, according to institutional standards for SRS. If a BM is within or 
adjacent to the brainstem, the PTV margin will be 0 mm. If in an institution, a smaller 
GTV to PTV margin is used when lesions are treated using multiple isocentres, then this 
technique is to be considered to reduce the V12Gy of the largest BM if it would otherwise 
be more than 10 cm3.  
Patients will be immobilized in a supine position within a thermoplastic mask or stereo-
tactic noninvasive frame, with or without bite block and/or other fixation, according to 
institutional standards for SRS. The accuracy of the stereotactic fixation system should 
be good enough to justify the CTV to PTV margin used. This means the intrafraction 
motion should at least be within the CTV-PTV margin used. If a margin of 0 mm is used, 
the maximum intrafraction motion should be <0.5 mm, with the SD being less than 0.25 
mm. A planning CT scan with ≤2 mm thick contiguous slices (preferable CT slice thick-
ness = 1 mm) will be fused to a contrast-enhanced stereotactic MRI scan. The interval 
between the planning-MRI and actual SRS treatment is a maximum of 3 weeks. Single or 
multiple isocentres are allowed for delivering SRS according to the preference of treat-
ment center. Tissue density inhomogeneity correction will be used. Positional verifica-
tion and correction prior to (and/or during) radiation should be executed according to 
the institutional protocol for stereotactic radiotherapy and should be in accordance 
with the CTV-PTV margin used. All techniques that result in the dose requirements be-
ing met are allowed. Participating institutes will have to define their radiation delivery 
treatment prior to the initiation of the study. Techniques that have a shorter treatment 
time duration are preferred as this is more comfortable for the patient and might pre-
vent an increase in the intrafraction displacement over the treatment time. All vendors 
are allowed to deliver SRS, such as a linear accelerator, Gamma Knife and CyberKnife. 
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Table 1 SRS dose prescription in trial. All BMs are dosed equally in the same patient. If the V12 Gy exceeds 10 
cm3 of the healthy brain tissue nearby the largest brain metastasis, it is allowed to lower the fraction dose to a 
single dose of 21, 18, 16, or 15 Gy. 
PTV of the largest brain metastasis Doses in each PTV BM in brainstem (GTV=PTV) 
<1  cm3 1 x 24 Gy 1x  16Gy 
1-10  cm3 1 x 21 Gy 1 x 16Gy 
10-20  cm3 1 x 18 Gy 1 x 16Gy 
20-65  cm3 1 x 15 Gy  No SRS 
Number of patients and recruitment 
Questionnaires measuring QOL with the EQ5D EUROQOL questionnaire are collected 
from patients with multiple BM treated with WBRT or SRS at baseline and at 3 months 
after treatment. For this phase III trial, sample size calculation is based on the clinically 
relevant difference of 0.10 points of the EQ5D-5L index value (range 0 – 1) at 3 months 
after treatment with regard to baseline, with a standard deviation of 0.25 points. For 
every patient this difference in EQ5D-5L QOL score is calculated (score at 3 months 
minus score at baseline). The average score of all patients in the SRS group is calculated 
and this average score is compared to the calculated average score of all patients in the 
WBRT group. This is accordingly the method described by Pickard.[6] Sample size calcu-
lation is performed for a comparison of means with two-sided alpha 0.05 and power of 
0.80. This leads to a sample size per group of 100 patients. To account for drop out, the 
sample size for this study will be increased by 15% to 230 patients (115 per group). 
After 86 patients treated, an interim analysis is performed to monitor the safety of the 
trial regarding the experimental SRS arm. 
Patient accrual was started on 1st July, 2016. Up to 14th April, 2017, nine patients were 
randomized. With expected participation of 12 centers, it is estimated that patient’s 
accrual can be completed within 2 years with an expected accrual of 10–15 patients 
each year per center. 
For this phase III study, a comparison of the above described difference in EQ5D score 
between SRS and WBRT group will be performed using an independent samples Stu-
dent’s t-test with two-sided significance level alpha set at 0.05. A clinical significant 
difference in EQ5D is determined at 0.10 points in the index score.[4]  For the total 
patient cohort, a multivariate analysis is performed to identify prognostic factors for a 
difference in EQ5D score at 3 months with regard to baseline. Differences in secondary 
endpoints that repeat in time are analyzed with Kaplan Meyer curves including log-rank 
test or ANOVA test. Time-to-event data (e.g. overall survival) will be compared using 
Kaplan–Meier curves and log-rank test. Means will be compared using independent 
samples Student’s t-tests. Frequencies (e.g. WHO-PFS) will be compared using Chi-
square test.  
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DISCUSSION 
A typical SRS treatment requires a high-resolution contrast-enhanced planning-MRI, 
frameless mask, a planning-CT, a treatment plan and quality assurance. Generally, all 
preparations will take a maximum of 2 weeks. Duration of SRS delivery depends on the 
number of isocentres, arcs and dose rate, but usually in the range of several minutes up 
to 45 min. With WBRT, all other preparation steps are required, but treatment planning 
and quality assurance are less complex. WBRT treatment is delivered in five fractions 
compared to a single treatment fraction with SRS. Questionnaires will be assessed at 
baseline, 3 months after treatment and every 3 months thereafter until 1 year after 
treatment. Questionnaires can be assessed by telephone, or during scheduled outpa-
tient clinic visits. Not all hospitals have the logistic capacity to perform neurocognitive 
tests and extensive QOL assessment; hence, neurocognitive function (Hopkins Verbal 
Learning Test) and more extensive QOL (EORTC QLQ-C30, EORTC BN20, and EORTC 
QLQ-FA13) will be facultative endpoints and will only be performed at baseline and at 3 
months after radiotherapy at the outpatient clinic in centers willing to participate. Alt-
hough these secondary endpoints are facultative, these endpoints will also provide 
valuable information, and participating centers are recommended to monitor them. 
LIST OF ABBREVIATIONS 
BM=brain metastases; CT=computed tomography; CTCAE=common criteria of adverse 
events; GTV=gross tumour volume; Gy=Gray; ICRU=International Commission on Radia-
tion Units & Measurements; MRI=magnetic resonance imaging; PTV=planning target 
volume; QOL=quality of life; SRS= stereotactic radiosurgery; WBRT=whole brain radio-
therapy 
DECLARATIONS 
Ethics approval and consent to participate 
This study was approved by the ethics committee of the following hospital: the Maas-
tricht University medical center (MUmc+), Maastricht, the Netherlands: reference num-
ber protocol NL53852.068.15/METC153053. The responsible investigator will ensure 
that this study is conducted in agreement with the Declaration of Helsinki (Brazil, Octo-
ber 2013) and in accordance with the Medical Research Involving Human Subjects Act 
(WMO). The protocol has been written, and the study will be conducted according to 
the ICH Harmonized Tripartite Guideline for Good Clinical Practice (ref: 
http://www.ifpma.org/pdfifpma/e6.pdf). All patients will be informed about the aims of 
Whole brain radiotherapy versus Stereotactic Radiosurgery for 4 - 10 brain metastases 
105 
the study, the possible adverse events, the procedures and possible hazards to which 
they will be exposed. They will be informed about the strict confidentiality of their data, 
and that their medical records may be reviewed for trial purposes by authorized indi-
viduals other than their treating physician. Information will be given in both spoken and 
written form as given in the Patient Information text. The Patient Informed consent 
statement and the Patient Information text are given as an appendix to this protocol. It 
will be emphasized that the participation is completely voluntary, and the patient does 
not need to give any further explanation for not participating. The patient is allowed to 
refuse further participation in the protocol whenever he wants. This will not prejudice 
the patient’s subsequent care. Documented informed consent must be obtained for all 
patients included in the study before they are registered in the study. 
Consent for publication 
All patients have provided written informed consent for participation in this trial, and 
publication of the results gathered in this trial. The publication does not contain recog-
nizable individual patient data, but an analysis of the results of the whole study popula-
tion (n=230). 
Availability of data and material 
The study coordinator (JZ) has full access to the original data, the sequence of authors 
has been determined upfront, and all authors will read the final report before publica-
tion. The first author on papers with results of the study will be JZ (Jaap Doeke Zindler), 
second author AB (Anne Marie Bruynzeel), third author DE (Danielle Eekers), fourth 
author CH (Coen Hurkmans), fifth author Ans Swinnen and the last author will be PL 
(Philippe Lambin). The same policy will be applied to side results. Everyone who further 
contributed, such as investigators or participating centers, will also be considered as co-
authors. The sequence co-authorship of participating investigators will be determined 
by the number of patients included in the study. Persons who contributed in a minor 
way to a study may be considered for the acknowledgments section. Results will be 
published unreservedly regardless of their nature in accordance with the CCMO state-
ment on publication policy. 
Competing interests 
The department of radiotherapy of MAASTRO clinic has a research agreement with 
Varian Medical Systems, Palo Alto USA. Varian Medical Systems is not involved in the 
design of the study, and collection/storage/analysis of the data gathered in this study.  
Chapter 8 
106 
Funding 
According to the research agreement of MAASTRO clinic with Varian Medical Systems, 
this trial is mentioned and financially supported. Varian Medical Systems is not involved 
in the design of the study, and collection/storage/analysis of the data gathered in this 
study.  
Authors contributions 
JZ has written the study protocol in close cooperation with AB and PL. CH, DE, and AS 
also commented on the content of the study protocol. All authors have read and ap-
proved this manuscript. 
Acknowledgements 
MAASTRO clinic: Rody Zuidema, Anita Botterweck, Kim Smits, and Andre Dekker for 
their support and collaboration in this trial. Ruud Houben for advice considering statisti-
cal analysis.  
VUmc Amsterdam: Frank Lagerwaard for commenting on the study protocol. 
All patients willing to participate, all referring physicians supporting this trial and co-
investigators of other hospitals who participate in this multicentre study. 
Author information 
JZ: radiation oncologist, MAASTRO clinic Maastricht, the Netherlands; AB: radiation 
oncologist, VU university medical centre, the Netherlands; DE: radiation oncologist, 
MAASTRO clinic Maastricht, the Netherlands; CH: clinical physicist radiation oncology, 
Catharina Hospital, Eindhoven, the Netherlands; AS: clinical physicist radiation oncology, 
MAASTRO clinic, Maastricht, the Netherlands; PL: radiation oncologist and research 
professor, MAASTRO clinic, Maastricht, the Netherlands 
  
Whole brain radiotherapy versus Stereotactic Radiosurgery for 4 - 10 brain metastases 
107 
REFERENCES 
[1]  Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain 
Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical 
Trial. JAMA. 2016 Jul 26;316(4):401-9 
[2]  Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole 
brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable 
for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised 
trial. Lancet. 2016 Oct 22;388(10055):2004-2014. 
[3]  Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain me-
tastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014 
Apr;15(4):387-95 
[4]  Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62]. Cancer 
Radiother. 2001 Oct;5(5):472-8. 
[5]  Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in 
children: a radiation oncologist's guide for delineation in everyday practice. Radiother Oncol. 
2015;114(2):230-8. 
[6]  Pickard, A Simon, Maureen P Neary, and David Cella. “Estimation of Minimally Important Differences in 
EQ-5D Utility and VAS Scores in Cancer.” Health and Quality of Life Outcomes 5 (2007): 70. PMC. Web. 
23 Feb. 2015. 
  
 
  
109 
Chapter 9 
Propensity-score matched pair comparison of 
whole brain with simultaneous in-field boost 
radiotherapy and stereotactic radiosurgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radiother Oncol. 2013 Feb;106(2):206-9 
 
Rodrigues G, Zindler J, Warner A, Bauman G, Senan S, Lagerwaard F. 
  
Chapter 9 
110 
ABSTRACT 
Purpose To compare lesional stereotactic radiosurgery to whole brain (WBRT) radiother-
apy with simultaneous in-field boost for brain metastases in terms of overall survival. 
Methods A retrospective review was performed on two institutional databases of 500 
patients diagnosed with brain metastatic disease who received either stereotactic radi-
osurgery (SRS, n = 381) or whole brain with simultaneous in-field boost radiotherapy 
(SIB, n = 119), between 2002 and 2011. Propensity-score matching was utilized to ob-
tain two groups with similar known prognostic factor characteristics. Kaplan–Meier and 
univariable/multivariable Cox modeling were conducted to assess the treatment impact 
on overall survival (OS). 
Results Propensity-score matching created a matched cohort of 178 patients (89 
SRS/SIB) with similar baseline characteristics. Multivariable analysis demonstrated that 
presence/absence of systemic metastases, patient age, tumor volume, and pres-
ence/absence of active primary were found to be more predictive of OS than treatment 
assignment (p = 0.38). SIB was associated with reduced intracranial failure likely due to 
the WBRT component of the treatment (HR 0.36, p < 0.001). 
Conclusions Adjusting for other predictive factors, treatment with either SRS or SIB did 
not result in any statistically significant difference in OS; however, observed intracranial 
failure was different due to the use of WBRT in the SIB cohort. 
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INTRODUCTION 
The management of brain metastases has been the subject of multiple randomized 
controlled trials and knowledge translation documents [1] and [2]. Aggressive therapy 
with neurosurgical resection or stereotactic radiosurgery (SRS) is usually reserved for 
patients with good performance status, low burden oligometastatic disease, and con-
trolled extracranial/primary disease. Important clinical endpoints to be optimized with 
treatment include: survival, neurological stabilization/improvement, prevention of neu-
rologic death, lesion control, steroid dose reduction, symptom palliation, and quality-of-
life. 
Important unanswered questions remain in the field of brain metastases radiotherapy. 
One such question relates to the therapeutic ratio of whole brain radiotherapy (WBRT) 
when given in conjunction with single fraction or multiple fraction SRS or radiation ther-
apy in terms of important clinical outcomes such as survival and lesional control. While 
the use of WBRT has been shown to increase intracranial control [3], [4] and [5], some 
published evidence suggests negative effects in terms of neurocognitive function and 
overall survival [6]. However, the measurement of neurocognitive function and associ-
ated quality-of-life changes can be challenging [7] due to changes in toxicity over time 
and inadequate late assessments [8]. 
Matching patients together by known prognostic factors can be an alternative method 
to explore differences in patient outcome between treatment groups, in the absence of 
randomized controlled clinical trial data, specifically, propensity-score matched pair 
analysis allows for a statistical model-based approach to create similar comparison 
groups for analysis and interpretation [9]. This approach has an advantage over tradi-
tional matching techniques due to minimization of the bias related to treatment selec-
tion/assignment [10]. We report on such a matched pair analysis comparing SIB (whole 
brain with simultaneous in-field boost radiotherapy) to SRS treatment (without WBRT). 
The impact of differences in local (single dose SRS vs. fractionated radiotherapy) and 
regional (SRS alone vs. WBRT within SIB approach) treatments in terms of important 
clinical outcomes such as overall survival (OS) and intracranial failure (from both local 
lesion failure and/or distant failure in the brain) is examined. 
METHODS AND MATERIALS 
Database composition 
A retrospective review was performed on two institutional review board approved insti-
tutional databases of 500 patients diagnosed with brain metastatic disease who re-
ceived either SRS (n = 381) or SIB (n = 119) between 2002 and 2011 with outcome in-
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formation on OS and Response Evaluation Criteria in Solid Tumors (RECIST) intracranial 
failure. Patients were treated at one of two cancer centers: London Regional Cancer 
Program (LRCP, London, ON, n = 69 SIB patients) or at VU Medical center (VUmc, Am-
sterdam, The Netherlands, n = 381 SRS patients plus n = 50 SIB patients). Institutional 
ethics approval was obtained for this joint database analysis. 
SRS cohort 
The VUmc SRS database contains baseline characteristics, treatment details and follow-
up data for patients with 1–3 BM diagnosed with high resolution (2 mm slice thickness, 
triple dose gadolinium) MRI scans who were eligible for linac-based SRS as a single mo-
dality. SRS was delivered by 5 dynamic conformal arcs on a Novalis (2002–2008, n = 50 
for matched cases) or Novalis TX (2008–2012, n = 39 for matched cases) linear accelera-
tor using a relocatable Gill-Thomas-Cosman frame (2002–2008) or a frameless mask 
system (2008–2012) [BrainLAB, Feldkirchen, Germany]. The SRS target volumes consist-
ed of the gross tumor volume contoured on the planning MRI with a 1 mm margin to 
correct for potential setup-inaccuracies for both SRS systems. SRS was prescribed with 
the 80% isosurface covering the GTV and a ‘risk-adapted’ dose based on lesion volume: 
≤7.5 cm3 21 Gy, 7.5–25 cm3 or lesions near brainstem 18 Gy with other all other lesions 
15 Gy in 1 fraction or 24 Gy in 3 fractions. Follow-up was standardized as per institu-
tional guidelines and consisted of 3-monthly clinic visits with contrast-enhanced MRI 
investigation during the first year, followed by 6-monthly MRI scans during the second 
year, and yearly scans thereafter. 
SIB cohort 
Technical details of the SIB techniques at both the VUmc and LRCP have been published 
[11], [12] and [13] and are summarized as follows. Patient selection criteria for treat-
ment in the VUmc series included: not rapidly progressing extracranial disease that in 
the opinion of the investigator would, WHO score 0–3, and 1–6 lesions with cumulative 
volume <30 cm3. Patients were positioned supine in a frameless mask system [Brainlab 
AG, Feldkirchen, Germany]. Planning CT scans (GE Healthcare) without intravenous 
contrast were obtained with a 2.5 mm slice thickness. Contrast-enhanced T1-sequences 
(slice thickness 2 mm, with a 3D-distortion correction protocol) of a co-registered re-
cent (<3 weeks) diagnostic MRI scan were used for GTV definition. The whole brain 
radiotherapy planning target volume (WBRT_PTV) was derived from autosegmentation 
of the brain on the CT scan, with the addition of a 2 mm symmetric margin. The SIB PTV 
was derived by contouring the outer contrast-enhancing border of the brain metastases 
and adding a 2 mm margin. Treatment planning, calculation and quality assurance were 
performed using two complementary volumetric modulated arcs [RapidArc with Eclipse 
v8.6.3, Varian medical systems] calculated using the AAA calculation model and con-
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firmed using film dosimetry as previously described [12]. The SIB plan delivered a total 
dose of 20 Gy to the WBRT volume with a total lesional dose of 40 Gy all in 5 fractions. 
Treatment was delivered on a Novalis TX linear accelerator, with patient setup using the 
6D robotic couch and the Brainlab ExacTrac system [BrainLAB, Feldkirchen, Germany]. 
Routine patient follow-up was similar to that after SRS, described above. 
LRCP patient selection generally included WHO performance status 0–3, systemic dis-
ease absent/controlled and 0–3 metastases none larger than 3 cm. All patients had a 
custom thermoplastic shell created prior to planning CT (S-frame, CIVCO, Iowa, USA). A 
planning CT (Phillips Healthcare) was obtained with a 3 mm slice thickness and fused 
with contrast-enhanced MRI (CT simulation with contrast was utilized if MRI was una-
vailable). The individual contrast enhancing lesions were contoured as the SIB targets 
without margin. The whole cranial contents with a 3 mm 3D margin were contoured as 
the target for the whole brain treatment. A variety of total SIB doses ranging from 35–
60 Gy were utilized at the LRCP; however, in all cases the whole brain dose was 30 Gy 
and all treatments were delivered over 10 fractions. Dose–volume histogram optimiza-
tion, planning parameters, evaluation criteria, and image-guidance procedures were as 
published previously. All patients were clinically or radiologically (CT or MRI brain) eval-
uated in a similar manner to the VUmc (every 3 months). 
Statistical analysis 
All patients were eligible for the matching procedure which utilized propensity scores 
generated from a multivariable logistic regression model predictive of treatment group 
(SIB vs. SRS), and adjusting for covariates including: age, year of treatment, primary 
tumor type, presence of systemic metastases, WHO performance status, initial diagno-
sis to brain metastases time interval, total volume of brain metastases, and status of 
primary tumor. To assess the degree of similarity between treatment groups and the 
overall performance of the matching procedure, univariable analysis was performed on 
all covariates included in matching procedure by treatment group (using Chi-
square/Fisher’s exact tests and two-sample t-tests for categorical and continuous varia-
bles, respectively). It was determined that using a ratio of 1 SIB: 1 SRS patient and a 
calliper distance of 0.025 yielded sufficient power and similarity between treatment 
groups to proceed with matching (final matched cohort of 89 SIB patients with 89 SRS 
patients). 
The primary endpoint for this study was OS (defined as date of initiation of radiotherapy 
to date of last follow-up or death). The secondary endpoint for this matched pair analy-
sis was radiological confirmation of intracranial failure which is composed of two sepa-
rate types of failure: local lesional failure and distant failure in the brain not involving 
the treated lesions. Estimates of overall survival were obtained using Kaplan–Meier 
method on the final matched cohort of 178 patients (89 SRS and 89 SIB) stratified by 
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treatment group (SRS vs. SIB). To identify significant predictors of OS, backward elimina-
tion multivariable cox regression analysis (using p < 0.15 Wald Chi-square test for model 
halting) was performed on the matched cohort (n = 178) after initial univariable model-
ing (p > 0.30 for removal for further consideration). The remaining set of covariates was 
included in a multivariable cox regression, which included treatment group (SRS vs. SIB) 
as a covariate. 
RESULTS 
Descriptive statistics relating to patient, tumor, and treatment parameters for all pa-
tients (n = 500, n = 119 SIB and n = 381 SRS) as well as propensity-score matched pa-
tients (n = 178, n = 89 SIB and n = 89 SRS) are summarized in Supplementary Table e1. 
Review of this summary table demonstrates that the propensity-score matching 
achieved the goal of balancing the SRS and SIB patient populations with regard to 
known prognostic factors and published prognostic indices. Only one variable remained 
statistically different between the SRS and SIB groups; which was year of treatment. 
This is a reflection of the longer use of SRS over newer SIB techniques. The Kaplan–
Meier curve comparing SRS (median survival = 4.50 months) vs. SIB (median survival = 
5.62 months) matched patients is depicted in Fig. 1 (p = 0.32). Median survival for un-
matched patients was higher at 7.73 months for SRS and 5.82 for SIB (p = 0.06, Kaplan–
Meier plots not shown). Kaplan–Meier plots of radiologically confirmed intracranial 
failure demonstrated less intracranial failure with SIB treatment (16/89 (8 lesional fail-
ure + 4 distant brain failure + 4 both lesion and distant brain failures) cases for SIB vs. 
35/89 (13 lesional failure + 15 distant brain failure + 7 both lesion and distant brain 
failures) cases for SRS, HR 0.36, log rank p < 0.001). 
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Figure 1 Overall survival with Kaplan Meyer analysis for matched patients treated with SRS and SIB techniques. 
Legend: SIB=simultaneous integrated boost, SRS=stereotactic radiosurgery  
 
Univariable Cox modeling for matched (n = 178) and all patients (n = 500) is summarized 
in Table 1. Treatment assignment was not a statistically significant predictor of OS. Re-
sults of the backward elimination are shown in Table 2. Given that the primary covariate 
of interest, treatment group was not retained in the initial model (Model 1: Matched 
Cohort without SRS/SIB), an additional model was constructed including it as a covariate 
(Model 2: Matched Cohort with SRS/SIB). To assess the relative strength of covariates 
on the original cohort and the impact of propensity-score matching on survival out-
comes; both models were constructed based on the complete cohort of patients (Mod-
els 3 and 4, Supplemental Table e2). 
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Table 1 Summary of p-values reported from univariable cox regressions for overall survival (dependent varia-
ble), reported from analyses based on matched patients (n=178) and all patients prior to matching (n=500) 
 
DISCUSSION 
This analysis has demonstrated that treatment assignment (SRS without WBRT vs. 
WBRT with SIB) did not significantly predict for OS outcome. Stated differently; adjust-
ing for other known prognostic factors, OS of patients treated with SIB (with WBRT) and 
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SRS (no WBRT) were similar to each other. Prognostic factors such as presence/absence 
of systemic metastases, patient age, tumor volume, and presence/absence of active 
primary were found to be more predictive than treatment assignment. Many of these 
factors have been demonstrated to be important for patient outcome in various prog-
nostic indices [14]. This finding of treatment prognostic effect being less than other 
baseline prognostic factors was subjected to a sensitivity analysis for both the matched 
and unmatched patient populations and was maintained in both populations. 
 
Table 2 Multivariable cox regression models examining relationships between individual predictors of overall 
survival based on propensity-score matched patients (n=178). Model 1: Main model adjusting for all covari-
ates. Model 2 Adjusting for all covariates forcing inclusion of treatment. Legend: SRS=stereotactic radiosur-
gery; SIB simultaneous integrated boost; CI=confidence interval. Bold if p<0.1. 
 
 
Investigations and clinical trials related to brain radiotherapy have questioned the utility 
of the WBRT component of the combined WBRT + SRS treatment. These studies have 
generally demonstrated that patients who do not receive the WBRT component of 
treatment may have better neurocognitive function with similar survival but an in-
creased risk of regional brain relapse from 40% to 60% [2], [3] and [5]. Our matched pair 
analysis also detected a 64% absolute decrease in radiological intracranial failure with 
the inclusion of WBRT, which is consistent with these published prospective studies. 
Despite the difference in intracranial control, radiation oncologists are increasingly 
excluding the WBRT component of SRS treatment and considering salvage SRS treat-
ment for clinically significant intracranial recurrences in order to optimize neurocogni-
tive functioning given the equivalent OS characteristics observed in various reports 
including the present one. 
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Prospective clinical trials assessing fractionated radiotherapy (either alone or given with 
concurrent WBRT with SIB) are currently limited to one randomized controlled trial 
assessing hyperfractionation [15] and one phase I SIB dose-finding study [13]. Most 
other literature reports consist of single institution retrospective reports with no 
matched comparison group(s) [16]. Compared to other fractionated brain metastases 
reports, the current work is novel as a matching procedure was conducted to control 
for known prognostic factors. This work suggests that the fractionated approach (given 
by WBRT plus SIB) may provide equivalent OS and intracranial/intralesional control 
results when compared to single dose SRS without WBRT. 
The most significant limitation of this work is that it is based on retrospective data and 
that despite patient matching important differences between treatments may exist that 
can be detected in an adequately powered randomized controlled trial. For instance, 
the lack of toxicity data for direct comparison between radiotherapy approaches is 
another limitation of this report. Additionally, this study does not define potential good 
prognosis subpopulations of patients that may benefit from single fraction SRS tech-
niques. Ideally, future phase III clinical trials comparing fractionated stereotactic radio-
therapy techniques (with or without WBRT) against standard of care approaches (SRS 
with or without WBRT, neurosurgery plus WBRT, or WBRT alone) need to be conducted 
in order to draw more robust conclusions to guide patient care. Prior to such definitive 
trials, a new set of prospective phase I and II trials assessing fractionated stereotactic 
radiation treatment are currently underway in order to define optimal treatment strat-
egies that balance treatment outcome, intracranial control, and neurocognitive side 
effects [16]. Future research into the neurocognitive impact(s) of delivering an SIB ap-
proach with hippocampal sparing should be also investigated. 
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ABSTRACT 
To obtain a favorable tradeoff between treatment benefits and morbidity (“therapeutic 
ratio”), radiotherapy (RT) dose is prescribed according to the tumor volume, with the 
goal of controlling the disease while respecting normal tissue tolerance levels. We pro-
pose a new paradigm for tumor dose prescription in stereotactic ablative radiotherapy 
(SABR) based on organ-at-risk (OAR) tolerance levels called isotoxic dose prescription 
(IDP), which is derived from experiences and limitations of conventionally fractionated 
radiotherapy. With IDP, the radiation dose is prescribed based on the predefined level 
of normal tissue complication probability of a nearby dose-limiting OAR at a prespeci-
fied dose-volume constraint. Simultaneously, the prescribed total tumor dose (TTD) is 
maximized to the technically highest achievable level in order to increase the local tu-
mor control probability (TCP). IDP is especially relevant for tumors located at eloquent 
locations or for large tumors in which severe toxicity has been described. IDP will result 
in a lower RT dose or a treatment scheduled with more fractions if the OAR tolerance 
level is exceeded, and potential dose escalation occurs when the OAR tolerance level 
allows it and when it is expected to be beneficial (if TCP < 90%). For patients with small 
tumors at noneloquent sites, the current SABR dose prescription already results in high 
rates of local control at low toxicity rates. In this review, the concept of IDP is described 
in the context of SABR. 
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INTRODUCTION 
Stereotactic ablative radiotherapy (SABR), also referred to as stereotactic radiotherapy 
(SRT), stereotactic body radiotherapy (SBRT), or radiosurgery (RS), is a form of radio-
therapy (RT) in which a high dose per fraction is delivered in a limited number of frac-
tions with the aid of dedicated imaging and patient immobilization devices to minimize 
the treatment set-up margins of the irradiated tumor. With SABR, there is a steep-dose 
gradient outside the target volume to minimize the dose to organs at risk (OAR) and 
hence reduce the normal tissue complication probability (NTCP). SABR is increasingly 
being used in patients with metastasized cancer. 
To obtain a favorable tradeoff between treatment benefit and morbidity (“therapeutic 
ratio”), the radiation dose is typically prescribed according to the target volume, with 
the goal of controlling the disease while respecting normal tissue tolerance levels. The 
therapeutic ratio is explained in Figure 1.[1] In resemblance to conventionally fraction-
ated radiotherapy, we propose a paradigm shift for dose prescription in SABR from 
target-based to OAR-dependent tolerance levels called isotoxic dose prescription 
(IDP).[2 ,3] With IDP, radiation dose is prescribed based on the predefined level of NTCP 
of a nearby dose-limiting OAR at a prespecified dose-volume constraint.[4–6] Simulta-
neously, the prescribed total tumor dose (TTD) is maximized to the technically highest 
achievable level in order to increase the local tumor control probability (TCP). The con-
cept of IDP is shown in Figure 2 . IDP is especially relevant for tumors located at elo-
quent locations or for large tumors in which severe toxicity has been described. IDP will 
result in more fractions to achieve an ablative dose for SABR or to reduce the pre-
scribed dose if the OAR tolerance level is exceeded. IDP will facilitate dose escalation 
when tolerance dose to critical OAR allows it and when it is expected to be beneficial (if 
TCP < 90%). For patients with small tumors at noneloquent sites, the current SABR dose 
prescription already results in high rates of local control at low toxicity rates, and then 
IDP is less relevant. In this review, the concept of IDP is described in the context of 
SABR.  
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Figure 1 Therapeutic ratio in radiotherapy.  
Legend: The therapeutic ratio denotes the relationship between the probability of tumor control and the 
likelihood of normal tissue damage. An improved therapeutic ratio represents a more favorable tradeoff 
between tumor control and toxicity.[53] The numbers 1, 2, and 3 represent potential stereotactic ablative 
body radiotherapy (SABR) dose prescriptions. With the dose prescribed in example 1, there is a relatively low 
TCP of +/-40% with a normal tissue complication probability (NTCP) of 0%. At the dose prescribed in example 
2, the TCP is +/-80% with a low NTCP of +/-5%. The prescribed dose in example 3 results in a TCP of +/-95%, 
but at the cost of a NTCP 50%, which is often regarded as being an unacceptable risk for NTCP. There are two 
options for lowering the NTCP: The SABR dose is lowered to example 2, or the SABR dose is delivered in more 
fractions in which the NTCP curve moves to the right (red dotted line), which results in a larger therapeutic 
ratio.  
 
 
Figure 2 Concept of isotoxic dose prescription.  
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Legend: Concept of isotoxic dose prescription (IDP): The radiotherapy dose is prescribed in relation to a 
volume of a dose-limiting adjacent organ at risk (OAR) based on a predefined level of acceptable normal tissue 
complication probability (NTCP). The total tumor dose (TTD) is escalated to the technically highest achievable 
level. An example of IDP for stereotactic ablative body radiotherapy of a brain metastasis is that a maximum 
volume of 10cm 3 of adjacent brain tissue may receive at least 12 Gy in a single fraction, which corresponds to 
an NTCP of 10% for symptomatic radionecrosis independent of tumor volume.[6] The tumor dose can be as 
high as technically achievable but should at least be 15 Gy in a single fraction. Conventional dose prescription 
in radiotherapy is based on tumor volume, not on the OAR tolerance. An example of a conventional dose 
prescription is a fixed single-fraction dose of 15 Gy prescribed on the target volume for every individual pa-
tient. However, uniformity in TTD prescription does not guarantee uniformity in NTCP. Because of the differ-
ence in tumor volume amongst patients, for some the OAR dose-volume constraint will not be met, whereas 
for others it is exceeded unless the prescribed tumor dose is lowered. With IDP, it is possible to individually 
tailor the dose prescription to a predefined level of acceptable toxicity (also see Figure 1 ). OAR = organ at 
risk; RT = radiotherapy.  
CURRENT STATUS OF SABR 
Dose prescription with SABR is far beyond the 2 Gy dose level of conventional fractiona-
tion, ranging from 7.5 to 100 Gy in one to eight fractions. Typical hypofractionation 
schedules comprise three to five fractions ranging from 10 to 20 Gy for early-stage non–
small cell lung cancer (NSCLC), a single fraction of 24 Gy for a small brain metastasis, a 
single fraction of 12 Gy for vestibular schwannoma, and a single fraction of 70 Gy for 
trigeminal neuralgia.[7] The difference in SABR fractionation schedules is explained by 
the difference in disease entities (eg, a benign or malignant, type of tumor) while also 
taking into account life expectancy; high local control rates of approximately 90% are 
already achieved in vestibular schwannoma with a relatively low single-fraction dose, 
whereas for early-stage NSCLC, much higher doses are mandatory. In some countries 
(eg, the United States and the Netherlands), reimbursement may be, in part, dependent 
on the number of fractions or the dose per fraction, and this may influence the choice 
of fraction schedules and thereby the therapeutic ratio. There is evidence that the 2 Gy 
equi–effective dose (ie, the biologically equivalent total dose delivered using a fraction 
size of 2 Gy) in the SABR of early-stage NSCLC should be above 100 Gy to achieve local 
control rates of above 90%.[8] In patients with oligometastatic cancer, lower SABR dos-
es are often used, which results in relatively low local TCP. In a large retrospective study 
on patients treated with SABR for oligometastases, several fractionation schedules were 
used depending on the location of the metastasis and its proximity to an OAR, resulting 
in the vast majority of patients being treated with a 2 Gy equi–effective dose of less 
than 100 Gy.[9] Not surprisingly, local control two years after SABR was only 33% and 
was statistically significantly ( P = .02) better for lesions treated with a 2 Gy equi–
effective dose greater than 75 Gy compared with a dose of less than 75 Gy. Life expec-
tancy also plays a role. If the tumor is near an organ that is at risk for radiation toxicity 
(eg, spinal cord, brain, bowel) or the tumor volume is unfavorably large, fractionation 
schedules are often protracted to a relatively large number with an accordingly low 
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dose per fraction in order to decrease the risk of late toxicity. An example of such a risk-
adapted fractionation schedule in early-stage NSCLC is eight fractions of 7.5 Gy for cen-
trally located tumors instead of three fractions of 18 to 20 Gy for peripherally located 
ones. In general, the fractionation sensitivity (characterized by the reciprocal α/β-value) 
of a relevant biological endpoint of late-responding normal tissue is lower than that for 
tumors. If the α/β-value of the tumor is higher than that of the late-responding normal 
tissue, then a reduction of dose per fraction improves the therapeutic ratio, provided 
the overall treatment time is not extended.[10] Although the concept of SABR has been 
around for more than half a century, its clinical use has strongly expanded over the last 
decade, mainly because of high local control rates at acceptably low proven toxicity 
rates.[11] 
Furthermore, the concept of the “oligometastatic disease state” has widened the indi-
cation for SABR to patients with stage IV solid tumors that were previously not eligible 
for (stereotactic) radiotherapy except for palliative purposes.[12] The aim of SABR in 
patients with a limited number of metastases (oligometastases typically comprise up to 
five lesions in a maximum of three visceral organ sites) is the prolongation of progres-
sion-free survival, postponing systemic treatment, and the long-term maintenance of 
quality of life.[13] For patients with one to three brain metastases, SABR is currently a 
standard treatment.[14,15] In stage I lung cancer treated with SABR, local control rates 
are comparable with surgery while simultaneously avoiding the morbidity and mortality 
of invasive approaches.[16,17] Randomized clinical trials are currently being designed to 
directly compare the outcome of SABR to surgery in operable patients, although patient 
accrual may be problematic because of the lack of equipoise from different special-
ties.[18,19] Other applications of SABR are the treatment of metastases or primary 
tumors in the liver, vertebra, adrenal gland, kidney, prostate, or lymph nodes.[13] There 
are several studies suggesting that the hypofractionated SABR of metastases may in-
duce a so-called “abscopal” effect, ie, when highly immunogenic tumor antigens result-
ing from local SABR activate the immune system causing shrinkage of other metastases 
at nonirradiated sites.[20 ,21] This phenomenon has been described in primary tumor 
types such as melanoma, lymphoma, and renal cell carcinoma. It is hypothesized that 
cytotoxic T-cells and natural killer cells play a crucial role in the underlying biological 
mechanisms.[22,23] The widespread use of SABR at intra- and extracranial tumor sites 
has become possible because of several technical advances, making SABR a safe and 
patient-friendly technique.[24–27] Randomized studies are needed to identify which 
oligometastatic patients really benefit from ablative doses of SABR.[12]  
Toxicity of SABR 
Local control rates of SABR on small tumors at noneloquent locations are high (>90%) 
when applied according to current state-of-the-art procedures.[28] However, severe 
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complications have been described in other situations because nearby OARs receive 
doses that can lead to organ dysfunction. Examples of severe toxicities are the follow-
ing:  
•  SABR in early-stage NSCLC: risk of radiation pneumonitis in large-volume lung tu-
mors (eg, planning target volume >80 cm 3 ) if the V 5Gy (the volume that receives 
at least 5 Gy) of the contralateral lung is ≥ 26%;[29] 
•  SABR in centrally located lung tumors: bronchial stenosis and/or necrosis;[30] 
•  SABR in brain metastases: symptomatic brain necrosis if more than 10 cm 3 of the 
uninvolved brain tissue is irradiated with a single dose of at least 12 Gy;[6]  
•  SABR in abdominopelvic tumors: bowel obstruction, perforation, and bleeding;[31]  
•  SABR in spinal metastases: myelopathy and vertebral fracture;[32,33]  
•  SABR in close to mediastinal structures: esophageal fistula.[34]  
 
To minimize the risk of the severe toxicity of SABR, clinical researchers have developed 
dose-volume constraints for OARs.[35,36] However, most of these constraints remain 
unvalidated and only serve as a starting point of sorts in order to develop some uniform 
guidelines to guide practitioners in the rapid proliferation of SABR.  
CURRENT GUIDELINES FOR DOSE PRESCRIPTION IN CONVENTIONALLY 
FRACTIONATED RT AND SABR 
In radical, conventional, fractionated RT, the TTD is prescribed according ICRU guide-
lines at the planning target volume (PTV) ( 37 ). The PTV comprises the tumor with mar-
gins for microscopic extension (margin from gross tumor volume, GTV, to clinical target 
volume, CTV) and uncertainties of patient positioning, interobserver variation, treat-
ment delivery, and imaging (margin from CTV to PTV). Typically, the dose distribution 
within the PTV is relatively homogeneous, in the range of 95% to 107% of the pre-
scribed dose. The TTD in SABR is also prescribed at the rim of the PTV, but it differs from 
conventional fractionated RT in that the dose distribution within the PTV is deliberately 
heterogeneous. The maximum dose often exceeds 130% of the prescribed dose.[19,28] 
The aim of the steep dose gradient at the rim of the PTV is to achieve optimal sparing of 
nearby OARs while simultaneously allowing for dose escalation within the PTV in order 
to achieve maximal TCP. Typically, the used GTV-CTV and CTV-PTV margins are mini-
mized by the use of dedicated onboard imaging and patient immobilization devices.  
LIMITATIONS OF DOSE PRESCRIPTION BASED ON TUMOR VOLUME 
Currently, several clinical trials with SABR are ongoing. In these studies, a fixed dose 
level is prescribed to the PTV in the same way for every patient. During treatment plan-
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ning, the OAR dose constraints are respected and, if necessary, nearby OARs are active-
ly spared. If the OAR is very close to the PTV, there is an insurmountable conflict be-
cause it is technically not feasible to respect the OAR dose-volume tolerance while sim-
ultaneously achieving sufficient PTV coverage. Several potential solutions are chosen in 
daily practice: 
1.  A more fractionated approach is chosen in order to increase the therapeutic ratio. 
SABR is delivered as conventionally fractionated RT, which may result in protracted 
schemes of multiple fractions over several weeks. However, long fractionation 
schedules are undesirable in a metastatic setting where disease progression at other 
metastatic sites may occur within months. One to five fractions are more desirable 
for patient convenience. 
2.  Underdosage of the PTV is accepted in a region near the OAR while the number of 
fractions remains unchanged. This may result in a decreased TCP. Moreover, when 
reporting SABR, it is often unclear exactly what dose has been delivered in the PTV 
and in the OAR. 
3.  Underdosage of the PTV is achieved by reducing the number of fractions in order to 
respect the OAR constraint. 
4.  PTV coverage is not compromised by altering the dose prescription, although the 
OAR constraint is not respected, which results in increased NTCP rates. 
 
Evidently, these four solutions have the substantial clinical disadvantages of protracted 
treatment duration, decreased TCP, and increased NTCP. Another disadvantage of SABR 
dose prescription based on the tumor volume is its application in phase I dose escala-
tion trials. A paradox may occur because tumors typically have different volumes. SABR 
of large tumors causes a large volume of the nearby OAR to be irradiated at certain 
doses. A patient with a large tumor volume in a phase I study in a low-dose treatment 
arm may have a higher NTCP than a patient with a small tumor volume in a high-dose 
treatment arm. For example, with the SABR of brain metastasis NTCP (eg, radionecrosis) 
is dependent on the V12Gy and increases rapidly above 10% if the V 12Gy is 10cm 3 or 
larger.[6 ,35,36] The V12Gy of nearby uninvolved brain tissue may be above 10cm 3 in the 
low-dose arm with large-volume metastasis and less than 10cm 3 in the high-dose arm 
with a small-volume metastasis. This was also shown in a randomized trial on SABR in 
brain metastases, in which a 1mm GTV-PTV margin was compared with a 3mm GTV-PTV 
margin with a primary endpoint of a 12-month local control.[38] Dose prescription was 
based on the maximum diameter of the PTV as shown in Table 1 . In the 3mm GTV-PTV 
arm, prescription dose was generally lower, with an equal GTV diameter as that of a 
1mm GTV-PTV arm. BED and TCP are calculated based on the method described by 
Wiggenraad et al.[39] with an α/β-ratio of 12 Gy. In this study, the median GTV in both 
arms was the same (0.38cm 3 in both arms). The median V12Gy, which corresponds with 
NTCP, was higher in the 3mm arm compared with the 1mm arm: 11.4cm3 vs 6.0cm3 . 
The therapeutic ratio was higher in the 1mm margin arm with a higher prescribed dose 
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to the PTV and TCP and a lower V12Gy and NTCP.[Table 1] Therefore IDP, especially in a 
fractionated approach, may increase the therapeutic ratio of SABR in large brain metas-
tases.  
 
Table 1 SABR dose prescription schedule for brain metastases in a randomized trial comparing outcomes for 
1mm vs 3mm GTV-PTV margins.  
 
Legend: BED=biologically effective dose; GTV=gross tumor volume; PTV=planning target volume; 
SABR=stereotactic ablative body radiotherapy; TCP=tumor control probability. 
ISOTOXIC DOSE PRESCRIPTION BASED ON OAR TOLERANCE 
We propose an isotoxic dose prescription (IDP) strategy to overcome the limitations of 
current tumor volume–based dose prescription protocols, especially in the design of 
phase I SABR-based clinical trials. In IDP, the SABR dose is prescribed in relation to a 
volume of a dominant OAR based on an acceptable normal tissue complication proba-
bility (NTCP) level. The TTD is escalated up to the technically highest achievable level 
but within a specified range of minimal TCP. If the TCP is unacceptably low because of 
limitations by NTCP, more fractionated SABR will allow a more favorable therapeutic 
ratio and the allowance of a higher TCP with a constant low NTCP. In the context of IDP 
and NTCP, it is essential to achieve international consensus in OAR delineation and the 
reporting of RT dose in OAR.[40] Moreover, IDP will help to determine the exact OAR 
tolerance dose in a prospective setting and will validate current predictive NTCP mod-
els.[41,42] If OAR dose volume tolerance levels are unknown for a certain fraction 
scheme, phase I studies may discern this. There are several potential designs for phase I 
studies with IDP:  
1.  The TTD is escalated until a predefined OAR dose volume tolerance level is met (with 
an accompanying NTCP rate). The volume of the OAR in relation to which the dose is 
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prescribed is fixed, and the number of fractions is fixed. An example of this strategy 
is illustrated in Figure 3 .  
2.  The OAR volume in relation to which the dose is prescribed is escalated while main-
taining the RT dose in the OAR and the number of fractions fixed. 
3.  The number of fractions is increased until the predefined OAR dose volume con-
straint is met. The RT dose for each fraction is fixed, and the volume of the OAR to 
which the dose is prescribed is fixed. 
 
 
Figure 3 Potential gain in tumor complication probability (TCP) with isotoxic fractionated dose prescription in a 
patient with a large brain metastasis.  
Legend: Treatment plan (Eclipse, Varian, Palo Alto, CA) of a single fraction of 15 Gy with stereotactic ablative 
body radiotherapy of a large brain metastasis with a diameter of 28mm. The illustrated radiation doses are in 
the range of 12 to 18 Gy. The TCP of a single dose of 15 Gy is 40%. In this treatment plan, the V 12Gy is 5cm 3 
. If isotoxic dose prescription (IDP) is applied and the V 12Gy is escalated up to 10cm 3 , the total tumor dose 
increases to 18.9 Gy with a TCP of 65%. Thus, the gain in TCP for this brain metastasis with IDP is 25% if an 
NTCP of 10% on symptomatic radionecrosis is accepted. Wiggenraad calculated TCP estimates based on the 
review article.[39]  
 
For a phase I study, a time-to-event continual reassessment methodology (TiTe-CRM) 
design is suitable, which utilizes a Bayesian approach to reassess the dose on all pa-
tients in the study and permits short- and long-term adverse events to be incorporated 
as an alternative approach to a commonly used 3x3 designs.[43 ,44] For the design of a 
phase I study, the OAR constraint based on available literature is determined. Next, the 
TCP is calculated using an in silico study with the available treatment planning and de-
livery technique and using the margins of several tumor sizes. If there is no potential 
with the current technique and GTV-PTV margins, critical evaluation of the GTV-PTV 
margins will be needed to investigate whether a decrease in the margins is safe at the 
treatment department. This will provide the potential for further dose escalation with 
equal NTCP. If the TCP is still unsatisfactory (<90%), more fractionated approaches are 
used. However, the OAR constraint of common used fractionation schedules is often 
relatively well described but is often unknown for uncommon used fractionation sched-
ules. For example, the V12Gy for a common used single-fraction SABR in brain metastases 
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is well described, but the OAR constraint for a five- or 10-fraction approach is poorly 
documented. It is not trivial to convert the particular OAR constraint from a given frac-
tionation scheme into an equivalent constraint for a new scheme. Therefore, it is im-
portant to perform a phase I study for fractionated approaches in order to carefully 
assess the OAR tolerance level.  
Predictive modeling studies for IDP have already been published. In an in silico trial for 
advanced NSCLC, an individualized isotoxic dose prescription enabled therapeutic gains 
(ie, TTD escalation) in 79% of case patients compared with conventionally prescribed 
fractionated RT ( 45 ). This was achieved by altering the dose per fraction and/or the 
number of fractions based on a clinically relevant mean or a maximum OAR tolerance 
dose for the uninvolved healthy lungs, brachial plexus, spinal cord, esophagus, and 
heart. Two different approaches were described in order to assess the predicted gain in 
a tumor-effective dose, either based on an IDP approach or on a maximum tolerable 
dose. Clinical experience has also been gained with IDP. In a prospective single-arm 
study in stage I to III NSCLC, a radical dose of chemotherapy was prescribed using a 
sequential approach by increasing the number of fractions until the first dose-limiting 
OAR tolerance level was met.[46] The observed toxicity rates were acceptable (grade 3 
or more toxicity was 24%), and survival was comparable with the results achieved with 
historical controls of concurrent radiotherapy and chemotherapy. In a predictive model-
ing study, the authors had already published an expected increase in TCP of 25% with 
this approach.[47] Recently, favorable clinical results were published with IDP in NSCLC 
in a concurrent radiotherapy and chemotherapy setting.[48] The observed gain in a 
therapeutic ratio encourages further exploration into this approach for disease entities 
other than NSCLC with fractionated approaches, but also in extreme hypofractionated 
approaches with SABR. Fractionated approaches (eg, up to 30 fractions) are needed 
when the tumor is abutting a radiosensitive organ with a relatively low tolerance dose 
for serious complications. Examples are gastro-intestinal organs such as the stomach 
(eg, bleeding) and bowel (eg, perforation). Obviously, when employing more fractions at 
a lower fraction size, the dose to the GTV is to a lesser extent limited by the maximum 
tolerable dose to the surrounding radiosensitive organs, and it may be possible to cover 
the GTV to an ablative BED of 100 Gy. For this means, a schedule of 12 fractions may 
not be sufficient, and more fractionated approaches may be needed to achieve a better 
therapeutic ratio. For designing prospective IDP trials with both conventional fraction-
ated and more hypofractionated approaches, published tolerance dose of OARs should 
be used. The QUANTEC group has published comprehensive reports of known tolerance 
doses for conventional multiple fractionat approaches.[6] For example in the QUANTEC 
paper, the tolerance dose of the bowel for grade 3 or higher toxicity is a V45Gy value of 
less than 195cm3 using a conventional fraction schedule with fractions of 2 Gy. For a 
hypofractionated approach, Lo and Timmermans have also published OAR con-
straints.[35,36] For example, the tolerance dose of the small bowel in a single SABR 
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fraction is only a V 9.8Gy value of less than 5cm3.[36] If the therapeutic ratio is unsatis-
factory with a hypofractionated SABR IDP schedule, a treatment schedule with more 
fractions IDP is used. The OAR tolerance dose for this multiple fractions schedule may 
be unknown. Then a phase I study is needed to determine the OAR tolerance level for 
this specific fractionation schedule. Another option is to choose a multiple fractions 
schedule from which the OAR tolerance dose is known, such as a conventional 2 Gy 
fractionation schedule. In Maastricht, an in silico study for SABR in brain metastases is 
ongoing, which aims to explore the theoretical therapeutic gain obtained by using IDP 
followed by a prospective clinical trial to validate the predictive modeling with clinically 
observed outcomes.  
FUTURE CHALLENGES 
By further applying IDP, more evidence becomes available regarding the exact tolerance 
doses of OARs. This may pave the way towards personalized medicine where shared 
decision-making aids physicians and patients in making evidence-based treatment deci-
sions and balancing the benefit and toxicity of SABR in an individually tailored man-
ner.[49] The TCP achieved by IDP may depend on the technology and the size of the 
margins that are used. Future research will focus not only on exploration of IDP in SABR 
but also on improving the prediction of outcomes based on multifactorial decision sup-
port systems.[50] An example of multifactorial predictive models can be found at 
www.predictcancer.org . Another area of research is the further improvement of radia-
tion modalities such as particle therapy (eg, protons and carbon ions), which may fur-
ther increase the therapeutic ratio of IDP.[51,52] With these techniques, an even higher 
degree of normal tissue sparing may be achieved, which could potentially lead to a 
reduction of the number of fractions, making these modalities less expensive per 
treatment course, with implications for increasing the number of patients who could 
benefit from them.  
CONCLUSION 
Isotoxic dose prescription is a new paradigm in stereotactic ablative radiotherapy. The 
radiation dose is prescribed based on nearby organs-at-risk tolerance dose. Simultane-
ously, the prescribed total tumor dose is maximized to the technically highest achieva-
ble level to increase the probability of tumor control. This strategy has the potential to 
overcome several limitations of traditional radiotherapy dose prescription based on 
tumor volume, and this strategy is expected to improve the overall therapeutic ratio of 
tumor control and toxicity. 
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ABSTRACT  
Introduction The 12-month local tumor control probability (TCP) of single-fraction ste-
reotactic radiosurgery (SRS) in large brain metastases (BM) with 4 cm diameter is about 
42% (www.predictcancer.org). This in-silico study tests the hypothesis that isotoxic dose 
prescription (IDP) has the potential to improve the effectiveness of SRS in large BM 
significantly while respecting a low risk of radionecrosis. 
Materials and Methods A treatment-planning study with 8 perfectly spherical and 46 
clinically realistic gross tumor volume (GTV) shapes was conducted. The effects of GTV 
size (0.5-4 cm diameter), set-up margins (0, 1, and 2 mm), and beam arrangements 
(coplanar vs non-coplanar) on the IDP dose level and the predicted TCP for single-
fraction and five-fraction SRS schemes were assessed. For single-fraction and five-
fraction IDP dose-volume constraints of V12Gy = 10 cm3 and a V20Gy = 20 cm3 were used, 
respectively, to limit the risk of radionecrosis to 10%. 
Results In BM of 4 cm in diameter, the maximum achievable single-fraction IDP dose 
was 14 Gy compared to 15 Gy for standard SRS dose prescription, with respective TCPs 
of 32% and 42%. Fractionated SRS with IDP was needed to improve the TCP. For five-
fraction IDP, a maximum predicted TCP of 68% was achieved by exploiting non-coplanar 
beams and a 1 mm set-up margin. 
Conclusions With five-fraction IDP, treatment effectiveness is predicted to increase from 
42% up to 68% TCP compared to standard single-fraction SRS. More fractions are need-
ed to further improve the therapeutic ratio under isotoxic conditions. 
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INTRODUCTION 
In stereotactic radiosurgery (SRS) for brain metastases (BM), the dose is generally pre-
scribed according to a risk-adapted approach depending on the size of the planning target 
volume (PTV): for smaller PTVs higher SRS doses are prescribed than for larger PTVs with 
the aim to limit toxicity to acceptable levels in large BM.[1] In Radiation Therapy Oncology 
Group (RTOG) study 90-05, the maximum tolerated single-fraction dose for BM with a 
diameter >3 cm was 15 Gy, as a higher dose of 18 Gy was associated with an unacceptably 
high rate of severe central nervous system toxicity of 50%.[3] Recently, consensus was 
reached within the Netherlands for SRS dose prescriptions: a single dose of 24 Gy is pre-
scribed to PTV sizes < 1 cm3 and the dose level is stepwise decreased to 21, 18 and 15 Gy 
for PTV sizes between 1-10 cm3, between 10-20 cm3, and > 20 cm3, respectively. In clinical 
practice, SRS is used for inoperable BM up to a diameter of 4 cm. The consequence of this 
PTV size-based dose prescription protocol is a 12-month local tumor control probability 
(TCP) of about 86% in small BM and a TCP of around 40% in large BM.[4,5] Given the low 
TCP for large BM and taking into account that patients with large BM are often medically 
inoperable, there is a clear need for improvement of SRS in these patients, but not at the 
cost of an unacceptably high risk of toxicity. This is currently being investigated in phase I 
studies.[6] An alternative to PTV size-based dose prescription is isotoxic dose prescription 
(IDP).[7-14] The quintessence of this strategy is to increase the prescribed tumor dose 
while simultaneously respecting a constant normal tissue complication probability (NTCP) 
constraint that is considered clinically acceptable. Here, the prescribed dose is individually 
maximized until a predefined dose-volume limit for the nearby healthy tissue is reached. 
The IDP concept is different from the PTV size-based dose prescription approach, where 
fixed prescription doses are used that solely depend on the size of the target volume and 
for large BM do not respect the predefined dose-volume constraint for normal tissue. 
From previous studies of single-fraction SRS for BM, it is known that the risk of radi-
onecrosis increases rapidly if the volume of the surrounding healthy brain tissue receiving 
at least 12 Gy is greater than 10 cm3 (that is, V12Gy >10 cm3).[15-17] Apart from being 
dependent on the tumor prescription dose, the V12Gy also depends on the gross tumor 
volume-to-planning target-volume (GTV-PTV) margin used, as well as on the beam ar-
rangement (i.e., coplanar vs non-coplanar) and the beam-shaping technique (dynamic 
conformal arc vs volumetric modulated arc) that affect the degree of dose conformity and 
the steepness of the dose gradient at the outer rim of the PTV.[18]  
In this study, the hypothesis is tested that through IDP the predicted TCP in large BM up 
to 4 cm diameter can be improved from the disappointing low level of 42% that is ob-
tained with a standard single SRS dose of 15 Gy while simultaneously respecting an ac-
ceptably low NTCP. Furthermore, the effects of GTV volume, different GTV-PTV margins, 
and beam arrangements on the predicted TCP are systematically assessed.[4,19,20] Both 
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single-fraction and fractionated stereotactic radiotherapy (FSRS) IDP schemes are con-
sidered to assess the effect of fractionation. 
MATERIALS AND METHODS  
This study comprises 3 phases. First, the potential to increase TCP under isotoxic condi-
tions is investigated for single-fraction and five-fraction IDP schemes, with artificial BM 
having spherical GTV shapes of different diameters (0.5 cm-4.0 cm, with stepwise in-
creasing diameter of 0.5 cm). This allows us to systematically derive empirical relation-
ships between the GTV size and the maximum achievable predicted TCP as a function of 
the GTV-PTV margin and the beam arrangement. Second, these results are compared 
against clinically delivered SRS treatment plans in 46 patients with realistically shaped 
GTVs.  
Nominal treatment plans: target-volume definition and treatment-planning 
technique 
A computed tomography (CT) scan (Siemens Somatom Sensation Open, Erlangen, Ger-
many) of an anonymized patient treated with SRS for BM was used to design nominal 
treatment plans having a dose prescription according to the Dutch consensus guide-
lines. The head and neck region was imaged until the claviculae with a slice thickness of 
1 mm. In the treatment-planning system (Eclipse version 11.0.42, Varian, Palo Alto, CA, 
USA), 8 perfectly spherical GTVs with diameters ranging from 0.5 to 4.0 cm in steps of 
0.5 cm were contoured in the right parietal lobe so that the brain stem and optic sys-
tem did not overlap with the PTV. For each GTV, a PTV was created by isotropic expan-
sion with a margin of 0, 1, and 2 mm. The dose prescription based on PTV size was a 
single fraction of 24, 21, 18, and 15 Gy for PTV sizes < 1, 1-10, 10-20 cm3, and 20-65 
cm3. With the prescribed dose, 99% of the PTV was covered, while having a steep dose 
gradient outside the PTV for brain sparing and allowing large dose inhomogeneity with-
in the PTV. Per the PTV, two 10 MV photon-based volumetric modulated arc therapy 
(VMAT, calculation grid size 1 × 1 × 1 mm3) plans were made by the same treatment 
planner (JS), one with 2 overlapping coplanar arcs at a couch angle of 0° and one with 3 
non-coplanar arcs having a couch angle of 0°, 45°, and 315° and a collimator angle of 
30° or 330°. In total, 48 treatment plans were generated. For each treatment plan, the 
V12Gy of the healthy brain minus the GTV was determined.  
Renormalized treatment plans: IDP based on normal tissue dose constraint  
For single-fraction IDP-based dose prescription, the nominal treatment plans with 
spherical GTVs were renormalized (by altering the monitor units) such that V12Gy = 10 
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cm3 for the healthy brain minus the GTV. The corresponding IDP dose levels for each of 
the 48 treatment plans were assessed for further analysis. The same procedure was 
used for the five-fraction IDP scheme, but a V20Gy = 20 cm3 constraint for the healthy 
brain minus the GTV was used instead.[21] The predicted TCP was calculated from the 
IDP prescription dose by using a dose-response model that was statistically fitted to the 
data points of Wiggenraad et al.[4] (see Appendix). For calculation, plotting, and rescal-
ing of the dose volume histograms (DVHs), in-house developed MATLAB scripts (Version 
8.5; The MathWorks, Inc., Natick, NA, USA) were used.  
Validation of IDP results in clinically delivered SRS plans 
Since in clinical practice the GTVs of BM are not perfectly spherical and the plan quality 
may slightly vary due to inter- and intra-treatment planner differences, we compared 
the IDP dose levels obtained from the 48 treatment plans with perfectly spherical GTVs 
to those of clinical treatment plans comprising 46 consecutive patients who had been 
treated with SRS for a single BM at our institution between January 2013 and June 2014 
with a dose of 15-24 Gy in 1-3 fractions. Patients had been considered eligible for SRS if 
they had less than five BM from metastasized solid primary tumors (e.g., non-small cell 
lung cancer, breast cancer, colorectal cancer, melanoma, and bladder cancer) at the 
pre-treatment contrast-enhanced magnetic resonance imaging (MRI) scan, a Karnofsky 
performance status of 70 or more, and extracranial treatment options. The selected 
cohort was identified from a database containing all patients who had been treated 
with SRS for newly diagnosed BM in our institution. Prior to treatment, a gadolinium 
contrast-enhanced MRI scan (3D T1-weighted sequence on a 1.5T Ingenia/Intera or 3T 
Achieva scanner, Philips Medical Systems, Eindhoven, Netherlands) was made with a 
slice thickness of 1 mm. Patients had been immobilized with a frameless mask and un-
derwent an iodide contrast-enhanced CT scan (Siemens Somatom Sensation Open, 
Erlangen, Germany) with a slice thickness of 1 mm. For treatment-planning purposes, 
the MRI scan had been rigidly co-registered with the CT scan in Eclipse (Varian, Palo 
Alto, CA, USA). The BM had been delineated as GTV contours on the MRI scan and visu-
ally checked on the CT scan thereafter. A GTV-PTV margin of 2 mm had been applied. A 
VMAT (RapidArc) technique with 10 MV coplanar beams had been used to design the 
dose distribution for delivery with a TrueBeam STX linear accelerator (Varian, Palo Alto, 
CA, USA). To derive the IDP dose levels for our study, these treatment plans were 
renormalized such that the constraints V12Gy = 10 cm3 and V20Gy = 20 cm3 were satisfied 
for the single- and five-fraction schemes, respectively. 
Potential value of IDP for phase I study 
We studied the potential of both single and five-fraction IDP to increase the TCP above 
the standard SRS dose prescription. An FSRS scheme of 5 × 7 Gy with the normal-tissue 
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dose constraint of V20Gy = 20 cm3 has been shown to be associated with an acceptable 
risk of radiation necrosis for patients with large BM.[20,21] Because this constraint has 
not yet been widely validated, we also investigated the sensitivity of the TCP for less 
stringent constraints for five fraction IDP, such as V22Gy = 20 cm3 and V24Gy = 20 cm3.  
RESULTS 
The application of a non-zero GTV-PTV margin results in an increase in the PTV size and 
may hence influence the PTV size-based dose prescription and thereby the therapeutic 
ratio. As indicated by the change in symbol shapes in Figure 1, applying a GTV-PTV mar-
gin of 1 mm instead of 0 mm resulted in lowering the nominal prescription dose from 
21 to 18 Gy for a GTV diameter of 2.5 cm, while for the other 7 GTV diameters, the 
prescribed dose did not change. Applying a GTV-PTV margin of 2 mm instead of 0 mm 
resulted in decreasing the nominal prescription dose from 24 to 21 Gy, from 21 to 18 
Gy, and from 18 to 15 Gy for GTV diameters of 1.0, 2.5, and 3.0 cm, respectively, while 
for the other 5 GTV diameters, the prescribed dose remained the same.  
Applying a non-zero GTV-PTV margin also results in an increase of the dose absorbed in 
uninvolved healthy brain tissue and therefore affects the NTCP and therapeutic ratio. 
When the single-fraction PTV size-based dose prescription protocol is applied to the 8 
perfectly spherical GTVs, V12Gy shows a clear tendency to increase with increasing GTV 
size and increasing GTV-PTV margin and is generally lower for the non-coplanar beam 
arrangement than for the coplanar beams (Figure 1). From this figure, it is evident that 
for GTV diameters > 2 cm, V12Gy exceeds the 10 cm3 constraint level irrespective of the 
GTV-PTV margin or the beam arrangement. Furthermore, this figure shows that for a 
GTV diameter of 4 cm, V12Gy is reduced from 33 cm3 to 13 cm3 in case a GTV-PTV margin 
of 0 mm instead of 2 mm is used in combination with non-coplanar beams instead of 
coplanar beams. 
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Figure 1 Commonly used risk-adapted dose prescription based on PTV size. The V12Gy as function of GTV size is 
presented for different GTV-PTV margins and beam arrangements.   
Legend: The GTV-PTV margin: 0 mm (A), 1 mm (B), and 2 mm (C). The open and filled symbols represent non-
coplanar and coplanar beams, respectively. The single-fraction PTV size-based dose prescription: 24 Gy (trian-
gle), 21 Gy (square), 18 Gy (diamond), and 15 Gy (circle). 
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Figure 2 A comparison of the single-fraction IDP dose level with V12Gy = 10 cm3 for coplanar beam arrangement 
and GTV-PTV margin of 2 mm between perfectly spherical GTVs (filled dots) and non-spherical GTVs of clinical 
plans (open dots).   
Legend: The solid lines represent single-fraction PTV size-based dose prescription protocols. The dashed line 
represents a logistic regression model fitted to data of perfectly spherical GTVs. 
 
 
Figure 3 The prescribed dose and predicted TCP for single-fraction IDP with the V12Gy = 10 cm3 constraint as a 
function of the GTV diameter for coplanar and non-coplanar beam arrangements with a GTV-PTV margin of 0-
2 mm and spherical GTVs. A GTV-PTV margin enlargement results in an increase of the PTV size. An increase in 
the PTV size results in different cut-offs with a PTV size-based dose prescription with 24, 21, 18, and 15 Gy. 
The diamond (green line), circle (blue line), and cross (red line) represent the cut-offs with dose prescriptions 
with GTV-PTV margins of 0, 1, and 2 mm, respectively.   
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To test whether the single-fraction IDP dose levels derived for the spherical GTVs apply 
to the non-spherical GTVs of the clinical treatment plans, an empirical relationship be-
tween the PTV size of the spherical GTVs and the single-fraction IDP dose level was 
derived by fitting an exponential decay model to the data of the coplanar beam ar-
rangement with a GTV-PTV margin of 2 mm (Figure 2). The same was done for the IDP 
dose of the 46 clinical treatment plans with non-spherical PTVs. It could be shown that 
there is no statistically significant difference between these fits. The median (± SD) IDP 
dose difference between the spherical GTVs of the artificial treatment plans and the 
non-spherical GTVs of the clinical treatment plans was 0.25 ± 1.70 Gy and ranged from -
3.92-2.16 Gy.  
As shown in Figure 3, for a 0 mm GTV-PTV margin, single-fraction IDP with the V12Gy = 10 
cm3 constraint offers no potential for isotoxic dose escalation in spherical GTVs with 
diameters > 2 cm, even when non-coplanar beams are used. For BM with a GTV diame-
ter of 4 cm, this approach achieved an IDP dose of 14.1 Gy with a significantly lower TCP 
of 32% compared to the 42% that was predicted for the PTV size-based dose prescrip-
tion at 15 Gy. Therefore, we have explored the potential of five fraction IDP to increase 
the TCP. For five-fraction IDP with the V20Gy = 20 cm3 constraint, the predicted TCP for a 
GTV diameter of 4 cm was 73%, 68%, and 50% when using a GTV-PTV margin of 0, 1 and 
2 mm, respectively, with the non-coplanar beam arrangement. Using coplanar beams, 
the predicted TCPs were 69%, 60%, and 42%, respectively (Figure 4).  
 
 
Figure 4 The prescribed dose and predicted TCP for 5-fraction IDP with the V20Gy = 20 cm3 constraint as a 
function of the GTV diameter for different GTV-PTV margins and beam arrangements. 
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Exploiting a dedicated frameless mask in combination with advanced online image-
guidance and a 6 degrees-of-freedom couch may render a setup accuracy of 1 mm 
feasible in clinical practice.[18] We found that the normal-tissue constraint of V20Gy = 20 
cm3 needed to be relaxed to V24Gy = 20 cm3 for the five-fraction IDP to escalate the TCP 
up to 80% in a spherical GTV of 4 cm diameter (Figure 5). This was achievable for cases 
where a 1 mm GTV-PTV margin is used in combination with the non-coplanar beam 
arrangement. 
 
 
Figure 5 The prescribed dose and predicted TCP for 5-fraction IDP with 1 mm GTV-PTV margin and non-
coplanar beams as a function of the GTV diameter for three different normal tissue dose constraints.  Legend: 
The black horizontal solid line represents a SRS scheme of 5 daily fractions of 6 Gy up to a total dose of 30 
Gy.[21] 
DISCUSSION 
In this in silico study, the potential of IDP was investigated for improving the TCP from 
42% with a single fraction of 15 Gy in large BM up to 4 cm diameter, while simultane-
ously respecting an acceptably low NTCP limit. The concept of IDP is of clinical relevance 
for BM with a diameter of 2 cm or more, as the constraint of a V12Gy of 10 cm3 for the 
surrounding brain tissue is exceeded with SRS independent of the GTV-PTV margin and 
the beam arrangement with the current PTV-based dose prescription (Figure 1). In a 
large cohort of patients treated with SRS alone for a maximum of 3 BM, the median 
diameter of the BM was 2.3 cm, so this study is of relevance for at least half of BM pa-
tients treated with SRS in daily clinical practice.[2] Despite avoiding a GTV-PTV margin 
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and exploiting a coplanar beam arrangement, the single-fraction IDP SRS approach with 
the V12Gy = 10 cm3 constraint for the nearby healthy brain tissue did not improve the 
predicted TCP over the standard SRS dose prescription with 15 Gy. As expected, five-
fraction IDP had a better therapeutic ratio than single-fraction IDP. The predicted gain 
of from 32% to 73% in 1-year TCP using five-fraction IDP instead of single-fraction IDP is 
significant. Such gain is especially relevant for oligometastases patients treated with 
curative intent in whom ablation of metastases and hence maximization of TCP is the 
goal. For patients with a relatively short life expectancy (for example, 6 months) treated 
with palliative intent, a lower 1-year TCP could be considered acceptable. For these 
patients, a single-fraction approach having a relatively low 1-year TCP may be preferred 
over a multiple-fraction approach for patient convenience.  
To further improve the 1-year TCP above 73%, the normal tissue constraint V20Gy = 20 
cm3 needs to be relaxed, but this may result in an unacceptably high risk of radionecro-
sis. Alternatively, an approach with more than five fractions could be investigated if this 
approach increases the therapeutic ratio. The calculated TCPs are based on the model 
of Wiggenraad based on single-fraction SRS data for BM, and the same model was used 
to calculate the TCP with five fraction SRS.[4] However, a fractionated approach may be 
beneficial for re-oxygenation of the tumor, which may increase its radiosensitivity.[22] 
Therefore, the calculated TCP of 73% in very large BM (e.g., with a diameter of 4 cm) 
may be an underestimation of a clinically observed TCP using five fraction IDP. The cur-
rent TCP model includes only prescription dose as a prognostic variable, but further 
extension of this model with other factors such as BM volume and possibly imaging 
characteristics reflecting hypoxia may further improve its accuracy. However, the influ-
ence of tumor size is difficult to quantify because in many series, lower doses are pre-
scribed for larger BM or prescribed doses vary widely. Furthermore, the model needs to 
be externally validated and calibrated in other patient cohorts treated with SRS for BM. 
Dose-volume thresholds for an acceptably low risk of radionecrosis for schemes other 
than single-fraction and five-fraction SRS do not exist in literature. Therefore, only sin-
gle- and five fraction schedules were used in the current study. 
To exploit the full potential of IDP in SRS, it is necessary to minimize the GTV-PTV mar-
gin and to optimize the beam arrangements by increasing the setup accuracy (6 degrees 
of freedom couch and a robust frameless mask).[23-24] Taking into account that the 
risk of radionecrosis increases rapidly above 10% as the V12Gy exceeds 10 cm3 for single-
fraction SRS, it is clinically highly relevant to strive for a smaller GTV-PTV margin and to 
explore the feasibility of dose delivery with non-coplanar beam arrangements.[15] This 
is supported by a recently published randomized trial demonstrating that a decrease of 
the GTV-PTV margin from 3 to 1 mm does not decrease the local control probability for 
LINAC-based SRS.[18] As this study showed that there was a significantly larger V12Gy in 
the 3 mm GTV-PTV margin group, the authors stated that a 1 mm GTV-PTV margin 
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should be used to avoid any unnecessary risk of radionecrosis and serious risk of neuro-
logic morbidity.  
A limitation of our research is the lack of clinical validation of the models to predict TCP 
and NTCP. The TCP model is based on retrospective clinical studies.[4] Prospective clini-
cal validation is needed for the NTCP model by using a V12Gy = 10 cm3 constraint for 
single-fraction IDP and a V20Gy = 20 cm3 constraint for five-fraction IDP.[3,15, 21]  
In conclusion, with five-fraction IDP, non-coplanar beams and a 1 mm set-up margin, 
the predicted 1- year TCP was safely increased from 42% to 68% in very large BM com-
pared to single-fraction 15 Gy SRS. For the treatment to be more effective either relaxa-
tion of the normal tissue constraint V20Gy = 20 cm3 or a fractionated approach with more 
than five fractions is needed. A prospective clinical trial is needed to validate the pre-
dicted effectiveness in terms of 1-year TCP and to assess the safety of IDP regarding 
NTCP.  
APPENDIX 
Fitted TCP model for 12-month local rate 
In Wiggenraad et al. (2011), a dose-response relation between the biologically effective 
dose of the linear-quadratic-cubic model using an α/β of 12 Gy (BED12) and the 12-
month local control rates were constructed by eye fitting. Herein we obtained a statisti-
cal better fit by first digitizing the data points from Wiggenraad’s figure (4, Figure 1) 
using GraphClick software (version 3.0.2, Arizona Software) and subsequently fitting a 
logistic dose-response model by the maximum likelihood estimation: where D = BED12, 
D50 is the BED12 at 50% local control, γ50 is the normalized slope at D50, and TCPmax 
is the asymptotic local control rate for large D. The fitted dose-response graph is shown 
in Figure 6. The model parameters obtained are D50 = 28.97 Gy (95% CI: 24.80-33.14 
Gy), γ50 = 1.41 (95% CI: 0.40-2.87), and TCPmax = 86.86% (95% CI: 70.62-103.10%). 
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Figure 6. A fitted dose-response curve based on data from Wiggenraad et al.[4]  
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The aim of the research in this thesis is to improve patient selection and outcome with 
stereotactic radiosurgery (SRS) for brain metastases (BM). The main hypotheses of this 
thesis are: 
1) Individualized prognostic models predict survival and the occurrence of distant 
brain recurrences after SRS alone for BM more accurately than currently availa-
ble prognostic models  
2)  A multicenter randomized phase III trial can be initiated to investigate whether 
SRS alone provides a better quality of life than WBRT in patients with 4 to 10 BM   
3)  The 1-year tumor control probability of SRS for large BM can be improved by iso-
toxic dose prescription (IDP) in a modelling study 
The first hypothesis was tested to optimize and individualize the information for pa-
tients to facilitate the decision-making process for patients and caretakers. Patients 
make decisions based on the advice of their physician, but also based on personal, emo-
tional, social, and psychological factors. The final choice of the patient for any treatment 
may differ from the advice of the physician because of the personal preferences of the 
patient.[1] The physician informs the patient about the standard of care according to 
guidelines, but also about individualized perspectives per treatment regarding survival, 
chances of disease control, and toxicity. The patient then makes the final decision about 
treatment options, a process called shared decision-making. Prognostic models may 
help the physician and patient to estimate the outcome per treatment modality. In this 
thesis, prognostic models for stereotactic radiosurgery (SRS) in the treatment for pa-
tients with brain metastases (BM) were developed to more accurately predict outcome 
than existing models to better facilitate the shared decision-making process.  
To achieve improvement in giving personalized advice to patients with BM, in this the-
sis, the first focus was on existing prognostic classification systems and investigated 
potential advancements in these models (chapter 2).[2] The major limitation of current-
ly available prognostic models is the lack of individualized outcome prediction, and only 
a group-based prediction by categorizing patients into favorable, intermediate, and 
unfavorable prognostic groups can be derived. In addition, there appears to be an un-
balanced patient distribution over the prognostic classes: the proportion of patients in 
the intermediate prognostic group(s) far outweigh those in the unfavorable and favora-
ble prognostic group(s). Having an unfavorable or favorable prognosis is of specific 
relevance to the patient with respect to the decision to undergo a treatment, contrary 
to having an intermediate prognosis. The clinical characteristics of patients with BM 
differ enormously, even within prognostic classes; for example, a young female with 
HER2/neu positive breast cancer and small BM can be in the same class as a relatively 
old male patient with a larger, more central BM from undifferentiated non-small cell 
lung cancer. The expected outcomes after BM treatment of these 2 examples differ 
with respect to survival, probability for long-term survival, systemic treatment options, 
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and toxicity of treatment. Therefore, there is a need for models incorporating all poten-
tial relevant factors for the prediction of outcomes for clinical endpoints including pa-
tient, tumor, and treatment characteristics. The current available models are not so-
phisticated enough to allow accurate and individualized patient information per tumor 
type and treatment. 
The primary goal of SRS is to control BM and maintenance of neurologic function, which 
is also valuable in a palliative setting (chapters 3 & 7). Paralysis, epilepsy, and neurocog-
nitive damage by progressive BM have an important negative impact on quality of life 
and survival and may be prevented or postponed by SRS.[4] However, personal consid-
erations of the patient and their caretakers on costs and benefits of treatment may 
differ from the perspectives of clinicians. A patient may choose best supportive care 
over SRS if the anticipated life expectancy is short and can be measured in weeks.[3] 
Although the definition of “short life expectancy” or “early death” can be debated, for 
our analysis, a subjective period of 3 months was chosen. It can be argued that having a 
significant risk of dying within 3 months, the investments for both patients and society 
(costs) outweigh the efforts of SRS; patients need several outpatient clinical visits, fabri-
cating a customized immobilization mask, and generating a planning CT scan, a planning 
MR scan, and the SRS treatment delivery itself. In addition, there is also a risk of side 
effects that cannot be ignored. Although the side effects of SRS are usually modest and 
temporary, including an increase in fatigue and (pre-existing) neurologic symptoms, 
these may be unacceptable in case of a short expected life span. Obviously, it is essen-
tial that the prediction of “short life expectancy” is accurate in order not to inappropri-
ately withhold the beneficial effects of SRS. Chapter 6 shows that our developed indi-
vidualized prognostic model predicts “early death” after SRS from BM of non-small cell 
lung cancer (NSCLC) more accurately than current available models, such as the recur-
sive partitioning analysis (RPA). The area under the curve for the prediction of early 
death with recursive operating characteristics (ROC) analysis was 0.70 vs 0.55 (P < 0.01) 
for the nomogram and the RPA, respectively, in the external validation cohort.[5]  
Another related issue with clinical relevance is an estimation of the likelihood of long-
term survival. Again, this definition remains arbitrarily, but survival for longer than 1 
year after a diagnosis of BM would best reflect the label ”long term.” Defining the likeli-
hood of long-term survival is of importance, not only for patient information, but also 
for determining the appropriateness of more aggressive (or costly) forms of treatment 
for extracranial cancer sites, such as surgery, immunotherapy, or other combined 
treatment modalities. The goal of aggressive extracranial treatment in cerebral metas-
tasized patients is to control the extracranial disease and achieve long-term survival, 
preferably over several years.[6] However, because only a small proportion of patients 
with BM will survive over several years (5-10% depending on patient selection),2 it is 
important to correctly identify these patients. As part of this thesis, an extensive data-
base was used of patients with BM of NSCLC, the most frequent origin of BM, treated 
General discussion and future perspectives 
157 
with SRS as a single modality to refine current prognostic classification systems and to 
develop nomograms for the individualized prediction of “early death” and ”long-term 
survival,” respectively. These nomograms were published, but for wider diffusion into 
clinical practice, these models were uploaded on www.predictcancer.org. Using a rela-
tively straightforward input of a limited number of variables such as gender, age, per-
formance status, presence or absence of extracranial metastases, and volume of the 
largest BM, a fast estimation of the risk of ”early death” and likelihood of ”long-term 
survival” after SRS is immediately provided. By presenting accurate and individualized 
outcome information to the patient it is likely that this tool will be informative for both 
clinicians and patients and may provide further guidance for shared decision making. 
SRS is increasingly used as an alternative to WBRT, mostly to prevent subacute and 
delayed adverse sequelae such as neurocognitive deficits resulting from irradiating 
normal brain tissue. However, being a form of high-precision local treatment, the 
downside of using SRS as a single modality is that occult micrometastases are left un-
treated (chapter 7). As a consequence, this approach results in a significant risk of find-
ing new BM during follow-up, so-called distant brain recurrences (DBR) in 39-70% of 
patients within 1 year (chapter 5).[7,8] These new metastases can be the result of the 
outgrowth of radiologically occult metastatic deposits or reseeding from extracranial 
active disease. An indication that the latter also plays a role can be obtained by the 
observation that if patients survive for several years after SRS, the vast majority will 
suffer from DBR (cumulative incidence of 86% at 2 years with Kaplan Meyer analysis). 
The issue of development of new BM following SRS has consequences, both for follow-
up strategies and for salvage therapy with SRS, WBRT, systemic therapy, or occasionally 
even surgery. In general, most Dutch centers advice 3-monthly follow-up MRI scans 
after SRS for BM. Therefore, SRS as a single modality is the standard treatment for pa-
tients with a maximum of 3 BM. As part of this thesis, the incidence and characteristics 
of these new lesions were investigated after SRS alone and a nomogram was developed 
for individualized prediction of the risk for DBR (chapter 4). For this prediction model, 
the number of initially treated BM, age, the volume of largest BM, and WHO perfor-
mance status were important.[9] For clinical use, this calculation model to predict DBR 
within 1 year after SRS for BM is also available on www.predictcancer.org. It should be 
stressed, however, that this model is based on clinical data in which the vast majority of 
patients were treated for 1 or 2 BM and therefore is not validated in patients treated 
with SRS alone for more than 3 lesions. With this restriction in mind, this tool can be 
used to discuss the need and the frequency of follow-up MRIs with patients. Independ-
ent of this calculation, scheduled MRI follow-up will also be determined by the overall 
disease progression status and performance of the patient.  
The individualized models, and especially the nomograms, that were developed in this 
thesis for patients with SRS of BM are a major improvement compared to traditional 
group-based prognostic models in the support of shared decision-making. A methodol-
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ogy for the development of individualized models was illustrated. These developed 
models are still relatively simple and based on small patient cohorts. More complex 
models are needed for more clinical endpoints, for more primary tumor types, and 
more treatment options to further individualize the treatment of BM patients. In addi-
tion, web-based shared decision tools need to be developed incorporating all relevant 
treatment options for all potential clinical settings. Therefore, it is likely that these 
models were just the first steps for the support of real individualization of the treat-
ment of patients with BM, which is appropriate in the era of personalized medicine.  
The second hypothesis is defined to test whether it was possible do a prospective ran-
domized phase III trial to potentially change clinical practice for patients with more than 
3 BM. According to guidelines in the Netherlands, SRS is advised for patients with a 
maximum of 3 lesions. Additional WBRT after SRS as a single modality decreases the risk 
of DBR but does not provide a survival benefit. Moreover, additional WBRT to SRS re-
sults in poorer quality of life than SRS only because of the side effects of WBRT (chap-
ters 7 & 9). For those with 4 or more BM, WBRT is the recommended strategy. Back-
ground for this advice is the lack of evidence that SRS has better outcomes than WBRT 
for multiple lesions, the notion that these patients had particularly poor prognosis, and 
that treatment for multiple lesions with SRS would be a time-consuming and costly 
palliative treatment, taking almost an hour of treatment per BM.[10] New evidence has 
recently become available for patients treated with SRS alone for multiple BM, which 
may result in a paradigm shift. In a large study, selected patients with 2-4 BM had com-
parable survival as patients with 5-10 BM.[11] In a sequential report, the same group 
showed that patients with 2-9 BM had the same survival as patients with 10 or more 
BM.[12] These studies raise the question of whether SRS alone should be reserved only 
for patients with 2-3 BM, or that patients having 4 or more BM may also benefit from 
this treatment. Recent technological advances enable accurate and precise treatment 
with SRS of multiple BM within several minutes. Also, more effective systemic treat-
ments have become available that control BM and thereby improve the prognosis of 
the patients with multiple BM. With the recent technological improvements allowing 
SRS in multiple BM, it is of interest if patients with more than 3 BM are better treated 
with SRS than with WBRT with respect to quality of life and survival probability. The 
potential advantages of SRS over WBRT are a higher probability of local tumor control 
and avoidance of some of the side effects of WBRT, such as hair loss, fatigue, and neu-
rocognitive damage.[13,14] The potential advantage of WBRT over SRS is the treatment 
of subclinical micrometastases in the brain, which, in regard of the frequent occurrence 
of DBR after SRS alone, will be present in the vast majority of patients. If these mi-
crometastases progress rapidly, they may cause neurologic symptoms during follow-up 
after SRS. Also, the risk of radionecrosis (RN) is avoided with WBRT, in contrast to SRS. 
To gain more insight on this issue, a multicenter randomized trial was successfully initi-
ated in the Netherlands that is currently ongoing (chapter 8).[15] Although some physi-
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cians already assume that SRS alone is a better treatment than WBRT for patients with 
more than 3 BM, high-level clinical evidence is absent. Selection bias is a problem in the 
current available literature and therefore a randomized trial is needed. It is our hope 
that the new standard of care for patients with multiple BM can be based on this trial 
and other prospective randomized trials that are being initiated in the United 
States.[16]  
Randomized phase III trials are not conflicting and are very useful for the process of 
shared decision making and personalized medicine. Data gathered in randomized trials 
are a solid basis to quantify a potential benefit in outcome between treatment options. 
In situations where randomized trials are lacking, such as in patients with more than 3 
BM, it is possible to estimate outcome of individual treatment options, but these esti-
mations remain hampered by selection bias and physician preferences. Although the 
costs and efforts of conducting a randomized trial are significant, this effort is certainly 
worth a try with the goal to provide reliable outcome information for the patient. 
Therefore, randomized trials are still a very good option to determine whether a change 
in clinical practice is justified, although the administrative burden, the process of design, 
and the efforts to stimulate accrual are significant in an era with limited health care 
budgets and limited time for research during busy daily clinical practice.  
The third hypothesis is defined to test whether a new form of SRS dose prescription is 
useful to potentially improve clinical outcome in patients with large BM. Patients with 
large BM are often inoperable, because of a poor life expectancy or a high-risk location 
of the BM. Because of concerns regarding the risk of RN in larger lesions, the SRS dose is 
generally lower than in smaller lesions. However, the results of single fraction SRS with 
a dose of 15 Gy are suboptimal.[12] A local recurrence of an inoperable BM may result 
in neurological damage and dysfunction followed by death. The probability of control 1 
year after SRS of the BM is approximately 40% with a single fraction of 15 Gy and de-
spite lowering the dose often there remains a relatively high risk of complications, 
named RN.[17] A potential solution for this clinical dilemma is a relatively new form of 
SRS dose prescription, isotoxic dose prescription (IDP, chapter 10).[18] In a modelling 
study, fractionated IDP enabled a safe increase in the predicted probability of control of 
BM 4 cm in diameter to +/- 70% while simultaneously maintaining an acceptable risk of 
RN (chapter 11).[19] This was achieved by respecting the tolerance dose of the healthy 
brain tissue, moderate fractionation up to 5 fractions, and simultaneous dose escalation 
in the BM to the technically highest achievable dose. 
An important technical aspect for the risk of RN is the GTV-PTV margin. This is an addi-
tional margin contoured around the BM of 1 up to 3 mm of nearby healthy brain tissue 
that is also irradiated to the prescribed dose to account for setup and other uncertain-
ties. The GTV-PTV margin is determined per institution based on an in silico model and 
is often to be advised to be at least 1 mm.[20] However, during clinical validation with 
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SRS for BM this in silico model appeared to not be in line with clinical results. In a ran-
domized trial, a GTV-PTV margin of 1 mm resulted in the same local control with SRS for 
BM as a GTV-PTV margin of 3 mm despite usage of non-coplanar beams.[21] Therefore, 
there is a need to use other models and to consider the clinical disadvantages for the 
patient of GTV-PTV margins larger than 1 mm. In the study, the patients in which a GTV-
PTV margin of 3 mm was applied were exposed to a higher RN risk than the patients 
with a 1 mm GTV-PTV margin. Therefore, the authors concluded that a 1 mm GTV-PTV 
margin is preferable above a 3 mm GTV-PTV margin. In this choice the clinical outcome, 
e.g. risk for RN and equal local control, are preferred above potential physical uncer-
tainties. The equal local control in the 1 mm GTV-PTV margin cohort can be explained 
by tumor cell sterilization outside the PTV of the high dose penumbra. This is a para-
digm shift, because in daily clinical practice often physical uncertainties dominate deci-
sion making with respect to GTV-PTV margin choice per institution. To minimize the risk 
of RN with SRS for BM and by considering the sterilization of tumor cells outside the 
PTV, it is defendable and advisable that radiation oncologists minimize or even avoid a 
GTV-PTV margin during SRS for BM. This is especially relevant in the setting of IDP. In 
our modelling study (chapter 11), avoidance of a GTV-PTV margin allowed for an opti-
mal therapeutic ratio (ratio tumor control probability: risk for RN) in the setting of both 
IDP and standard SRS dose prescription.[19] The promising results of 5 fraction IDP in 
large BM need further clinical validation, especially in patients with large inoperable BM 
(for example, PTVs larger than 10 cm3). A high local control probability of BM is relevant 
for patients with a high probability of long term survival.  
Based on the expected gain in clinical outcome, IDP will enable further individualization 
and improvement of the treatment of patients with BM. Physicians are currently decid-
ing about the prescribed dose and thereby the probability of tumor control without 
involving the patient. This is undesirable in the era of personalized medicine. For certain 
patients, it is more desirable to visit the clinic only once and have a 40% tumor control 
probability after 1 year: for example, for an old man with undifferentiated NSCLC with-
out systemic treatment options, a life expectancy of 5 months, and a strictly palliative 
SRS treatment a very short treatment duration is desirable to avoid unnecessary aggra-
vation of the patient. For other patients, long-term tumor control and a high probability 
of permanent ablation of the BM is desirable, such as a young female with breast can-
cer and several systemic treatment options with a life expectancy of several years. For 
this patient, the number of fractions may be less relevant if it results in an improved 
clinical outcome. In current daily clinical practice, both patients will receive the same 
standard dose and both the physician and patient are often unaware of the conse-
quences for tumor control probability and risk of RN. Applying IDP will force the physi-
cian to quantify tumor control probability to the patient and facilitate the process of 
shared decision making. Moreover, from a technical perspective, it will become clear 
that GTV-PTV margins will directly affect the therapeutic ratio. This will stimulate both 
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the radiation oncologist and the clinical physicist to optimize the accuracy of the SRS 
treatment to minimize or even avoid GTV-PTV margins for a minimization of the risk of 
RN and optimization of the tumor control probability as IDP is applied. Although our 
study is just a modelling study and needs further clinical validation, showing the poten-
tial of IDP will hopefully result in widespread application of IDP with SRS for BM with 
shared decision making. 
The limitations of the studies to the prognostic models are their retrospective design. 
These studies best reflect the outcome of patients treated in daily clinical practice and 
the data were relatively complete with only very limited missing data. Models based on 
cohorts of patients treated in randomized trials have the advantage that the data are 
more structured but may reflect better outcome than achieved in clinical practice out-
side the setting of a prospective trial. Another limitation was the relatively small sample 
size of the studied patient cohort and the relatively limited number of patients and 
treatment characteristics that were studied. Also, the prognosis of patients treated at 
present may be slightly better, because recently more systemic treatment options have 
become available, which also may control BM and improve outcome. Almost all patients 
in our studies received SRS as a first line of treatment and at present there is a trend to 
use SRS as a salvage treatment after the failure of primary systemic treatment of BM.  
The limitation of the randomized trial that was initiated is that a small minority of Dutch 
hospitals did not join the study. Hospitals that use Gamma Knife are lacking in our study 
and are encouraged to join. Another limitation is that all primary tumor types are al-
lowed in the study. Ideally trials are designed per tumor type, but these trials will be 
hampered by lack of accrual. Moreover, each tumor type, such as breast cancer or non-
small cell lung cancer, comprised of very heterogeneous tumor subtypes, such as 
HER2/neu- or hormone receptor-positive and -negative breast cancer. It will not be 
feasible to do randomized trials for all these subtypes of breast cancer. For our random-
ized trial, the primary tumor type and the subtypes may have very limited influence on 
the outcome of the trial because the primary endpoint is quality of life, not survival. The 
expectation is that the treatment type (WBRT or SRS) will be responsible for the quality 
of life after treatment and not the (sub)type of primary tumor.  
The IDP study is limited by the fact that it is just a modelling study and clinical data to 
show the benefit of IDP are currently lacking. These data will be provided in the near 
future.  
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FUTURE PERSPECTIVES 
Individualised treatment outcome modelling for shared decision making 
Individualized prognostic models for patients with BM need to be developed and re-
fined per treatment option (for example, SRS, WBRT, systemic therapy, or best support-
ive care) and per tumor type. Optimization of the accuracy of these models can be ac-
complished by incorporating more tumor characteristics, patient characteristics, imag-
ing characteristics, and biomarkers.[22,23] New prognostic models can be evaluated by 
the TRIPOD guidelines and software used to generate these models needs to be certi-
fied.[24] The patient information is stored worldwide in individual hospitals and can be 
extracted with a distributed learning approach enabling avoidance of harm of the priva-
cy of the patient. MAASTRO Clinic and MUmc+ are cooperating with several centers 
worldwide with the goal of developing accurate multifactorial prognostic and even 
predictive models. The eventual goal is so-called shared decision-making in which both 
the patient and the physician discuss the predicted outcomes per treatment, allowing 
the patient to take a more informed choice of treatment options.[25-28]  
A multicenter phase III trial to compare SRS with WBRT in patients with more 
than 3 BM 
The goal in the next years will be to finish the trial in 230 patients within a limited time 
span, preferably 2 years. At September 2017, 9 Dutch centers were open and patients 
from several hospitals were randomized. The goal for 2017 is to open another 4 Dutch 
centers (13 centers in total in the Netherlands) and discussion is ongoing to open the 
study in centers abroad, such as Belgium, the United Kingdom, Italy, and Germany. 
Another development is international cooperation to optimize the quality of SRS for 
BM. Three other randomized trials with comparable primary endpoints are being initi-
ated in the United States and Canada. There is contact between the study coordinators 
and medical physicists to synchronize the quality assurance of the SRS treatment tech-
nique. If all trials succeed, this will enable a meta-analysis of all data gathered in the 4 
randomized trials because of minimal variation in SRS treatment quality and thereby 
outcome. The meta-analysis will provide high-quality evidence for the potential addi-
tional value of SRS over WBRT in patients with more than 3 BM. This will serve as a basis 
for shared decision tools for patients with BM.  
Isotoxic dose prescription to individualize SRS and improve outcome in large BM 
IDP will likely replace standard SRS dose prescription and be the basis for the individual-
ized application of SRS for patients with BM. Currently, physicians prescribe standard 
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SRS doses and patients are not informed about tumor control probability (TCP) and 
normal tissue complication probability (NTCP). In the era of personalized medicine, IDP 
will provide a basis for shared decision making. By applying IDP, the physician will dis-
cuss with the patient the TCP and NTCP, what is achievable if the treatment schedule is 
extended with moderate fractionation. The patient will then decide about the 
TCP/NTCP and the number of fractions. Moreover, IDP will stimulate radiation oncolo-
gists and clinical physicists to optimize the precision and quality of the SRS treatment 
delivery to minimize GTV-PTV margins and achieve the highest therapeutic ratio with 
SRS. In the treatment planning system, not only dose should be visualized, but also TCP 
and NTCP. At the outpatient clinic, the radiation oncologist can show the patient the 
effect of the application of IDP on TCP and NTCP instead of standard SRS dose prescrip-
tion and the effect of moderate fractionation with SRS. IDP will also enable a safe in-
crease of the therapeutic ratio, especially in large inoperable BM as was shown in our 
modelling study.[19] With solid outcome registration, the observed outcome will be 
compared to the expected outcome. By applying this model-based approach, a random-
ized trial is not needed to replace standard SRS dose prescription with IDP in daily clini-
cal practice. In future trials incorporating IDP, minimal TCP and maximum NTCP will be 
defined instead of standard radiotherapy doses. 
Combining SRS with immunotherapy 
This thesis describes the outcome of patients with BM treated with SRS as single modali-
ty, mostly in the first line of BM treatment. At present, more effective systemic agents 
are available that have the potential to control BM. Systemic therapies are increasingly 
being used in the first line of treatment, especially for asymptomatic small BM. SRS will 
be reserved if the BM progress under systemic therapy and SRS will be part or a tool in a 
multimodality treatment of intracranial and extracranial treatment over several months 
or years. A very interesting potential improvement of outcome is the combination of SRS 
or conventional fractionated radiotherapy with immunotherapy. The goal is that the 
irradiated BM serve as a vaccine to treat microscopic disease in the brain and elsewhere. 
The patient’s immune system is enhanced with immunotherapy to attack microscopic 
cancer cells by annihilating checkpoint inhibitors and/or directly stimulating the immune 
system with immunocytokines. The hope is that this strategy provides a survival benefit 
compared to systemic or radiotherapy treatment only.[29-31]    
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The aim of the research in this thesis is to improve patient selection and outcome of 
stereotactic radiosurgery (SRS) for brain metastases (BM). The hypotheses of this thesis 
are: 
1)  Individualized prognostic models predict survival and the occurrence of distant 
brain recurrences after SRS alone for BM more accurately than currently availa-
ble prognostic models  
2)  A multicenter randomized phase III trial can be initiated to investigate whether 
SRS alone provides a better quality of life than WBRT in patients with 4 to 10 BM   
3)  The 1-year tumor control probability of SRS for large BM can be improved by iso-
toxic dose prescription (IDP) in a modelling study.  
Several prognostic models were developed to predict local control, distant brain recur-
rences, and survival after SRS. The nomograms are especially valuable for the prediction 
of individualized outcome per patient. The accuracy of these individualized models can 
be optimized with the incorporation of more patient characteristics, treatment charac-
teristics, tumor characteristics, and imaging characteristics with the aim to support 
shared decision making of the patient with his/her physician. 
The multicenter study is currently ongoing. In June 2017, 7 Dutch hospitals opened for 
accrual and an additional 6 Dutch hospitals are willing to join. We are currently discuss-
ing the trial with potential participation of hospitals from the United Kingdom, Belgium, 
Germany, and Italy . We are cooperating with centers in the United States and Canada 
to optimize the SRS technique. This and other studies will define the role of SRS in the 
treatment of patients with multiple BM. Moreover, SRS as a technique for patients with 
multiple BM will become available inside and outside the Netherlands as a modality for 
other types of studies, for example, SRS combined with immunotherapy.  
In the modelling study, IDP increased local control safely with SRS in large BM with a low 
radionecrosis (RN) risk. With solid outcome registration, the observed outcome will be 
compared to the expected outcome in clinical practice. By applying this model-based 
approach a randomized trial is not needed to replace standard SRS dose prescription 
with IDP in daily clinical practice. To achieve an optimal therapeutic ratio, margins 
around the BM should be minimized or avoided. Moreover, the SRS technique should 
be optimized to optimize treatment accuracy and achieve steep dose gradients outside 
the BM to minimize the risk of RN. 
In conclusion, the developed individualized prognostic models and the results of the 
ongoing multicenter study in patients with multiple BM will contribute to better patient 
selection. The hope is that the process of shared decision making between the patient 
with his/her physician is better supported. By application of IDP, especially in large BM, 
the clinical outcome with respect to local control, toxicity, and survival after SRS for BM 
is expected to improve. 
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Met het onderzoek dat beschreven is in dit proefschrift is getracht om patiëntselectie 
en uitkomst te verbeteren van stereotactisch radiochirurgie (SRS) als behandeling voor 
patiënten met hersenmetastasen (HM). De hypotheses in dit proefschrift zijn: 
1) Geïndividualiseerde prognostische modellen voorspellen overleving en het ont-
staan van nieuwe hersenmetastasen beter na SRS voor patiënten met HM dan 
bestaande prognostische modellen 
2) Een gerandomiseerde multicenter studie kan worden geïnitieerd in Nederland 
om te onderzoeken of de kwaliteit van leven beter is na SRS dan na totale sche-
delbestraling bij patiënten met minimaal 4 en maximaal 10 HM. 
3) De kans op lokale controle 1 jaar na SRS bij grote HM kan veilig worden verbetert 
met isotoxisch voorschrijven van de radiotherapiedosis 
Verschillende prognostische modellen werden ontwikkeld om lokale controle, het ont-
staan van nieuwe HM en overleving te voorspellen na SRS voor HM. Met name de no-
mogrammen zijn waardevol om geïndividualiseerd uitkomst te voorspellen per patiënt. 
De nauwkeurigheid van deze geïndividualiseerde prognostische modellen kan worden 
geoptimaliseerd door meer patiënt-, behandeling-, tumor- en beeldvorming eigen-
schappen toe te voegen. Het uiteindelijke doel is betere ondersteuning voor shared 
decision making van de patiënt met zijn/haar arts. 
De Nederlandse multicenter studie is opgestart en in september 2017 waren 9 deelne-
mende centra open om patiënten te includeren. Nog 4 andere Nederlandse ziekenhui-
zen zijn geïnteresseerd in deelname. Ook vindt overleg plaats met ziekenhuizen in het 
Verenigd Koninkrijk, België, Duitsland en Italië voor deelname aan de studie. Er is tevens 
samenwerking opgezet met ziekenhuizen in de Verenigde Staten en Canada om de SRS 
techniek te optimaliseren. Deze en andere studies zullen de indicatie voor SRS als be-
handeling voor patiënten met multipele hersenmetastasen vaststellen. Tevens komt 
SRS beschikbaar in Nederland en in het buitenland als behandeling voor andere type 
studies, bijvoorbeeld gecombineerd met immuuntherapie. 
In de modeleringsstudie bleek het mogelijk te zijn om met isotoxisch voorschrijven de 
kans op  lokale controle veilig te verhogen met SRS voor HM terwijl tegelijkertijd het 
risico op radionecrose laag gehouden werd. Met goede uitkomst registratie zal de voor-
spelde uitkomst vergeleken worden met de daadwerkelijke uitkomst. Door toepassing 
van deze modelmatige benadering is een gerandomiseerde studie niet nodig voor klini-
sche implementatie. Om een optimale therapeutische breedte te creëren dienen mar-
ges rondom de HM tijdens het intekenen geminimaliseerd of vermeden te worden. 
Tevens dient de SRS-techniek geoptimaliseerd te worden om de nauwkeurigheid van de 
behandeling te optimaliseren en om steile dosisgradiënten te bereiken buiten het doel-
gebied om het risico op RN te minimaliseren. 
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Concluderend dragen de ontwikkelde geïndividualiseerde prognostische modellen en de 
resultaten van de opgestarte gerandomiseerde trial bij aan betere patiënten selectie en 
voorlichting voor de indicatiestelling voor SRS als behandeling voor patiënten met HM. 
De verwachting is dat het proces van gezamenlijke besluitvorming voor behandelingen 
door patiënt samen met zijn behandelend arts (shared decision making) beter onder-
steund wordt. Door isotoxisch voor te schrijven wordt verwacht dat de klinische uit-
komsten van SRS voor patiënten met HM wat betreft lokale controle, toxiciteit en over-
leving zullen verbeteren. 
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Every year, approximately 75.000 cancer patients in the Netherlands develop brain 
metastases (BM).[1] Treatment for BM may have considerable impact on the national 
health care budget because of the number of patients affected. Traditionally, whole 
brain radiotherapy (WBRT) was the cornerstone of the treatment. Stereotactic radio-
surgery (SRS) became available as an alternative for WBRT for patients with a limited 
number of brain metastases.[2] With SRS, several side effects of WBRT may be avoided, 
such as hair loss, fatigue, and neurocognitive damage.[3] In the Netherlands, the costs 
of WBRT are depend on contracts between the treating hospital and the insurance 
company and may differ per center. The content of these contracts is confidential. A 
crude estimation is that the costs of WBRT are around 4000 to 6000 euros and for SRS 
treatment around 6000 to 8000 euros. For patients with BM, SRS is more cost-effective 
than WBRT for patients with a limited life expectancy by the avoidance of costs related 
to neurocognitive side effects despite initial higher treatment costs as was published in 
American studies.[4,5] The exact cost-effectivity of SRS compared to WBRT or WBRT 
combined with SRS should also be studied specifically for the situation in the Nether-
lands.  
The development of accurate prognostic models and shared decision tools allows indi-
vidualized patient information per treatment modality. This may diminish the problem 
of over-treatment and intensive follow-up schemes for poor prognosis patients with 
BM. If patients are informed that there is a significant risk of dying within 3 months 
after treatment despite SRS, they may instead choose best supportive care.[6] Patients 
who have a low probability of long-term survival may choose not to undergo aggressive 
extracranial treatments, such as a 5 week treatment of chemotherapy and radiotherapy 
on the primary extracranial tumor with its morbidity and mortality. Patients who have 
only a low risk of developing distant brain recurrences (DBR) may choose not to under-
go follow-up MRIs. All these choices may result in less treatment and imaging during 
follow-up of patients with BM and a reduction in the costs of their treatment. 
Another opportunity to optimize cost-effectiveness is the potential avoidance of sys-
temic therapies for patients with BM. For example, in a large trial in patients with a 
maximum of 3 BM of non-small cell lung cancer, RT only (WBRT + SRS) resulted in im-
proved survival compared to combining RT with erlotinib or combining RT with te-
mozolomide.[7] This can be explained by additional side effects caused by combining RT 
with relatively ineffective systemic agents, which may result in decreased general health 
condition and thereby survival. Because the RT-only arm resulted in the best survival, it 
is obvious that both trial arms with the combination treatments (RT + erlotinib or RT + 
temozolomide) are less cost-effective by additional costs of the systemic agents with 
even a detrimental effect on survival compared to RT only. One year of treatment with 
a daily dose of 150 mg erlotinib costs 28.568 Euros in the Netherlands. One year of 
treatment with a daily dose of 100 mg temozolomide costs 6732 Euros in the Nether-
lands (www.medicijnkosten.nl). Thus, combining systemic agents with RT will only be 
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cost-effective if survival is actually improved over RT only and additional side effects of 
combining treatments are absent.  
Another opportunity to optimize cost-effectiveness is the application of isotoxic dose 
prescription (IDP). With IDP, the risk of radionecrosis (RN) is low because the SRS dose is 
prescribed based on normal tissue tolerance levels. With standard risk-adapted SRS 
dose prescription in large BM, there is a relatively low risk of local control and a relative-
ly high risk of RN.[8] Application of IDP in large inoperable BM (for example, PTV > 10 
cm3) is expected to result in a lowering of the incidence of RN compared to the current 
daily clinical practice. Patients suffering from RN become often dependent on steroids. 
Steroids have significant side effects such as a risk of diabetes mellitus with a need for 
medication, myopathy with a need for adaptations at home in daily care, and sleepiness 
with a need for medications. Symptoms resulting from RN and side effects resulting 
from steroids may also increase health care costs. It is to be expected that the applica-
tion of IDP in daily clinical practice with SRS for BM will result in a reduction in costs due 
to a lower incidence of RN and simultaneously an increase in cost-effectivity by higher 
local control probability in large BM. 
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